Modulation of ATF7IP in Huntington's disease patientderived iPSCs prevents neural gene expression changes induced by H3K9 trimethylation

Inaugural-Dissertation

zur

Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln



vorgelegt von Dilber Irmak aus Bielefeld, Deutschland

Köln 2018

Berichterstatter: Dr. David Vilchez

Prof. Dr. Aleksandra Trifunovic

Tag der mündlichen Prüfung: 11.06.2018

Isolation is the gift,

all the others are a test of your endurance, of how much you really want to do it and you'll do it. despite rejection and the worst odds and it will be better than anything else you can imagine.

> If you're going to try, go all the way. there is no other feeling like that. you will be alone with the gods and the nights will flame with fire.

> > do it, do it, do it. do it. all the way all the way.

- Charles Bukowski

Table of contents

A	bstra	ct	7
Z	usamı	menfassung	8
1	Intr	oduction	9
		Huntington's disease	
		Huntingtin	
		The role of HTT in development and cell differentiation	
	1.4	Stem cells and their epigenetic landscape	13
	1.5	The role of the HTT interacting protein 2 "UBE2K"	16
2		erial and Methods	
		Materials	
		Methods	
	2.2		
	2.2		
	2.2	1 0	
	2.2		
3	Roc	ults	22
5		The role of HTT in epigenetic control of embryonic stem cell differentiation	
	3.1		
	3.1	-	
	3.1		00
		iral genes	39
	3.1	8	
	3.2	The role of UBE2K in epigenetic control of embryonic stem cell differentiation	
	3.2		
	3.2		
	neu	ironal genes	53
	3.2	.3 UBE2K modulates JARID2 levels	56
4	Dice	cussion	50
4		HTT	
		HTT:	
		Conclusion and the missing link between HTT and UBE2K	
		_	
R	eferei	nces	67

List of figures

Figure 1. HTT interacts with the chromatin factor ATF7IP in both hESCs and neuror	ıs.34
Figure 2. Proteomic analysis of co-immunoprecipitation (Co-IP) experiments with H	ΗTT
and control FLAG antibodies in H9 hESCs and neurons.	36
Figure 3. Loss of HTT induces trimethylation of H3K9me3	37
Figure 4. Loss of HTT induces trimethylation of H3K9me3 in H1 hESCs	38
Figure 5. HTT KD hESCs retain their ability to differentiate into NPCs	38
Figure 6. HTT modulates ATF7IP and its interaction with SETDB1	39
Figure 7. Altered H3K9me3 marks upon HTT knockdown impairs the induction of	
distinct neural genes	40
Figure 8. Analysis of the proteome of HTT KD hESCs	41
Figure 9. Significantly enriched GO Biological Processes in ChIP experiments with	
H3K9me3 antibody in HTT KD hESCs	43
Figure 10. Knockdown of HTT in hESCs affects expression of SMC1B and ADGRB1 in	l
their NPC counterparts	44
Figure 11. Mutations in HTT reduce its interaction with ATF7IP and induce H3K9me	e3
levels	45
Figure 12. Knockdown of ATF7IP reduces H3K9me3 levels in HD-iPSCs without affe	cting
their ability to differentiate into NPCs	46
Figure 13. Loss of ATF7IP reduces H3K9me3 levels in HD-iPSCs	47
Figure 14. UBE2K is highly expressed in hESCs and iPSCs	49
Figure 15. Loss of UBE2K does not impair the induction of NES and SOX1 during the	
early stages of differentiation into NPCs	50
Figure 16. Loss of UBE2K impairs neurogenesis from hESCs	52
Figure 17. UBE2K regulates trimethylation of H3K9	53
Figure 18. Significantly enriched GO Biological Processes in UBE2K KD hESCs in ChI	Р
experiments with H3K9me3 antibody	55

List of tables

Table 1: Cell lines	.18
Table 2: hESC Culture and chemicals	.18
Table 3: Antibodies & chemicals	.21
Table 4: Lentiviral vectors	.22
Table 5: Kits	.22
Table 6: qRT-PCR Primers	.23
Table 7: Electrical devices	.24
Table 8. Protein interactors of HTT in H9 hESCs	.35
Table 9. List of proteins significantly changed in both HTT knockdown hESC lines	
(shRNA #1 and shRNA #2)	.42
Table 10. Quantitative proteomic analysis of E2 enzymes comparing hESCs with their	
NPC and neuronal counterparts	.48
Table 11. Protein interactors of UBE2K in H9 hESCs	.54
Table 12. Quantitative proteomic analysis of UBE2K KD hESCs	.58

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by mutations in the huntingtin gene (HTT). These mutations expand the CAG triplet repeat region resulting in an unstable polyglutamine stretch (polyQ) in the Nterminal domain of the protein. Epigenetic marks such as histone methylation are significantly altered in HD patients as well as HD cellular and organismal models. Specifically, H3K9 trimethylation (H3K9me3) is markedly increased in HD patients and HD mouse models, which correlates with transcriptional repression. In this study we make use of induced pluripotent stem cells (iPSCs) as they present a unique tool for disease modeling and hold a great promise for regenerative medicine. We use iPSCs from patients with HD (HD-iPSCs) and induce their differentiation into neuronal HD-IPSCs (HD-NPCs) to identify mechanisms that can correct HD disease-related changes. Therefore, in a first step we asked for the normal function of HTT. We show for the first time that HTT interacts with chromatin factor ATF7IP and its specific H3K9 methyltransferase SETDB1. In addition, we observed that loss of HTT increased the levels of ATF7IP and global H3K9me3 in hESCs. In pluripotent stem cells the levels of heterochromatin-associated histone modifications such as H3K9me3 are usually reduced which indicates that HTT regulates H3K9me3 levels in hESCs. Next, we show that knockdown of ATF7IP in HD-iPSCs and their neuronal differentiated counterparts results in a decrease of H3K9me3. As with HTT, upon knockdown of huntingtin interacting protein 2 (UBE2K) we observed increased H3K9me3 in hESCs, probably through the histone methyltransferase regulator JARID2, an interactor of UBE2K found firstly in this study. However, UBE2K KD came with a dramatic dysfunctional phenotype towards the neural differentiation abilities of the cells. Therefore, UBE2K and the normal function of HTT could be required within a bigger complex of epigenetic regulators to maintain the H3K9me3 landscape of hESCs and HD-iPSCs.

Zusammenfassung

Die Huntington-Krankheit (HD) ist eine autosomal dominante neurodegenerative Erkrankung, die durch Mutationen im Huntingtin-Gen (HTT) verursacht wird. Diese Mutationen erweitern den CAG-Triplett-Wiederholungsbereich, was zu einem instabilen Polyglutamin-Stretch (polyQ) in der N-terminalen Domäne des Proteins führt. Epigenetische Marker wie die Histonmethylierung sind bei HD-Patienten sowie bei zellulären und organismischen HD-Modellen signifikant verändert. Insbesondere die H3K9-Trimethylierung (H3K9me3) ist bei HD-Patienten und HD-Mausmodellen deutlich erhöht, was mit einer transkriptionellen Repression korreliert. In dieser Studie verwenden wir induzierte pluripotente Stammzellen (iPSCs), da sie ein einzigartiges Werkzeug zur Modellierung von Krankheiten darstellen und ein großes Potenzial für die regenerative Medizin bieten. Wir verwenden iPSCs von Patienten mit HD (HD-iPSCs) und induzieren deren Differenzierung in neuronale HD-IPSCs (HD-NPCs), um Mechanismen zu identifizieren, die krankheitsbedingte Veränderungen bei HD korrigieren können. Daher haben wir in einem ersten Schritt nach der normalen Funktion von HTT gefragt. Wir zeigen hier zum ersten Mal, dass HTT mit dem Chromatinfaktor ATF7IP und seiner spezifischen H3K9-Methyltransferase SETDB1 interagiert. Darüber hinaus beobachteten wir, dass der Verlust von HTT das Ausmaß von ATF7IP und globalem H3K9me3 in hESCs erhöhte. In pluripotenten Stammzellen sind die Werte von Heterochromatin-assoziierten Histon-Modifikationen wie H3K9me3 in der Regel reduziert, was darauf hindeutet, dass HTT den Gehalt an H3K9me3 in hESCs reguliert. Als nächstes zeigen wir, dass der Knockdown von ATF7IP bei HD-iPSCs und ihren neuronal differenzierten Gegenstücken zu einem Rückgang von H3K9me3 führt. Wie bei HTT beobachteten wir beim Knockdown des mit Huntingtin interagierenden Proteins 2 (UBE2K) einen Anstieg von H3K9me3 in hESCs, vermutlich mit Hilfe des Histon-Methyltransferase-Regulators JARID2, einem Interaktor von UBE2K, der erstmals in dieser Studie gefunden wurde. Der UBE2K KD hatte jedoch einen drastisch dysfunktionalen Phänotyp in Bezug auf die neuronalen Differenzierungsfähigkeiten der Zellen. Daher könnten UBE2K und die normale Funktion von HTT in einem größeren Komplex epigenetischer Regulatoren erforderlich sein, um den H3K9me3-Spiegel aus hESCs und HD-iPSCs zu erhalten.

1 Introduction

1.1 Huntington's disease

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by mutations in the huntingtin gene (HTT). The characteristic symptoms of the HD which entail abnormal movements (chorea), cognitive decline (dementia) and psychosis, manifest usually from the age of 35 to $50^{1,2}$. The disease leads to death approximately 20 years after onset of first symptoms³. The mutations of the *HTT* gene expand a CAG triplet repeat region in exon 1 resulting in an unstable polyglutamine stretch (polyQ) in the Nterminal domain of the protein. In its wild-type form, HTT contains 6-35 glutamine residues. However, in individuals affected by HD, it contains greater than 35 polyQ repeats⁴. Although HTT is ubiquitously expressed^{5,6}, mHTT particularly leads to neuronal dysfunction and death in many brain regions with the striatum undergoing the greatest neurodegeneration⁷. Extensive data and the dominant inheritance pattern of HD indicate that gain-of-function of mHTT is toxic and triggers neurodegeneration^{4,8,9}, especially in the striatal medium-sized spiny neurons¹⁰. However, growing evidence suggests that loss of normal HTT function also contributes to HD^{5,6}. For instance, loss of wild-type HTT induces HD-related changes such as progressive neurodegeneration and motor dysfunction or hastens these changes in human and mouse HD models¹¹⁻¹⁵. Moreover, ectopic expression of wild-type HTT improves brain cell survival and ameliorates the deleterious effects of the mutant protein^{12, 16–22}.

1.2 Huntingtin

The HTT gene is well conserved from flies to mammals and has no sequence homology with other proteins. It probably appeared millions of years ago, before the seperation of the protostoma (origin of insects) and deuterostoma (mammals) branches^{5,6}. HTT is a completely soluble high-molecular-weight protein of 348 kDa (3,144 amino acids) and is ubiquitously expressed.

In HTT protein structure, the region of highest interest in HD-research is the expandable polyQ region. The polyQ tract starts at the eighteenth amino acid and contains up to 34 glutamine residues in healthy individuals. Moreover, there are also other proteins such as transcription factors which contain a polyQ region²³. A study showed

that the polyQ tract forms a three-dimensional protein motif that forms interactions with polar residues (Polar Zipper) and thus might have its physiological function in the binding of these proteins²⁴. A region found only in higher vertebrates is the polyproline stretch, which is assumed to aid in the solubility of the HTT²⁵. The protein also contains several HEAT domains of ~40 amino acids which enable protein-protein interactions^{26,27}. In HTT around 37 HEAT repeats were discovered²⁸, of which three key clusters were identified²⁷.

Further downstream, a carboxy (C)-terminal nuclear export signal (NES) sequence and a nuclear localization signal (NLS) are localized. The NLS was found to be less active than the NES. This indicates that this location of the protein is responsible for molecular transportation from the nucleus to the cytoplasm²⁹. In addition, the widespread distribution of HTT within the cell nucleus and other cell compartments supports this idea. In more detail studies showed, that HTT functions as a nuclear export protein through its interaction with the nuclear pore protein TPR (translocated promoter region). In support of this role was the observation that HTT accumulates in the nucleus, when the amino acids of the interacting region were deleted³⁰.

The three protease cleavage sites split the protein into normal and mutant HTT (mHTT) fragments^{31–33}, which are found in the nucleus and cytoplasm^{34–38}. Caspase and calpain family members have a proteolytic role for mHTT^{36,38–40}. HTT has several consensus caspase³⁸ and calpain cleavage sites⁴⁰, also known as cysteine proteases. Calpains, however are Ca²⁺-dependant intracellular cysteine proteases⁴¹. It should be noted that excessive glutamatergic signaling and impaired excessive Ca²⁺ influx in the brain striatum, lead to mitochondrial dysfunction and cell death⁴². This pathway is an activator of cysteine proteases like caspases and calpains⁴¹. Caspase cleavage is activated by proteolytic processes such as apoptosis⁴¹ and is a common process, as this event was observed in control human brains as well as in HD-brains in the early stage of disease, or in WT and HD transgenic mouse brains before neurodegeneration commenced³⁸. It is known that HTT is a substrate of calpain to induce cleavage. The activation of calpain cleavage is initiated by programmed cell death in the cell⁴³ and also targets other polyQ containing proteins causing neurodegenerative diseases³².

HTT fragments resulting from caspase-and calpain proteolysis tend to accumulate in the nucleus. This is because mHTT cleavage only releases the polyQ containing Nterminal fragments, which are prone for aggregation and are toxic in the cell^{32,39}. Interestingly, reducing the activity of calpain and caspase cleavage sites decreased the cleavage of the mHTT and thus delayed the onset of the disease^{33,39,44}.

The post-translational modifications of HTT include sumoylation, ubiquitination, phosphorylation and palmitoylation. The amino (N)-terminal lysines K6, K9 and K15 get either ubiquitinated⁴⁵ or sumoylated²⁵. Further, the serines 421 and 434 get phosphorylated, which influences the cleavage and toxicity of mHTT. Studies showed that phosphorylation of these serines is reduced in the HD⁴⁶⁻⁴⁹. The palmytoylation of huntintin is done by the HTT-interacting protein 14 (HIP14) which is a palmitoyl transferase⁵⁰. Proteins which are palmitoylated are known to regulate components which control vesicle trafficking and thus support the role of HTT in vesicle trafficking^{50,51}.

HTT is capable of binding to its numerous interactors in both its wild-type and mutant form^{52,53}. This feature indicates that it has a flexible structure which adapts its conformation and function depending on the current subcellular location, state of maturation or cell type^{54,52,28,55,56}. For example, the expanded polyQ region is capable of changing the three-dimensional structure of the HTT, making it accessible to different interacting proteins^{24,52}. The protein epitopes presented by HTT are supposedly differentially accessible by the same antibodies, depending on the intracellular compartment the HTT is found in^{57,58}.

In humans and rodents HTT is found mainly in the cytoplasm⁵¹, with the highest levels in the CNS neurons and the testes^{59–61}. Within the cell it is found in several organelles including the nucleus, endoplasmic reticulum and golgi complex^{51,62–65}. HTT has many binding partners and the most important ones are involved in transcriptional regulation, intracellular trafficking and cytoskeletal organization. Interestingly many of the known interactors of HTT have functions in endocytosis and only a few in exocytosis⁶⁶. HTT has been associated with synaptic vesicles^{51,62}, microtubule-based axonal transport, endosomal structures and clathrin-coated vesicles⁶³. Taken together, an important function of normal HTT seems to lie in membrane trafficking. HTT also facilitates trimethylation of H3K27 by the chromatin regulator polycomb repressive complex 2 (PRC2) in mouse embryonic stem cells (mESCs), a mechanism further induced by a gain of function of the mHTT⁶⁷.

1.3 The role of HTT in development and cell differentiation.

Remarkably, conditional knockout of *Htt* in mice at embryonic day 14.5 causes progressive neurodegeneration that mimics HD phenotypes¹¹. At earlier stages, complete depletion of HTT results in severe neural developmental defects and embryonic lethality⁶⁸⁻⁷⁰, providing a link between normal function of HTT and development. Mice with reduced levels of HTT to below 50% bypass the lethality phenotype but display aberrant brain development, suggesting a role of HTT in neurogenesis⁷¹. Loss of HTT during embryonic neurogenesis decreases the pool of cortical progenitors by accelerating their differentiation, a process that results in altered cell fate decisions⁷². *In vitro*, neural progenitor cells (NPCs) derived from *Htt^{-/-}* mouse ESCs (mESCs) can be terminally differentiated into neurons. However, a study demonstrated that their neuronal differentiation efficiency is altered as they tend to give rise to more astrocytes compared with wild-type NPCs⁷³. Another study finds even earlier phenotypes such as decreased self-renewal, increased cell death and alterations in the lineage potential of NPCs derived from *Htt*^{-/-} mESCs⁷⁴. Although patients with HD and disease mouse models do not exhibit striking developmental phenotypes as HTT knockout models^{5,71,75,76}, cumulative evidence indicates developmental deficits in HD mouse models and human pathological specimens^{77–80}. For instance, polyQ-expanded HTT induces deficits such as impairment in the maintenance of striatal neural stem cells and their specification into medium spiny neurons⁸⁰. Furthermore, both HD patients and mouse models exhibit abnormalities in brain morphology and synaptic plasticity before the onset of apparent clinical deficits⁸¹⁻ ⁸⁷. It is also known that HTT improves brain cell survival when it is overexpressed^{18,19,21,22,88}.

Research showed that HTT has anti-apoptotic effects, both in vitro^{19,46,89} and in vivo^{17,88} and protects neurons from excitotoxicity in vivo¹⁸. These cell-autonomous activities originate from the 548 amino acid terminus (N548) of the HTT protein and affect neuronal and non-neuronal cells⁵. An important function of HTT, which is more specific to neurons, is the stimulation of brain-derived neurotrophic factor (BDNF) gene transcription. It controls the transcription of the gene by inhibiting the silencer element "Repressor element 1" (RE1), or "neuron-restrictive silencer element" (NRSE) on the BDNF gene promoter^{21,22}, but also of many other genes which carry these silencer elements on their promoters. Besides, HTT is responsible for vesicle and BDNF transport,

and the regulation of many processes important to normal brain function, such as fast axonal trafficking and synaptic transmission⁵. When mESCs are genetically modified to express polyQ-expanded HTT, they maintain their ability to form NPCs. Upon neuronal induction, these cells exhibit a higher percentage of neuronal cell death resulting in a decreased percentage of neurons remaining at the end of the differentiation process⁷³. Although HD-iPSCs from patients and control iPSCs differentiate into NPCs with indistinguishable efficiency, HD-NPCs exhibit abnormalities in cytoskeleton, cell adhesion and energetics⁹⁰. Moreover, HD-NPCs present HD-related transcriptional dysregulation in genes involved in cell cycle, signaling, axonal guidance and neuronal development⁹⁰. HD-NPCs can be terminally differentiated into neurons that exhibit HD-related changes such as alterations in calcium homeostasis, electrophysiology, increased vulnerability to excitotoxic stressors and cumulative risk of death over time³⁷. Altogether, these findings suggest a role of HTT during development whereas its potential dysregulation by mutant polyQ could predispose neurons to degeneration and/or other HD-related changes.

1.4 Stem cells and their epigenetic landscape

Given the role of HTT in neuronal development, it is of importance to understand its regulatory function in embryonic stem cells (ESCs). Human embryonic stem cells (hESCs) are derived from the inner cell mass of blastocysts. These cells replicate continuously in the absence of senescence while maintaining their ability to differentiate into all cell lineages^{91,92}.

One essential mechanism in order to maintain stem cell identity is the maintenance of the proteome via the ubiquitin-proteasome system (UPS). The UPS administers selective protein degradation by covalent ligation to a 76-amino-acid-residue protein called ubiquitin⁹³. There are numerous targets for the ubiquitin-mediated degradation, such as regulatory proteins, which control cell-cycle progression, signal transduction or transcriptional regulation among many other important processes^{93,94}. Importantly, the UPS was found to coordinate pluripotency in embryonic stem cells and induced pluripotent stem cells⁹⁵. Furthermore, ubiquitin-mediated degradation is known for its important role in development and programmed cell death^{93,94}. In eukaryotic cells the degradation of proteins is usually accomplished through a multi-step ubiquitination process, which includes the reversible covalent conjugation of polypeptides to its substrates in an adenosine triphosphate (ATP)-dependent manner. The synthesized polyubiquitin chain, linked mostly through lysine 48 of the ubiquitin peptide, is recognized and hydrolyzed into short peptides by the 26S (2000 kDa) proteasome. The released ubiquitin molecules are then re-used^{94,96}. As a first step a ubiquitin polypeptide is adenylated by the ubiquitin activating enzyme (E1). Next a sulfhydryl group of the proteasome is added to build a E1–ubiquitin thiolester and the activated ubiquitin is directed to one of the many E2 enzymes via transthiolation. As a last step the protein ubitquitination is catalyzed by the E2 enzyme, either alone or with an E3 ligase⁹⁷.

Extensive progress has been made in characterizing the transcriptional network that regulates self-renewal and differentiation of hESCs, including transcription factors such as OCT4, NANOG and SOX298. Likewise, epigenetic modifiers regulate hESC pluripotency and cell reprogramming^{99,100}. In comparison with their differentiated counterparts, hESCs have a unique nuclear and chromatin architecture such as fewer condensed heterochromatin foci¹⁰¹. This less compact chromatin pattern facilitates its dynamic reorganization during development. The chromatin state is modulated by DNA methylation and dynamic assembly/disassembly of histones as well as other related proteins. hESCs have a specific signature of DNA methylation, a key epigenetic regulatory mechanism to modulate gene expression¹⁰². Whereas differentiated cells exhibit more DNA methylation genome-wide suggesting a less active chromatin structure, hESCs have less DNA methylation reflecting a more open and dynamic architecture of chromatin^{103,104}. Furthermore, ESCs exhibit a specific histone modification pattern, named bivalent domains, consisting of large regions of H3K27me3 repressive marks harboring smaller regions of H3K4me4 activation marks¹⁰⁵. These bivalent domains could have a function to silence developmental genes in ESC while keep them poised for activation. Moreover, the levels of heterochromatin-associated histone modifications such as H3K9me3 are usually reduced whereas the levels of transcriptional activations marks such as acetylated histones are generally increased in hESCs^{106,107}. A complex network of proteins such as the polycomb repressive complex 2 (PRC2) regulates histone modifications. In ESCs, PRC2 forms a complex with the Jumonji and ARID-domaincontaining protein (JARID2) maintaining H3K27me3 chromatin marks¹⁰⁸. Although the histone code has a critical role in chromatin and gene regulation, the molecular mechanisms that modulate the unique chromatin pattern of hESCs remain largely

unknown. Given their specific chromatin structure signature, hESCs could provide a different paradigm to discover novel epigenetic regulatory mechanisms and their impact on differentiation. Moreover, a better understanding of chromatin regulation in hESCs could lead to novel pathways to facilitate cell reprogramming of somatic cells. Thus, a firm understanding of the epigenetic machinery involved in hESC self-renewal and cell fate decisions is central importance.

Importantly, NPCs and neurons derived from HD-iPSCs show transcriptional changes consistent with those observed in HD brain, including dysregulation of genes involved in cell cycle, cell signaling, neuronal development and axonal guidance⁹⁰. Transcriptional dysregulation is a prominent defect observed in postmortem HD brains and distinct HD mouse models^{6,109}. Epigenetic marks such as DNA methylation and post-translational modifications of histone proteins are significantly altered in HD patients as well as HD cellular and organismal models¹¹⁰. Thus, epigenetic alterations could contribute to transcriptional abnormalities in HD¹¹⁰. Among these epigenetic changes, H3K9 trimethylation (H3K9me3) is robustly increased in HD patients and HD mouse models¹¹¹⁻¹¹⁴. H3K9 hypermethylation is accompanied by upregulation of its specific methyltransferase SETDB1¹¹³. SETDB1 activity is regulated by ATF7IP. H3K9me3 is associated with heterochromatin and correlates with transcriptional repression¹¹⁵.

ATF7IP regulates chromatin formation by binding and directing transcriptional factors to the general transcriptional machinery. Depending on the subcellular conditions the protein can operate either as an activator or a repressor¹¹⁶⁻¹¹⁹. In particular, ATF7IP has an effect on histone methylation that is essential for chromatin structure and function. In particular, the histone methyltransferase (HMTase) activity of Histone-lysine N-methyltransferase SETDB1 (SETDB1) depends on the assistance of ATF7IP. It triggers the transformation of the dimethyl (H3K9me2) to the trimethyl state (H3K9me3) by increasing the turnover rate of the reaction, both in vitro and in vivo.

To conclude, pluripotent stem cells are an invaluable resource for disease modeling and hold a great promise for regenerative medicine, in particular for understanding disease mechanisms in neurodegenerative diseases. The observations raise an intriguing question: does HTT regulate H3K9me3 levels in pluripotent stem cells via the described ATF7IP/SETDB mechanisms? In this thesis, I use human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) from HD-patients (HDiPSCs) to identify epigenetic mechanisms that can correct disease-related changes.

1.5 The role of the HTT interacting protein 2 "UBE2K"

As described above, HTT has many binding partners. One of the first described interactors of HTT is the HTT interacting protein 2 (UBE2K or HIP2). UBE2K is a member of the E2 ubiquitin ligase family, which consists of approximately 35 enzymes. E2 ligases are essential for the proper functioning of the UPS. Briefly, as an E2 ubiquitin conjugating enzyme, UBE2K accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other protein lysine residues via E3 ubiquitin ligases¹²⁰. Although it is known that HTT is ubiquitinated it is not known whether UBE2K targets HTT for ubiquitination⁴⁵. The 22 kDa protein was discovered as an HTT interactor in a yeast two-hybrid system study. They found that the human protein consisted of an amino acid sequence identical to the bovine ubiquitin-conjugating enzyme (E2-25K), and was further described to interact with the amino terminus of the HD protein. Specifically, by using an anti-E2-25K polyclonal antibody, a protein slightly bigger than UBE2K was bound and exclusively located in HD-affected brain regions⁴⁵. Further studies showed that UBE2K is highly expressed in the frontal cortex and striatum of the brain¹²¹.

Like HTT, mRNA expression of the mouse UBE2K homolog (mHIP-2) was shown to increase with maturation of neurons, and thus, both are likely to have an impact brain development. Also, both HTT and mHIP-2 have the same regional mRNA distribution pattern. This indicates a common transcriptional regulation for the two proteins, although the mHIP-2 expression started earlier than HTT expression¹²².

A different study using the yeast two-hybrid system identified UBE2K as one of six E2's interacting with the human heterodimeric RING E3 BRCA1-BARD1 ubiquitin-protein ligase complex. UBE2K binds to the BRCA1 RING and mediates the synthesis of Lys63- or Lys48-linked polyubiquitin chains on BRCA1¹²³. Moreover, UBE2K could be a involved in the pathogenesis of Alzheimer's disease, by suppressing the proteasome activity and causing aggregation of ubiquitin conjugates in neurons, also referred to as amyloid- β peptide (A β) neurotoxicity^{124,125}. It is known that protein aggregation is a hallmark of

neurodegenerative diseases such as HD and that the protein modification molecule ubiquitin aids in the localization and degradation of toxic aggregates¹²⁵. Another study looked at the subcellular localization in neuronally differentiated cells and showed positive staining of UBE2K primarily co-aggregates with expanded polyglutamine proteins in apoptotic cells. This finding is in line with staining experiments in postmortem brain cells from HD patients¹²⁶.

UBE2K might be involved also in other biological systems, for instance in the ubiquitination of proteins in atherosclerosis, caused by macrophages and human monocytes. The aggregated low-density lipoprotein (agLDL) hinders the apoptosis of atherosclerosis causing, lipid-bearing macrophages, leading to unwanted foam cell formation. One of the genes induced by agLDL, termed low-density lipoprotein (LDL)inducible gene (LIG) contained the coding sequence for UBE2K. This anti-apoptotic function could be revoked in the presence of proteasome inhibitor¹²⁷. In mice, the SUMOylation of UBE2K ortholog E2-25K protects against neuronal cell death during oxidative stress. By SUMOylation the proteasome activity of subunit S5a is downregulated means of protection against cell death. UBE2K also interacts with a regulatory protein named cyclin B1, which is involved in mitosis. It thereby ameliorates cyclin B1-induced apoptosis by regulating the stability of the cyclin B1 protein¹²¹. In the model organism *C*. elegans knockdown of RNAi mediated ubiquitin-conjugating enzymes (UBC's) showed severe effects on aggregates. Especially, after the knockdown of *ubc-1*, *ubc-13*, *or uev-1*, aggregates could not be localized by the ubiquitin molecule, suggesting that these ubc enzymes are necessary for aggregate ubiquitination¹²⁵.

It is currently unclear if UBE2K plays a role in the abundant modifications of histone lysine residues during epigenetic changes (methylation, acetylation, ubiquitylation) in stem cell differentiation. Therefore, the aim of this thesis was to dissect the role of Huntington and UBE2K on the epigenetic landscape and on the function of neuronal differentiation in hESCs.

2 Material and Methods

2.1 Materials

Table 1: Cell lines

NAME	DESCRIPTION	SOURCE
H9 (WA09)	hESC	WiCell Research Institute
H1 (WA01)	hESC	WiCell Research Institute
HFIB2-IPS4	iPSCs control	(Park, Zhao et al. 2008) ¹²⁸
HD-IPSC#1	iPSC Q71	(Park, Arora et al. 2008) ¹²⁹
ND42242	iPSC Q21 control	Coriell Institute
ND36997	iPSC Q33 control	Coriell Institute
ND42229	HD iPSC Q71	Coriell Institute
ND36999	HD iPSC Q180	Coriell Institute

Table 2: hESC Culture and chemicals

NAME	COMPANY
1X PBS, W/O CA/MG	Life technologies
2-MERCAPTOETHANOL	Sigma
2-PROPANOL	Sigma
2,4,6-TRICHLORANISOL (TCA)	Sigma
4X LAEMMLI SAMPLE BUFFER	BioRad
4X500ML ACRYLAMIDE/BIS SOLUTION	Serva
37,5:1	
5-BROMO-2`DEOXYURIDINE	Sigma
10X DPBS	Life technologies
10X TRIS BUFFERED SALINE	BioRad
10X TRIS/BORIC ACID/EDTA	BioRad
10X TRIS/GLYCINE	BioRad
10X TRIS/GLYCINE/SDS	BioRad
ACCUTASE 100 ML	Stem Cell Technologies
ACETON	Sigma
ADENOSINE 5' -TRIPHOSPHATE	Sigma
DISODIUM SALT HYDRATE	
AGAROSE, ULTRAPURE 500G	Life technologies
ALBUMINE FROM BOVINE SERUM	Sigma
AMMONIUM BICARBONATE	Roche
AMMONIUMSULFATE	Carl Roth
AMMONIUM PERSULFATE, 10 G	BioRad
ASCORBIC ACID	Sigma
APROTININ FROM BOVINE LUNG	Sigma
B27 SERUMFREE SUPPLEMENT	Life technologies
BDNF	Peprotech
BFGF	Joint Protein Central
CHLOROFORM	Sigma

	C
CITRIC ACID	Sigma
CF-1 MEFS	Amsbio
CLARITY WESTERN ECL SUBSTRATE	BioRad
COLLAGENASE TYPE IV	Life technologies
CYCLOHEXIMIDE	Sigma
D-(+)-GALACTOSE	Sigma
D-(+)-GLUCOSE	Sigma
DAPI (4,6 DIAMINIDO-2-PHENYLIN)	Life technologies
DEPC-TREATED WATER	Life technologies
DEOXYCHOLIC ACID SODIUM	Sigma
DIBUTYRYL-CYCLIC AMP	Sigma
DL-DITHIOTHREITOL (DTT)	Sigma
DISPASE	Stem Cell Technologies
DMEM, NO GLUCOSE	Life technologies
DMEM/F-12, HEPES	Life technologies
DMEM/F:12	Life technologies
DMSO	Sigma
DNA POLYMERASE I	Promega
DYNABEADS PROTEIN G	ThermoFisher
EDTA	Sigma (Roche Prot.)
EDTA SOLUTION PH 8,0	VWR
EGTA	Sigma
EPIDERMAL GROWTH FACTOR	Sigma
ETHANOL 99,5% (DENAT. 1% MEK)	VWR
ETHANOL PURE	Sigma
FBS SOUTH AMERICAN HI	Life technologies
FGF-BASIC HUMAN 1000MG	Peprotech
FLUORSAVE REAGENT	Merck
FORMALDEHYDE, 10%, METHANOL	Polyscience
FREE	
FORMIC ACID	Sigma
GDNF HUMAN	Peprotech
GELATIN FROM PORCINE SKIN	Sigma
GELTREX LDEV	Life technologies
GENTLE DISSOCIATION REAGENT	Stem Cell Technologies
GLACIAL ACETIC ACID	Sigma
GLUTAMAX 1	Life technologies
GLYCEROL, 500 ML	LifeTechnologies
GLYCOGEN	Life technologies
GLYCIN	Sigma
HEPES STERIL 1M PH7.3	VWR
HI-MARK PRE-STAINED PROTEIN	Life technologies
LADDER	_
HOECHST	LifeTechnologies
HYDROCHLORIC ACID	Sigma
HYDROGEN PEROXIDE 30%	Sigma
IGEPAL CA-630	Sigma
IMMOBILON WESTERN CHEMILUM HRP	Merck
SUBSTRATE	
INCUWATER-CLEAN	VWR

IODACETAMIDE (IAA)	Sigma
ISOPROPANOL	Sigma
KALIUMHYDROGENPHOSPAT	Roth
KNOCKOUT SERUM REPLACEMENT	ThermoFisher Scientific
LAMININ	Life technologies
L-ASCORBIC ACID	Sigma
L-GLUTAMINE	Joint Protein Central
LITHIUMCHLORID (LICL)	Sigma
MAGNESIUM CHLORIDE HEXAHYDRATE	Millipore
METHANOL	Sigma
MTESR1	Stem Cell Technologies
MOWIOL	Carl Roth
N2 SUPPLEMENT	ThermoFisher Scientific
N-LAUROYLSARCOSINE	Sigma
N-ETHYLMALEIMIDE	Sigma
NEUROBASAL MEDIUM	Life technologies
NITROCELLULOSE MEMBRANE 45MM	Bio-Rad
N,N-DIMETHYLFORMAMID	Sigma
NON-ESSENTIAL AMINO ACIDS	Life technologies
NONFAT-DRIED MILK FROM BOVINE	Sigma
NP-40	Sigma
PBS, W/O CA/MG (10X)	Life technologies
PENICILIN/STREPTOMYCIN	Life technologies
PHENOL CHLOROFORM	BD
PHENOL:CHLOROFORM:ISOAMYL	Sigma-Aldrich
ALCOHOL	
PHENYLMETHYLSULFONYL FLUORIDE	Sigma
(PMSF)	0
POLY-L-ORNITHINE HYDROBROMIDE	Sigma
PONCEAU S SOLUTION	Sigma
POTASSIUM ACETATE	Sigma
POTASSIUM CHLORIDE	Sigma
POTASSIUM DIHYDROGEN PHOSPHATE	Fisher
POTASSIUM HYDROGEN PHOSPHATE	ALFA
DIBASIC	
POTASSIUM HYDROXIDE	ALFA
PRECISION PLUS PROTEIN DUAL COLOR	BioRad
STANDARDS, 5X	
PROTEIN A BEADS	Miltenyi
PROTEIN ASSAY DYE REAGENT	BioRad
CONCENTRATE, 450 ML	
PROTEINASE K, RECOMBINANT	Sigma
PROTEASE INHIBITOR (25 TABL.)	Sigma
PUROMYCIN 10X1ML	Life technologies
PVDF.45UM IMMOBILON	Merck
RANDOM PRIMERS	ThermoFisher Scientific
RESOLVING GEL BUFFER, 1.5 M TRIS-	BioRad
HCL, PH 8.8, 1	
RNABEE	Tel-Test Inc.
RNASE A	Peqlab

RNASE H	Peqlab
ROCK INHIBITOR (Y-27632	Abcam
DIHYDROCHLORIDE)	
SDS- SODIUM DODECYL SULFATE	Sigma
SDS SOLUTION 20% (W/V)	BioRad
SODIUM 4-PHENYLBUTYRATE	Sigma
SODIUM ACETATE, ANHYDROUS	VWR
SODIUM ACETYL-L-CYSTEINE	Sigma
SODIUM AZIDE	Sigma
SODIUM BICARBONATE	Life technologies
SODIUM CHLORIDE	VWR
SODIUM DEOXYCHOLATE	Sigma
SODIUM FLUORIDE	Sigma
SODIUM HYDROGEN PHOSPHATE	ALFA
DIBASIC	
SODIUM HYPOCHLORITE SOLUTION	Sigma
SODIUM ORTHOVANADATE	Sigma
SODIUM SELENITE	Sigma
SUCROSE	Sigma
STACKING GEL BUFFER	BioRad
STEMDIFF DEFINITIVE ENDODERM KIT	Stem Cell Technologies
STEMDIFF NEURAL INDUCTION	Stem Cell Technologies
MEDIUM	
STEMDIFF NEURAL PROGENITOR	Stemcell Technologies
MEDIUM	
TEMED	BioRad
TETRAETHYLAMMONIUM	Sigma
BOROHYDRIDE (TEAB)	1 MAD
TRIS 1M PH 7,5	VWR
TRIS-HCL	Sigma, Roth
TRITON X-100	Sigma
TRYPSIN 0.25 EDTA	Life technologies
TWEEN® 20	Biochemica
ULTRAPURE DNASE/RNASE-FREE WATER	Life technologies
UREA	Deche
UKEA	Roche

Table 3: Antibodies & chemicals protein biochemistry

ANTIBODY	COMPANY
ALEXA FLUOR 488 GOAT ANTI	Life technologies
MOUSE IGG (H+L)	
ALEXA FLUOR 488 GOAT ANTI	Life technologies
RABBIT IGG (H+L)	
ALEXA FLUOR 546 GOAT ANTI	Life technologies
MOUSE IGM	
ANTI-ATF7IP	Proteintech 1:500 WB
ANTI-BETA ACTIN	Abcam 1:1,000 WB
ANTI-H3	Cell Signaling Technologies, 1:10,000 WB

ANTI-H3K9ME3	Abcam, 1:1000 WB
ANTI-HTT	Cell Signaling Technologies, 1:1000 WB
ANTI-HTT-POLYQ (MW1-S)	from DSHB, 1:500 WB
ANTI-MAP2	Sigma 1:500 WB
ANTI-NESTIN	Stem Cell Technologies, 1:1,000
ANTI-OCT4	Stem Cell Technologies, 1:500
ANTI-PAX6	Stem Cell Technologies, 1:200
ANTI-SETDB1	Abcam, 1:500
ANTI-SOX2	Abcam, 1:1,000
HRP AP DONKEY ANTI-MOUSE IGG	Jackson Immuno Research
(H+L)	
HRP AP DONKEY ANTI-RABBIT IGG	Jackson Immuno Research
(H+L)	
STEMDIFF NEURAL PROGENITOR	Stemcell Technologies
ANTIBODYPANEL	
ANTI-FLAG	Sigma

Table 4: Lentiviral vectors. in pLKO.1-puro vector Mission shRNA

NAME	COMPANY
LENTIVIRUS (LV)-NON-TARGETING SHRNA	Sigma
CONTROL	
LV-HTT SHRNA#1 (TRCN0000322961)	Sigma
LV-HTT SHRNA#2 (TRCN0000019869)	Sigma
LV-ATF7IP SHRNA#1(TRCN0000020827)	Sigma
LV-ATF7IP SHRNA#2 (TRCN0000338504)	Sigma
LV-UBE2K SHRNA#1 (TRCN0000237896)	Sigma
LV-UBE2K SHRNA#2 (TRCN0000237893)	Sigma

Table 5: Kits

NAME	COMPANY
ADDGENE FIRELAB KIT	Addgene
FUGENE	Promega
NORMOCIN	InvivoGen
PIERCE BCA PROETIN ASSAY KIT	Fisher Sientific
QIAGEN LONGRANGE 2STEP RT-PCR KIT	Quiagen
QIAGEN-TIP 20	Quiagen
QUANTA Q FLEX REVERSE TRANSCRIPTION KIT	VWR
RNA BEE	Gentaur
SSOADVANCED SYBR GREEN SUPERMIX	Bio-Rad
TMTSIXPLEX ISOBARIC MASS TAG KIT PROTOCOL	Thermo Scientific

Table 6: qRT-PCR Primers

GENE	FORWARD	REVERSE
АСТВ	CTGGCACCCAGCACAATG	CCGATCCACACGGAGTACTTG
GAPDH	GCACCGTCAAGGCTGAGAAC	GGATCTCGCTCCTGGAAGATG
HTT F	TGCAGCCCTGTCCTTTCAAG	CTCCAAGGCTTCTTCTTCTCCTAA
ATF7IP F	CACTGAACTACAGGCCAAGATAGC	GGTGGATGTTCATGTCTTTTCTTAAG
OCT4 F	GGAGGAAGCTGACAACAATGAAA	GGCCTGCACGAGGGTTT
NANOG F	AAATCTAAGAGGTGGCAGAAAAACA	GCCTTCTGCGTCACACCATT
DPPA4 F	CTGGTGCCAACAATTGAAGCT	AGGCACACAGGCGCTTATATG
SOX2 F	TGCGAGCGCTGCACAT	TCATGAGCGTCTTGGTTTTCC
PAX6 F	CATACCAAGCGTGTCATCAATAAAC	TGCGCCCATCTGTTGCT
NESTIN F	TGAAGGGCAATCACAACAGG	TGACCCCAACATGACCTCTG
MAP2	AAAGAAGCTCAACATAAAGACCAGACT	GTGGAGAAGGAGGCAGATTAGC
FGF5 F	ACGAGGAGTTTTCAGCAACAAAT	TTGGCACTTGCATGGAGTTTT
MSX1 F	CTCCGCAAACACAAGACGAAC	CACATGGGCCGTGTAGAGTC
ALB F	TGAGGTTGCTCATCGGTTTAAA	GCAATCAACACCAAGGCTTTG
GATA4 F	TCCGTGTCCCAGACGTTCTC	GAGAGGACAGGGTGGATGGA
GATA6 F	AGCGCGTGCCTTCATCA	GTGGTAGTTGTGGTGTGACAGTTG
ASCL2	CGCGCGATCACATTCTGTAA	TCGCAGATTTCGCCAGTTG
GBX1	TTTCTTCCCTCTGTTCGCCT	GGAAGGCCGAAAGAAAGCAA
SMC1B	GAGTGAGGGCAGAGAACAGG	CCTTCATCTCAGGGGGCTCC
ADGRB1	TTGTGATGGTGTTGGTGCTG	ACCATCATCACCACCACCAT
UBE2K	CGCGGTGCAGCGAATC	TTGCTCGTCTCCTCGCTCTT
ZFP42	CCTGCAGGCGGAAATAGAAC	GCACACATAGCCATCACATAAGG
AADC	GGACCCCACTTACCTGAAGCA	CTGCCAATGCCGGTAGTCA
TH+	TGTCCACGCTGTACTGGTTCAC	CGGCACCATAGGCCTTCA
TUJ1	GGCCAAGTTCTGGGAAGTCA	CGAGTCGCCCACGTAGTTG
SYN	CGCAGTGGAAGCGCTACA	CCCACCACCTCAATGATGTG
NEUN	ACCAACGGCTGGAAGCTAAA	GCATAGAATTCAGGCCCGTAGA
GABAR	TGCGAAGGACAGTGGAGAAGT	GAGGGCGGATGGAGATATCC
NEFL	GCTATGCAGGACACGATCAACA	TTAGGTATCGTGCCATTTCACTCTT
NEFM	CAGGACCTCCTCAACGTCAAG	CCTGCAAATGTGCTAAATCTAGTCTCT
SOX1	GCTGACACCAGACTTGGGTT	GTGCTTGGACCTGCCTTACT

Table 7: Electrical devices

DEVICE	COMPANY
ACHRO-PLAN 10X	ZEISS
AGILENT 2100	Bioanalyzer
AXIOCAM 506 MONO	ZEISS
AXIO ZOOM.V16	ZEISS
BINDER CB-150	BINDER GmbH
BIORUPTOR SONICATOR	Diagenode
C1000 TOUCH THERMAL CYCLER	Bio-Rad
CFC384 REAL-TIME SYSTEM	Bio-Rad
DRI-BLOCK DB-2D	Techne
EC-PLAN-NEOFLUAR 20X-40X	ZEISS
ENSPIRE MULTIMODE PLATE READER	Perkin Elmer
2300	
EPPENDORF 5430R, 5424, 5810R	Eppendorf
FUSION SOLO	Vilber Lourmat
HANNA INSTRUMENTS HI3220	HANNA Instruments GmbH
HEIDOLPH UNIMAX 1010	Heidolph Instruments GmbH
ILLUMINA HISEQ 4000 SEQUENCER	Illumina
IMAGER. Z1	ZEISS
INCUCELL MMM	MMM group
MINI TRANS-BLOT CELL	Bio-Rad
MINI-PROTEAN TGX, 10% ;10W; 10	Bio-Rad
MINI-PROTEAN TETRA CELL	Bio-Rad
MINI-SUB CELL GT SYSTEM W/ 7X7	Bio-Rad
MINI-TRANS-BLOT MODULE	Bio-Rad
NANODROP 8000	ThermoFisher Scientific
POWERPAC BASIC HC	Bio-Rad
PRECISA XB4200C	Precisa Gravimetrics AG
S1000 THERMAL CYCLER	Bio-Rad
SCANLAF CLASS 2 MARS	Labogene
SHAKING PLATFORM RM S-30V	M. Zipper GmbH
STEREO DISCOVERY.V8	ZEISS
THERMOMIXER COMFORT	Eppendorf
VTX-3000L MIXER UZUSIO	LMS Co., Ltd
ZEISS APOTOME .2	ZEISS
ZEN IMAGING SOFTWARE	ZEISS

2.2 Methods

2.2.1 Cell Culture

2.2.1.1 hESC culture and differentiation

hESC/iPSC lines were maintained on Geltrex (ThermoFisher Scientific) coated plates using mTeSR1 (Stem Cell Technologies). Undifferentiated colonies were passaged using dispase (2 mg ml⁻¹), and colonies were scraped with a glass pipette. Genetic identity of H9 and H1 hESCs was assessed by short tandem repeat (STR) analysis using the Promega PowerPlex 21 system (Promega Corporation) by Eurofins Genomics (Germany). The H9 and H1 hESC lines used in this study match exactly the known STR profile of these cells across the 8 STR loci analyzed. All the cell lines used in this study were tested for mycoplasma contamination at least once every three weeks and no mycoplasma contamination was detected. Research involving hESC lines was performed with approval of the German Federal competent authority (Robert Koch Institute).

Neural differentiation of hESCs/iPSCs was performed following the monolayer culture method with STEMdiff Neural Induction Medium (Stem Cell Technologies) based on Chambers, S. M. et al.¹³⁰.

The hESCs were rinsed once with PBS and 1 ml Gentle Dissociation Reagent (Stem Cell Technologies) was added. After 10 min at 37°C the pluripotent stem cells were gently dislodged using a p1000 pipette and 2ml of Dulbecco's Modified Eagle Medium (DMEM)-F12 + 10 μ M ROCK inhibitor (Abcam) were added. Accordingly, cells were centrifuged at 300*g* for 5 min in a 15 ml falcon. Cells were re-suspended on STEMdiff Neural Induction Medium + 10 μ M ROCK inhibitor and plated on polyornithine (15 μ g ml⁻¹)/laminin (10 μ g ml⁻¹)-coated plates (200,000 cells cm⁻²). Following this protocol, we were able to induce neural differentiation of H9, H1 and iPSCs.

For pan-neuronal differentiation, NPCs were dissociated with 1 ml Accutase (Stem Cell Technologies) and plated on polyornithine $(15 \ \mu g \ ml^{-1})$ /laminin (10 $\ \mu g \ ml^{-1}$)-coated plates in neuronal differentiation medium consisting of Dulbecco's Modified Eagle Medium (DMEM)/F12, B27, N2 (ThermoFisher Scientific), 1 $\ \mu g \ ml^{-1}$ laminin (ThermoFisher Scientific), 20 ng ml⁻¹ GDNF (Peprotech), 20 ng ml⁻¹ BDNF (Peprotech), 20 ng ml⁻¹ BDNF (Peprotech), 20 nM ascorbic acid (Sigma) and 1 mM dibutyryl-cyclic AMP (Sigma). Cells were

differentiated for 1 month (otherwise the time is indicated in the respective figures), with weekly feeding of neuronal differentiation medium.

Endoderm differentiation of H9 hESCs was performed using STEMdiff Definitive Endoderm Kit (Stem Cell Technologies).

2.2.1.2 Lentiviral infection of hESCs.

Transient infection experiments for shRNA screen were performed as follows. hESC colonies growing on Geltrex were incubated with mTesR1 medium containing 10 μ M ROCK inhibitor (Abcam) for 2 h. For de-attaching the cells 1 l Accutase per well were added for 5 min at 37°C and centrifuged at 300*g* for 5 min in a 15 ml falcon. Cells were then re-suspended with a p1000 pipette in order to produce single cells. Hundred thousand cells per well were seeded on Geltrex coated W12 plates and incubated with mTesR1 medium containing 10 μ M ROCK inhibitor. The next day cells were infected with 5 μ l of concentrated lentivirus. Plates were centrifuged at 800*g* for 1 h at 30 °C. Cells were fed with fresh media on day 2 after infection to remove virus. On day 3 cells were selected for lentiviral integration using 2 μ g ml⁻¹ puromycin (ThermoFisher Scientific). Cells were then collected for qPCR experiments after 4–6 days of infection.

For UBE2K shRNA experiments we generated stable transfected hESCs. To obtain shRNA stable lines, hESC colonies growing on Geltrex coated plates were incubated with mTesR1 medium containing 10 μ M ROCK inhibitor for 1 h. For dislodging the cells 1 ml Accutase per well were added for 5 min at 37°C and centrifuged at 300*g* for 5 min in a 15 ml falcon. Cells were then re-suspended with a p1000 pipette to obtain single cells. Fifty thousand cells were infected with 20 μ l of concentrated lentivirus in the presence of 10 μ M ROCK inhibitor for 1 h. Cell suspension was centrifuged to remove virus, pipetted up and down to obtain individual cells, and plated on a feeder layer of mitotically inactive mouse embryonic fibroblasts (MEFs) in hESC media (DMEM/F12, 20% knockout serum replacement (ThermoFisher Scientific), 0.1 mM non-essential amino acids, 1 mM L-glutamine, β -mercaptoethanol and 10 ng ml⁻¹ bFGF (Joint Protein Central)) supplemented with 10 μ M ROCK inhibitor. After a few days in culture, allowing small hESC colonies to grow, knockdown cells were selected by 1 μ g ml⁻¹ puromycin treatment for 2 days. Colonies were then passaged onto Geltrex coated plates to establish new hESC lines.

2.2.1.3 Immunocytochemistry.

Human cells were fixed with paraformaldehyde (4% in PBS) for 15 min, followed by permeabilization (0.2% Triton X-100 in PBS for 10 min) and blocking (3% BSA in 0.2% Triton X-100 in PBS for 10 min). Human cells were incubated in primary antibody for 2 h at room temperature (Rabbit anti-HTT (Cell Signaling Technologies #5656, 1:100), Mouse anti-OCT4 (Stem Cell Technologies, #60093, 1:200), Rabbit anti-PAX6 (Stem Cell Technologies, #60094, 1:300), Mouse anti-MAP2 (Sigma, #1406, 1:500), Rabbit anti-H3K9me3 (Abcam #8898, 1:500), Mouse anti-SETDB1 (Abcam, #107225, 1:200) and Rabbit anti-ATF7IP (Proteintech #14699-1-AP, 1:500)). Then, cells were washed with 0.2% Triton-X/PBS and incubated with secondary antibody (Alexa Fluor 488 goat antimouse (ThermoFisher Scientific, A-11029, 1:500), Alexa Fluor 568 goat anti-rabbit (ThermoFisher Scientific, A-11011, 1:500), and 2 μ g ml⁻¹ Hoechst 33342 (Life Technologies, #1656104) for 1 h at room temperature. The cover slips were washed with 0.2% Triton-X/PBS and distilled water before mounting.

2.2.2 Gene expression analysis

RNA isolation and quantitative RT–PCR. For human cell samples, total RNA was extracted using RNAbee (Tel-Test Inc.). cDNA was generated using qScript Flex cDNA synthesis kit (Quantabio). SybrGreen real-time qPCR experiments were performed with a 1:20 dilution of cDNA using a CFC384 Real-Time System (Bio-Rad) following the manufacturer's instructions. Data were analyzed with the comparative $2\Delta\Delta$ Ct method using the geometric mean of ACTB and GAPDH as housekeeping genes.

2.2.3 Biochemistry

2.2.3.1 Sample preparation for quantitative proteomics and analysis

For the comparison between Non-targeting control and HTT KD H9 hESCs, we performed label-free quantitative (LFQ) proteomics. Cells were collected in urea buffer (8 M urea, 50 mM ammonium bicarbonate and 1x complete protease inhibitor mix with EDTA (Roche)), homogenized with a syringe and cleared using centrifugation (16,000g, 20 min). Supernatants were reduced (1 mM DTT, 30 min), alkylated (5 mM iodoacetamide (IAA), 45 min) and digested with trypsin at a 1:100 w/w ratio after diluting urea concentration to 2 M. The next day samples were cleared (16,000g, 20 min) and supernatant was acidified. Peptides were cleaned up using stage tip extraction¹³¹. The liquid chromatography tandem mass spectrometry (LC-MS/MS) equipment consisted out of an EASY nLC 1000 coupled to the quadruple based QExactive instrument (Thermo Scientific) via a nano-spray electroionization source. Peptides were separated on an inhouse packed 50 cm column (1.9 µm C18 beads, Dr.Maisch) using a binary buffer system: A) 0.1% formic acid and B) 0.1% formic acid in ACN. The content of buffer B was raised from 7% to 23 % within 120 min and followed by an increase to 45% within 10 min. Then, within 5 min buffer B fraction was raised to 80% and held for further 5 min after which it was decreased to 5% within 2 min and held there for further 3 min before the next sample was loaded on the column. Eluted peptides were ionized by an applied voltage of 2.2 kV. The capillary temperature was 275°C and the S-lens RF level was set to 60. MS1 spectra were acquired using a resolution of 70,000 (at 200 m/z), an Automatic Gain Control (AGC) target of 3e6 and a maximum injection time of 20 ms in a scan range of 300-1750 Th. In a data dependent mode, the 10 most intense peaks were selected for isolation and fragmentation in the HCD cell using normalized collision energy of 25 at an isolation window of 2.1 Th. Dynamic exclusion was enabled and set to 20 s. The MS/MS scan properties were: 17,500 resolution at 200 m/z, an AGC target of 5e5 and a maximum injection time of 60 ms. All label-free proteomics data sets were analyzed with the MaxQuant software (release 1.5.3.8). We employed the LFQ mode¹³² and used MaxQuant default settings for protein identification and LFQ quantification. All downstream analyzes were carried out on LFQ values with Perseus (v. 1.5.2.4)¹³³.

2.2.3.2 Western blot

Cells were washed twice with PBS, then scraped from tissue culture plates and lysed in protein cell lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 10 EDTA, 50 mM NaF, 1% Triton X-100, 0.1% SDS supplemented with 20 μ g ml⁻¹ Aprotinin, 2 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride and protease inhibitor (Roche)) by incubating samples for 10 min on ice and homogenization through syringe needle (27G). Cell lysates were centrifuged at 10,000*g* for 10 min at 4°C and the supernatant was collected. Protein concentrations were determined with a standard BCA protein assay (Thermo Scientific). Approximately 10–20 μ g of total protein were separated by SDS–PAGE, transferred to PVDF membranes (Millipore) and subjected to immunoblotting.

2.2.3.3 Protein immunoprecipitation for interactome analysis.

hESCs were lysed in modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 M NaCl, 1% IgPal, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF) supplemented with protease inhibitor (Roche). Lysates were centrifuged at 10,000*g* for 10 min at 4°C. Then, the supernatant was collected and incubated with HTT antibody (Cell Signaling Technology, #5656, 1:50) for 30 min and subsequently with 100 µl Protein A beads (Miltenyi) for 1 h on the overhead shaker at 4°C. As a control, the same amount of protein was incubated with anti-FLAG antibody (SIGMA, F7425, 1:100) in parallel. After this incubation, supernatants were subjected to magnetic column purification. Three washes were performed using wash buffer 1 (containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5% glycerol and 0.05% IgPal). Next, columns were washed five times with wash buffer 2 (containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl). Then, columns were subjected to incolumn tryptic digestion containing 7.5 mM ammonium bicarbonate, 2 M urea, 1 mM DTT and 5 ng ml⁻¹ trypsin. Digested peptides were eluted using two times 50 µl of elution buffer 1 containing 2 M urea, 7.5 mM Ambic, and 5 mM IAA. Digests were incubated over night at room temperature with mild shaking in the dark. Samples were stage-tipped the next day for label-free quantitative proteomics and analyzed with MaxQuant software. The downstream analyzes were carried out on LFQ values with Perseus (v. 1.5.2.4).

2.2.3.4 RNA sequencing.

Total RNA was extracted using RNAbee (Tel-Test Inc.). Libraries were prepared using the TruSeq Stranded mRNA Library Prep Kit. Library preparation started with 1 µg total RNA. After selection (using poly-T oligo-attached magnetic beads), mRNA was purified and fragmented using divalent cations under elevated temperature. The RNA fragments underwent reverse transcription using random primers followed by second strand cDNA synthesis with DNA Polymerase I and RNase H. After end repair and Atailing, indexing adapters were ligated. The products were then purified and amplified (20 µl template, 14 PCR cycles) to create the final cDNA libraries. After library validation and quantification (Agilent 2100 Bioanalyzer), equimolar amounts of library were pooled. The pool was quantified by using the Peqlab KAPA Library Quantification Kit and the Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced on an Illumina HiSeq 4000 sequencer with a paired- end (2x 75bp) protocol. We used the human genome sequence and annotation (EnsEMBL79) together with the splice-aware STAR read aligner¹³⁴ (release 2.5.1b) to map and assemble our reference transcriptome. Subsequent transcriptome analyzes on differential gene and transcript abundance were carried out with the cufflinks package¹³⁵ cuffdiff program (version 2.2.1). Transcripts showing a log2-fold change at a FDR < 0.05 were retained as significantly differentially expressed.

2.2.3.5 Chromatin Immunoprecipitation ChIP-sequencing

Cells were cross linked by adding 1% formaldehyde to the medium on the tissue culture dish and incubated on balancer for 10 min at RT. Cross linked cells were quenched with 0,125 M glycine on a balancer for 10 min at RT and then scraped and transferred to a 15 ml falcon on ice. Centrifugation at 1200 rpm for 5 min at 4°C and afterwards 2 washing steps with 5 ml PBS 1x / PMSF 1 mM followed. The pellets were re-suspended with 5 ml lysis buffer 1 (50 mM Hepes, 140 mM NaCL, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% TX-100 and protease inhibitor (Roche)) and rotated vertically at 4°C for 10

min. Cell suspensions were centrifuged at 4°C and 1350g for 5 min. The pellets were resuspended with 5 ml lysis buffer 2 (10 mM Tris, 200 mM NaCL, 1 mM EDTA, 0.5 mM EGTA) and rotated vertically at RT for 10 min. Again, cell suspensions were centrifuged at 4°C and 1350g for 5 min with a re-suspension step of the pellets with 1.5 ml lysis buffer 3 (10 mM Tris, 100 mM NaCL, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-Lauroylsarcosine) and a p1000 to obtain single cells. Then, cells were sonicated at 4°C and centrifuged for 10 min at 16.000*g* at 4°C. The sonicated lysate was treated with 1% Triton X-100 and 75 µl were taken and stored as an input at -20°C. 750 µl were incubated with 10 µg antibody rotating vertically ON at 4°C. The next day, magnetic Dynabeads G (ThermoFisher) at 10x volume of Antibody were aliquoted into a new microtube. The beads were washed 3 times in cold blocking solution (0,5% BSA, 1 PBS) and with the tubes placed on the magnetholder. 1 ml of antibody-chromatin mix were added to the beads and rotated vertically for at least 2 h at 4°C. Then the beads were washed 5x with cold RIPA wash buffer (50 mM Hepes, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate) with the tubes placed on the magnetholder. Afterwards, the beads were washed 1x with 1 ml TE+ 50 mM NaCl on ice and samples were centrifuged for 3 min at 950g and 4°C. After removing all liquid from the beads, 210 µl elution buffer (50 mM Tris, 10 mM EDTA, 1% SDS) were added and mixed by flicking the tube. The proteins bound to the antibodies were eluted for 15 min at 65°C. Finally, beads were centrifuged for 1 min at 1600g at RT and placed on a magnetholder to settle and supernatants were transferred into a new tube. To reverse crosslinking, 3x volume of the elution buffer were added to the input and were incubated with the ChIP samples at 65°C ON. The next day, 1x volume of TE buffer and 0.2 mg ml⁻¹ RNase were added and incubated for 1h at 37°C. Afterwards 0.2 mg ml⁻¹ Proteinase K were added and left for 2 h at 55°C to digest proteins. The DNA was phenolchloroform extracted at RT with 1x volume of 25:24:1 phenol-chloroform-isoamyl alcohol and centrifuged for 5 min, at maximum speed at RT, to separate layers, 1x volume chloroform were added to extract the DNA and centrifuged again. The upper layer containing the DNA, was transferred to a new tube for ethanol precipitation as follows: 1/10 of NaOAc 3 M, 1 µl 20 mg ml⁻¹ glycogen, 2x volume of ice cold ethanol were added on ice and incubated for 30 min at -80°C to precipitate DNA. A centrifugation at max speed at 4°C was performed for 30 min to pellet the DNA. Supernatants were removed and 0.5 ml ice cold 70% ethanol were added to the pellets and centrifuged at 7500 rpm for 5 min. After removing the remaining ethanol, the pellets were air dried at RT and re-suspended in 40 µl dH2O and concentration of DNA determined.

2.2.3.6 Bioinformatic analysis of ChIP-sequencing

ChIP-Seq data was analyzed by using QuickNGS (Next-Generation Sequencing) pipeline. ChIP-Seq reads was mapped to the Homo Sapiens (Ensembl database version 87) using BWA¹³⁶. Quality check of the sequencing data were performed with FastQC (version 0.10.1.). For peak calling used MACS2 (version 2.0.10)¹³⁷. QuickNGS pipeline identifies all genes that are 2000 bp up- or downstream from the MACS2 peaks. The peak sequences are analyzed for enrichment of transcription factor binding motifs using MEME-ChIP (Version 4.10.0)¹³⁸. The results comprise lists of significant peaks and reports for motif enrichment. The result was uploaded into MySQL database. Basic QC statistics and password-protected track hubs for the UCSC Genome Browser with direct hyperlinks for visualization were used.

2.2.4 Statistics

PRISM 6 software was used for statistical analysis to determine median and percentiles. P-values were calculated using the log-rank (Mantel–Cox) method. The P-values refer to a single experiment. For the rest of experiments, unless stated otherwise, two-tailed unpaired students't-test was used to check for statistical significance. Error bars represent standard error of the mean (S.E.M.). (*p<0.05 **p<0.01 ***p<0.001)

3 Results

3.1 The role of HTT in epigenetic control of embryonic stem cell differentiation

3.1.1 HTT interacts with the chromatin regulator ATF7IP

In order to find out about the potential role of HTT as an epigenetic regulator in hESCs, in a first attempt we assessed its expression levels and abundance in hESCs compared to differentiated cells. Strikingly, we found that hESCs exhibit higher expression of HTT than their differentiated neuronal counterparts at both protein and mRNA levels (Figure 1A-B), supporting a role of HTT in hESC identity.

To determine the protein binding partners of HTT in hESCs, we performed coimmunoprecipitation experiments followed by a single shot label-free proteomic approach. We quantified approximately 2000 proteins and compared protein abundance in HTT antibody pulldowns with control FLAG antibody pulldowns in both hESCs and terminally differentiated neurons. Although HTT was the most enriched protein in both hESCs and neurons (Figure 1C-D), hierarchical clustering revealed a clear separation in HTT-interacting proteins between these cells (Figure 2).




Figure 1. HTT interacts with the chromatin factor ATF7IP in both hESCs and neurons. A, Western blot analysis of H9 hESCs and their differentiated counterparts with antibody to HTT. β -actin is the loading control. B, HTT relative expression to H9 hESCs represents the mean ± s.e.m. (n= 3 independent experiments). Statistical comparisons were made by Student's t-test for unpaired samples. p-value: **(p< 0.01). C, Volcano plot of HTT interactome in H9 hESCs (n= 3). –log (p-value) of a two-tailed t-test is plotted against the log2 ratio of protein label-free quantification (LFQ) values from co-immunoprecipitation (co-IP) experiments using HTT antibody compared to control co-IP with FLAG antibody. Blue coloured dots beyond the curved lines indicate significance after correction for multiple testing. D, Volcano plot of HTT interactome in neurons (n= 4). Red coloured dots beyond the curved lines demonstrate significance after correction for multiple testing. E, Scatterplot of protein enrichments in HTT co-IP from hESCs and neuronal cells. Significant intrinsic interactors in neurons, hESCs as well as common interactors in both cell types are indicated in red, blue and magenta, respectively. F, Venn diagram represents the number of specific and common co-immunoprecipitated proteins with HTT antibody in hESCs and neurons. G, Co-immunoprecipitation with HTT and FLAG antibodies in H9 hESCs followed by western blot with antibodies to HTT, SETDB1 and ATF7IP. The images are representative of two independent experiments.

Immunoprecipitation of HTT itself was more effective in hESCs when compared with neurons (Figure 1 E), consistent with increased HTT expression in hESCs (Figure 1 A). On the contrary, a major population of proteins specifically interacted with HTT in neurons, but not in hESCs (Figure 1 E-F).

Protein names	T-test difference	-log P-value
HTT	9.96	1.25
F8A1	7.69	1.33
NUP205	7.00	2.23
ASPSCR1	5.61	4.17
ATF7IP	5.55	1.08
VCP	5.30	2.01
U2AF2	1.76	3.42

Table 8. Protein interactors of HTT in H9 hESCs. Protein label-free quantification (LFQ) values from coimmunoprecipitation (co-IP) experiments using HTT antibody compared to control co-IP with FLAG antibody. (Student's t-test, n = 3, FDR< 0.05).

Whereas 102 proteins passed the criterions for significant interaction with HTT in neurons (Figure 1 D), only 7 proteins were significantly detected in hESCs (Figure 1 C,E and Table 8). Among them, NUP205 and U2AF2 were exclusively co-immunoprecipitated in hESCs whereas the other 5 proteins were also detected in neurons (Figure 1 F), including HTT itself and its known interactors F8A1¹³⁹ and VCP¹⁴⁰. In both hESCs and neurons, we found a novel interaction of HTT with ATF7IP (Figure 1 C-D), a factor that binds the H3K9 methyltransferase SETDB1 to regulate heterochromatin formation^{116,141,142-144}. Notably, co-immunoprecipitation experiments followed by western blot indicated that HTT could form a complex with ATF7IP and SETDB1 (Figure 1G).




Figure 2. Proteomic analysis of co-immunoprecipitation (Co-IP) experiments with HTT and control FLAG antibodies in H9 hESCs and neurons. Protein label-free quantification (LFQ) intensities indicating protein amounts are indicated by color code (red= high, blue= low abundance). Proteins (rows) and samples (columns) were clustered by Euclidean distance (neurons (n= 4), hESCs (n= 3). A clear separation of sample types and pulldowns was observable.

3.1.2 Loss of HTT induces trimethylation of H3K9 in hESCs

ATF7IP stimulates the H3K9 methyltransferase activity of SETDB1, facilitating H3K9 trimethylation and concomitant heterochromatin formation^{116,141}. Knockdown of ATF7IP dramatically diminished nuclear SETDB1 levels as well as trimethylation of H3K9 in hESCs (Figure 3 A-B), indicating that ATF7IP also regulates H3K9me3 in these cells. Interestingly, reduction of H3K9 trimethylation upon loss of ATF7IP did not affect the expression of pluripotency markers (Figure 3 C).

Given that HTT interacted with ATF7IP (Figure 1 C-G), we assessed whether modulation of HTT impairs H3K9 trimethylation in hESCs. Indeed, we observed a dramatic increase in H3K9me3 levels upon HTT knockdown (Figure 3 D-E). Since hESCs

can vary in their characteristics, we analyzed an independent hESC line and obtained similar results (Figure 4 A-B). With the role of HTT in brain development⁷², we asked whether alterations in H3K9me3 levels of hESCs are transmitted to their NPC counterparts. For this purpose, we performed neural induction and found that the expression of the early neuroectodermal marker PAX6¹⁴⁵ as well as other neural markers were triggered at the same extent in both control and HTT KD cells (Figure 5 A-C). These results indicate that HTT is not required for hESC commitment into NPCs. However, NPCs-derived from HTT KD hESCs maintained high levels of H3K9me3 compared with control NPCs (Figure 3 F-G).




Figure 3. Loss of HTT induces trimethylation of H3K9me3. A, Immunocytochemistry of H9 hESCs with antibodies to ATF7IP and SETDB1. Hoechst staining was used as a marker of nuclei. Scale bar represents 10 μ m. B, Western blot analysis of H9 hESC lysates with antibodies to ATF7IP, H3K9me3, and total H3. β -actin is the loading control. C, qPCR analysis of pluripotency markers. Graph (relative expression to NT shRNA H9 hESCs) represents the mean ± s.e.m. of three independent experiments. D, Western blot analysis of H9 hESC lysates with antibodies to HTT, H3K9me3 and total

H3. E, Immunocytochemistry of H9 hESCs with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar represents 20 μ m. F, Western blot analysis of H9 NPC lysates with antibody to H3K9me3 and total H3. G, Immunocytochemistry of H9 NPC with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar represents 20 μ m. All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), ***(P<0.001).




Figure 4. Loss of HTT induces trimethylation of H3K9me3 in H1 hESCs. A, Western blot analysis with antibody to HTT, H3K9me3 and total H3. β -actin is the loading control. B, Immunocytochemistry of H1 hESCs with antibody to H3K9me3. Hoechst staining was used as a marker of pluripotency of nuclei. Scale bar represents 20 μ m.

Loss of HTT did not affect the total levels of ATF7IP (Figure 6 A). However, loss of HTT changed the nuclear distribution of ATF7IP, which markedly concentrated in specific areas in contrast to the diffused pattern characteristic of control hESCs (Figure 6 A).




Figure 5. HTT KD hESCs retain their ability to differentiate into NPCs. A, Immunocytochemistry after 10 days of neural differentiation assay. OCT4, PAX6, and DAPI staining were used as markers of pluripotency, neuroectodermal differentiation, and nuclei, respectively. Scale bar represents 20 μ m. B, Western blot analysis with antibody to PAX6 in early NPCs (10 days after neural induction). β -actin is the loading control. C, Data represent the mean \pm s.e.m. of relative expression levels to NT shRNA early NPCs (n= 9).

Notably, loss of HTT induced the interaction of ATF7IP with SETDB1 as well as other alterations in the interactome of ATFTIP (Figure 6 B). Taken together, these preliminary results indicate that HTT modulates the interaction of SETDB1 with its activator ATF7IP to control trimethylation of H3K9.




Figure 6. HTT modulates ATF7IP and its interaction with SETDB1. A, Immunocytochemistry of H9 hESCs with antibody to ATF7IP. Hoechst staining was used as a marker of nuclei. Scale bar represents 10 μ m. B, Co-immunoprecipitation with ATF7IP and FLAG antibodies in H9 hESCs followed by western blot with antibodies to SETDB1 and ATF7IP. The images are representative of two independent experiments.

3.1.3 Aberrant H3K9me3 marks upon HTT knockdown impairs induction of distinct neural genes

Next, we asked whether the knockdown of HTT would alter the expression of marker proteins of pluripotency and neuronal differentiation. Knockdown of HTT did not impair the levels of pluripotency markers of hESCs (Figure 7 A-B). Moreover, we found no differences in the markers of the distinct germ layers (Figure 7 C).




Figure 7. Altered H3K9me3 marks upon HTT knockdown impairs the induction of distinct neural genes. A, Western blot analysis of H9 hESC lysates with antibodies to HTT, OCT4 and SOX2. β -actin is the loading control. B, Knockdown of HTT does not change the mRNA levels of pluripotency markers. Graph (relative expression to nontargeting (NT) shRNA H9 hESCs) represents the mean ± s.e.m. (n= 9). C, qPCR analysis of ectodermal (PAX6, NES, FGF5), mesodermal (MSX1) and endodermal (ALB, GATA4, GATA6) germ layer markers. Graph (relative expression to NT shRNA hESCs) represents the mean ± s.e.m. (n= 8). E, qPCR analysis of H9 hESCs. Graph (relative expression to NT shRNA) represents the mean ± s.e.m. of three independent experiments with two biological replicates. F, qPCR analysis after 20 days of neural induction. Data (relative expression to NT shRNA cells) represent three independent experiments. All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), ***(P<0.001), **** (P<0.0001).

To further assess changes induced by loss of HTT, we analyzed the proteome of hESCs. In quintuplicate analysis, we identified 6610 proteins, of which we quantified 4820 in all samples. Hierarchical clustering revealed separation of HTT knockdown and NT samples based on global protein expression profiles (Figure 8 A). The quantitative analysis revealed that 186 of proteins were changed in HTT shRNA#1 hESCs as compared to NT control, whereas 64 of proteins were changed in HTT shRNA#2 hESCs as compared to NT hESCs (Figure 8 B). Correlational analysis revealed a moderate, but significant correlation between HTT shRNA #1 and HTT shRNA #2 KD hESC lines (Figure 8 C). To examine the function of these proteins altered on HTT KD, we performed 2D Gene Ontology (GO) enrichment (Figure 8 D).





Figure 8. Analysis of the proteome of HTT KD hESCs. A, Label-free quantification (LFQ) of 4820 proteins reveals partial separation of HTT knockdown and control non-targeting (NT) H9 hESCs (n= 5). Proteins (rows) and samples (columns) are clustered according to euclidean distance (red= high, blue= low abundance). B, Volcano plot of LFQ intensities in HTT KD hESC lines (shRNA #1 and #2) as compared to NT shRNA. The significance of a two-tailed t-test is plotted against the log2 fold change of LFQs. Proteins coloured in green are termed significant after correction of multiple testing (FDR= 0.05, s0= 1). C, Comparison of protein expression ratios in HTT shRNA #1 vs HTT shRNA #2 hESCs. Protein changes in both conditions correlated significantly (-log(p)=14, Pearson's correlation). Kernel density is color-coded. D, 2D GO enrichment for GO terms, uniprot key words and KEGG pathways. Significantly altered terms changed in both conditions are labelled with their name (FDR < 0.05).

The analysis revealed that proteins related to HD were significantly enriched in the decreased protein population of HTT KD hESCs. Furthermore, the downregulated protein population was also significantly enriched for proteins involved in membrane function and organization (Figure 8 D). Proteins increased on HTT KD hESCs were significantly enriched for proteins involved in lipid biosynthesis, but also transcription, chromatin regulation and extracellular matrix structural constituents (Figure 8 D). Besides HTT, we found that other 14 (9 upregulated, 5 downregulated) proteins were significantly changed in both HTT KD hESC lines (Table 9). Among them, we found an increase in the levels of laminin subunits (*i.e.*, LAMA1, LAMB1 and LAMC1) and nidogen-1, a protein tightly associated to laminin (Table 9).

		T-test difference		-log P-value	
Gene names	Protein names	HTT shRNA #1	HTT shRNA #2	HTT shRNA #1	HTT shRNA #2
SUV39H1	Histone-lysine N- methyltransferase SUV39H1	5.07	3.92	5.87	1.47
ARHGEF11	Rho guanine nucleotide exchange factor 11	2.05	1.97	2.70	1.83
EML1	Echinoderm microtubule- associated protein-like 1	1.87	1.79	3.19	2.36
TINAGL1	Tubulointerstitial nephritis antigen-like	1.51	1.60	2.70	1.77
LAMA1	Laminin subunit alpha-1	1.40	1.57	3.21	2.98
FOXK2	Forkhead box protein K2	0.95	0.88	1.96	1.82
LAMB1	Laminin subunit beta-1	0.82	1.26	1.68	2.43
NID1	Nidogen-1	0.77	0.99	1.93	1.96
LAMC1	Laminin subunit gamma-1	0.73	1.03	1.99	2.41
PRPS1	Ribose-phosphate pyrophosphokinase;Ribose- phosphate pyrophosphokinase 1	-0.51	-0.46	5.36	5.58
HLA-A;MHC class I HLA-A;HLA;HLA- A*0226;HLA-A*02	HLA class I histocompatibility antigen. A-2 alpha chain;HLA class I histocompatibility antigen. A-31 alpha chain;HLA class I histocompatibility antigen. A- 29 alpha chain	-0.54	-0.44	3.46	2.71
GRN	Granulins;Acrogranin;Paragr anulin;Granulin-1;Granulin- 2;Granulin-3;Granulin- 4;Granulin-5;Granulin- 6;Granulin-7	-0.58	-0.68	1.72	2.00
F8A1	Factor VIII intron 22 protein	-0.81	-1.45	3.19	1.93
HTT;HD	Huntingtin	-0.87	-1.98	2.75	3.11
TAGLN	Transgelin	-1.47	-0.87	4.17	2.53

Table 9. List of proteins significantly changed in both HTT knockdown hESC lines (shRNA #1 and shRNA #2). Means are calculated from the log2 of LFQ values (LFQ HTT shRNA hESCs/Non-targeting shRNA hESCs). Statistical comparisons were made by Student's t-test (n= 5, FDR< 0.05). Red= upregulated, blue = downregulated. Moreover, both HTT KD hESC lines exhibit a significant increase in SUV39H1, a H3K9 methyltransferase^{146,147} that can form multimeric complexes with other H3K9 methylases such as SETDB1¹⁴⁸ and, therefore, could contribute to the aberrant H3K9me3 levels observed in HTT KD hESCs.

Although this proteomic experiment reveals moderate changes induced by loss of HTT in hESCs, it also presents important limitations for our study. For instance, this approach could be not sensitive enough to detect low abundant proteins in hESCs such as transcriptions factors or proteins upregulated during differentiation. We hypothesized that H3K9me3 repressive marks could further decrease the expression of these genes in hESCs or, more importantly, diminish their induction during differentiation. To test this hypothesis, we performed chromatin immunoprecipitation (ChIP) assays of hESCs using an antibody to H3K9me3. We found a >2-fold enrichment for H3K9me3 marks in 2006 regions upon HTT knockdown. Among them, 61 contained coding regions, of which G0 biological process term analysis indicated the strongest enrichment for factors involved in transcriptional regulation (Figure 9).



GOBP terms

Figure 9. Significantly enriched GO Biological Processes in ChIP experiments with H3K9me3 antibody in HTT KD hESCs. The 61 genes enriched for H3K9me3 in ChIP experiments comparing HTT shRNA #1 and HTT shRNA #2 H9 hESCs with non-targeting shRNA H9 hESCs were analyzed for enriched GO Biological processes (p-value <0.05).

These regulators include 4 zinc finger proteins (ZNF135, ZNF559, ZNF572, ZNF844), 3 transcription elongation factors (TCEB3C, TCEB3CL, TCEB3CL2) and 3 developmental transcriptions (ASCL2, DLX3, GBX1). Besides these transcription factors, we found an enrichment for H3K9me3 in other genes important for nervous system formation, neuronal function, neurotransmission and synapse genesis/stabilization (*i.e.*,

CELSR1, CPEB1¹⁴⁹, SMC1B, ADRA2B, MRGPRX3). Dysfunctions in calcium homeostasis is one of the major alterations observed in HD neurons^{150,90}. Interestingly, we have found H3K9me3 enrichment in genes involved in calcium metabolism such as OTOP1, ARPP21 (an inhibitor of calmodulin-dependent enzymes in striatal neurons¹⁵¹) and OPRD1, which regulates neurotransmitter release by modulating calcium currents¹⁵². Prompted by these findings, we asked whether H3K9me3 marks induced by HTT knockdown results in decreased expression of these genes. In particular, we focused on the transcription factors ASCL2 and GBX1 because their important role in neural development. Notably, we did not observe significant changes in the expression of these genes at the hESC stage (Figure 7 E). Given the low expression of these genes in hESCs is triggered upon neural differentiation (Figure 7 F), we hypothesized that H3K9me3 marks impair this induction. Indeed, loss of HTT in hESCs dramatically diminished their ability to induce the expression of ASCL2 and GBX1 during differentiation (Figure 7 F). In addition, we confirmed that HTT knockdown also resulted in diminished expression of other H3K9me3-enriched genes at the NPC stage (i.e., SMC1B, ADGRB1) (Figure 10). Altogether, these results suggest that HTT regulates the expression of distinct neural genes via modulation of H3K9me3.




Figure 10. Knockdown of HTT in hESCs affects expression of SMC1B and ADGRB1 in their NPC counterparts. A, qPCR analysis of H9 hESCs. Graph (relative expression to non-targeting (NT) shRNA) represents the mean \pm s.e.m. of three independent experiments with two biological replicates. B, qPCR analysis after 20 days of neural induction. Data (relative expression to NT shRNA cells) represent three independent experiments. All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), **** (P<0.0001).

3.1.4 Knockdown of ATF7IP rescues H3K9me3 changes induced by mHTT

With the increased trimethylation of H3K9 in brain tissues of HD patients and mouse models¹¹¹⁻¹¹⁴, we asked whether HD-iPSCs also exhibit alterations in H3K9me3 levels. Indeed, we found that HD-iPSCs with medium (71) and large (180) polyQ expansions have increased H3K9me3 levels as detected by immunofluorescence (Figure 11 A).




Figure 11. Mutations in HTT reduces its interaction with ATF7IP and induces H3K9me3 levels. A, Immunocytochemistry of control iPSC #1, HD-iPSCs #1 (Q71) and HD-iPSCs #1 (Q180) with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar represents 20 µm. B, Co-immunoprecipitation with PolyQ-expanded HTT and total HTT antibodies in HD iPSC line #1 (Q71) followed by western blot with antibodies to PolyQ-expanded HTT, total HTT, ATF7IP and SETDB1. The images are representative of two independent experiments.

The HD-iPSC lines used in this study express one mutant copy of HTT but also one normal copy (Figure 11 B)¹⁵³, allowing us to assess differences in the interaction of ATF7IP with wild-type and mHTT within the same cell. To determine these differences, we performed co-immunoprecipitation experiments using either an antibody against total HTT or polyQ-expanded HTT⁵⁹. After we confirmed the later antibody only immunoprecipitated mHTT, we performed western blot against ATF7IP and SETDB1 (Figure 11 B). Strikingly, we could not detect ATF7IP or SETDB1 in polyQ-expanded HTT pulldowns whereas total HTT pulldown showed interaction with the chromatin factor and the H3K9 methyltransferase (Figure 11 B), indicating that mutations in the polyQ stretch impairs HTT interaction with ATF7IP and SETDB1.

Prompted by these findings, we examined whether loss of ATF7IP diminishes trimethylation of H3K9 in NPCs derived from HD-iPSCs (Figure 12 A). Indeed, we found

that ATF7IP knockdown is sufficient to reduce H3K9me3 levels in HD-NPCs (Figure 12 A). Since differentiation of HD-iPSCs generate NPCs that already present HD-related changes^{90,154}, one step further was to rescue H3K9me3 levels at the pluripotent state.




Figure 12. Knockdown of ATF7IP reduces H3K9me3 levels in HD-iPSCs without affecting their ability to differentiate into NPCs. A, 20 days after neural induction, knockdown of ATF7IP in NPCs decreases H3K9me3 levels as assessed by western blot experiments. The images are representative of two independent experiments. B, Western blot analysis of HD-iPSC line #2 (Q180) lysates with antibodies to H3K9me3 and total H3. β-actin is the loading control. C, Immunocytochemistry of control iPSC line #3 (Q21), HD-iPSC line #1 (Q71) and HD-iPSC line #2 (Q180) with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar represents 20 μm. D, qPCR analysis of pluripotency (OCT4, NANOG, SOX2) and neuroectoderm (PAX6, TUBB3) markers in the indicated control and HD iPSC lines upon ATF7IP knockdown. Graphs (relative expression to NT shRNA) represent the mean ± s.e.m. (n= 3-4). All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), **** (P<0.001).

Notably, knockdown of ATF7IP diminished H3K9me3 levels in HD-iPSCs (Figure 12 B-C and Figure 13). However, loss of ATF7IP did not affect the expression of distinct pluripotency and neuroectoderm markers in iPSC lines (Figure 12 D). Moreover, ATF7IP knockdown did not impair the ability of HD-iPSCs to differentiate into PAX6-positive cells (Figure 12 E-F). Collectively, these data suggest that modulation of ATF7IP can correct H3K9me3 dysregulation in HD-iPSCs without affecting their ability to generate neural cells.

HD-iPSCs #1 (Q71)




Figure 13. Loss of ATF7IP reduces H3K9me3 levels in HD-iPSCs. Western blot analysis of HD-iPSC line #1 (Q71) lysates with antibodies to H3K9me3 and total H3. β -actin is the loading control. Images are representative of two independent experiments.

3.2 The role of UBE2K in epigenetic control of embryonic stem cell differentiation

3.2.1 Loss of UBE2K impairs neurogenesis from hESCs

Previously, our laboratory has discovered that hESCs have an intrinsic ubiquitin proteasome system when compared to differentiated cells such as neurons. For instance, we observed changes in the expression of multiple E3 enzymes as well as several E2 enzymes (Table 10). Among them, we found increased levels of the E2 enzyme UBE2K. Previous studies reported that HTT interacts with UBE2K. Thus, we asked whether the high levels of UBE2K also participate in the epigenetic regulation of hESCs.

	NPCs		Neurons		
	T-test difference	q-value	T-test difference	q-value	
UBE2C	-1.54	<0.0001	-2.47	<0.0001	
UBE2G1	-1.15	0.0005	-1.43	0.0001	
UBE2K	-1.04	0.0015	-1.03	0.0017	
UBE2O	-0.75	0.0241	-1.39	0.0002	
UBE2Z	-0.49	0.0164	-0.08	NS	
UBE2S	-0.98	NS	-1.71	0.0012	
UBE2V1	-0.01	NS	0.44	NS	
UBE2V2	0.06	NS	0.40	0.0090	
UBE2N	0.09	NS	0.04	NS	
UBE2R2	0.14	NS	0.01	NS	
UBE2M	0.20	NS	0.39	NS	
UBE2Q1/UBE2Q2	0.28	NS	0.81	NS	
UBE2I	0.83	0.0007	0.15	NS	
UBE2L3	1.26	<0.0001	0.76	<0.0001	

Table 10. Quantitative proteomic analysis of E2 enzymes comparing hESCs with their NPC and neuronal counterparts. UBE2K decreases during neural differentiation of hESCs. We used limma's moderated t-test to contrast hESCs (n= 9) versus NPCs (n= 5) and neurons (n= 6). Relative abundance differences are calculated from the log2 of label-free quantification (LFQ) values (LFQ NPCs/hESCs and LFQ Neurons/hESCs). Adjusted p-value (q-value) of <0.05 is considered significant. NS= non-significant.

First, we validated that the levels of UBE2K decrease during neural and terminal differentiation into neurons by western blot (Figure 14 A). The decrease in the protein amount of UBE2K correlated with a downregulation of the mRNA levels during differentiation (Figure 14 B).




Figure 14. UBE2K is highly expressed in hESCs and iPSCs. A, B and E, Western blot analysis with antibody to UBE2K. β -actin is the loading control. B, UBE2K relative expression in NPCs and neurons compared to H9 hESCs represents the mean \pm s.e.m. (n= 3 independent experiments). D, UBE2K relative expression in endoderm compared to H9 hESCs represents the mean \pm s.e.m. (n= 5). F, UBE2K relative expression to HFF1 fibroblasts represents the mean \pm s.e.m. (n= 6). G, qPCR analysis of UBE2K and pluripotency markers in H9 hESCs. Graph (relative expression to non-targeting shRNA) represents the mean \pm s.e.m. of three independent experiments with three biological replicates. H, Western blot analysis with antibodies to UBE2K, SOX2 and OCT4. β -actin is the loading control. I, qPCR analysis of ectodermal (PAX6, NES, FGF5), mesodermal (MSX1) and endodermal (ALB, GATA4, GATA6) germ layer markers. Graph (relative expression to NT shRNA) represents the mean \pm s.e.m. of three independent experiments with three biological replicates. H, Western blot analysis with antibodies to UBE2K, SOX2 and OCT4. β -actin is the loading control. I, qPCR analysis of ectodermal (PAX6, NES, FGF5), mesodermal (MSX1) and endodermal (ALB, GATA4, GATA6) germ layer markers. Graph (relative expression to NT shRNA) represents the mean \pm s.e.m. of three independent experiments with three biological replicates. All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), **** (P<0.001).

Although to a lesser extent, UBE2K also decreased during differentiation into either endoderm or mesoderm (Figure 14 C-D). Moreover, high levels of UBE2K were reprogrammed in iPSCs derived from fibroblasts (Figure 14 E-F). Given the strong correlation between UBE2K expression and pluripotency, we hypothesized that increased levels of UBE2K could be required to maintain the undifferentiated state of hESCs. To assess this hypothesis, we generated stable knockdown hESC lines by using two independent *UBE2K* shRNA (Figure 14 G-H). Loss of UBE2K did not result in significant differences in pluripotency markers compared to control hESCs (Figure 14 G-H). Moreover, we measured the expression of markers of the distinct germ layers and found no significant changes in endoderm, mesoderm and ectoderm markers (Figure 14 I). Since hESC lines can vary in their characteristics, we examined an independent line and obtained similar results (Figure 15).




Figure 15. Loss of UBE2K does not impair the induction of NES and SOX1 during the early stages of differentiation into NPCs. After 10 days of neural induction, cells were assessed by immunofluorescence with NES, SOX1, and Hoechst staining. Scale bar represents 20 μm.

Although loss of UBE2K did not significantly alter the levels of pluripotency markers in hESCs, another possibility is that UBE2K determines their ability to differentiate into distinct lineages. Given that UBE2K catalyzes the synthesis of Lys-48linked polyubiquitin chains targeting proteins for proteasomal degradation ^{123,155} and increased proteasome activity is required for neurogenesis from hESCs ^{156,157}, we focused on the neural lineage. For this purpose, we performed neural induction and monitored the expression of PAX6, an early marker of neuroectodermal differentiation ^{91,92}. After 10 days of neural induction, PAX6 levels were triggered at the same extent in both control and UBE2K knockdown (KD) hESCs resulting in cultures of ~100% PAX6-positive cells (Figure 16 A-C). We also analyzed the levels of other neural and neuronal markers and found no significant differences at this stage (Figure 16 C and Figure 15). These results indicate that UBE2K is not required for the commitment of hESCs to a neuroectoderm fate. However, we observed dramatic differences when we further differentiated these cells (20 days on neural induction treatment) to obtain NPCs with the ability to generate terminally differentiated neurons (Figure 16 D-G). At this stage, control NPCs decreased the expression of the early neural marker PAX6 whereas the levels of NPC (e.g., nestin, SOX1) and neuronal markers are upregulated (Figure 16 F-G). In contrast, UBE2K KD cells maintained high levels of PAX6 whereas the levels of neural and neuronal markers are significantly lower compared with control NPCs (Figure 16 D-G). Upon neuronal differentiation treatment, UBE2K KD cells did not develop neuronal extensions (Figure 16 H) and showed a dramatic impairment in the expression of neuronal markers such as MAP2, NEFL and synaptic proteins while retaining high levels of PAX6 expression (Figure 16 H-K). Taken together, these data suggest a critical role of UBE2K in maintaining the ability of hESCs to differentiate into NPCs with intact neurogenic properties.




Figure 16. Loss of UBE2K impairs neurogenesis from hESCs. A, After 10 days of neural induction, cells were assessed by immunofluorescence with OCT4, PAX6, and Hoechst staining. Scale bar represents 20 µm. B, Western blot analysis of NPCs after 10 days of neural induction with antibody to PAX6. β-actin is the loading control. C, qPCR analysis after 10 days of neural induction. Graph (relative expression to NT shRNA cells) represents the mean ± s.e.m. of three independent experiments with three biological replicates. D, After 20 days of neural induction, cells were assessed by immunofluorescence with OCT4, PAX6, and Hoechst staining. Scale bar represents 40 µm. E, Western blot analysis of NPCs after 20 days of neural induction with antibodies to MAP2, NES, PAX6 and β-actin. F, G, qPCR analysis after 20 days of neural induction. Graph (relative expression to NT shRNA cells) represents the mean ± s.e.m. of XX independent experiments with three biological replicates. H, After 3 weeks of neuronal induction, cells were assessed by immunofluorescence with MAP2, PAX6, and Hoechst staining. Scale bar represents 20 µm. I, Percentage of MAP2 and PAX6-positive cells/total nuclei after three weeks of neuronal induction (mean ± s.e.m. of two independent experiments, 300-400 total cells per experiment). All the statistical comparisons were made by Student's t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), ****(P<0.001), **** (P<0.0001).

3.2.2 Knockdown of UBE2K induces trimethylation of H3K9 and impairs induction of neuronal genes

To determine the mechanism(s) by which UBE2K impinges upon hESC function, we performed co-immunoprecipitation experiments followed by a single shot label-free proteomic approach (Table 11).




Figure 17. UBE2K regulates trimethylation of H3K9. A, Western blot analysis of nuclear and cytosolic fractions from H9 hESCs with antibodies to OCT4 and UBE2K. B, Western blot analysis of H9 hESCs with antibodies to H3K9me3 and total histones H3. C, Immunocytochemistry of H9 hESC cultures with antibody to H3K9me3 and Hoechst staining. Scale bar represents 20 μ m. D, After 3 weeks of neuronal induction, cells were assessed by immunofluorescence with H3K9me3 and Hoechst staining. Scale bar represents 20 μ m.

We observed that UBE2K, mitochondrial fission factor (MFF) and the histone H3.3 are the most enriched proteins upon UBE2K co-immunoprecipitation (Table 11). H3.3 is a highly conserved histone that differs from the canonical histones H3.1/H3.2 by only four to five amino acid, respectively. Interestingly, H3.3 is involved in cell differentiation and cell reprogramming^{158,159}. In support of a potential role of UBE2K in the nucleus, we detected significant amounts of this E2 enzyme in nuclear fractions of hESCs (Figure 17 A).

Gene names	Protein names	T-test difference	-log P-value
MFF	Mitochondrial fission factor	8.68	3.24
UBE2K	Ubiquitin-conjugating enzyme E2 K	5.29	2.74
H3F3B;H3F3A;H3F3C	Histone H3;Histone H3.3;Histone H3.3C	5.07	1.47
C14orf166	UPF0568 protein C14orf166	4.78	1.66
HCFC1	Host cell factor 1	4.41	2.27
DYNLT1	Dynein light chain Tctex-type 1	3.76	2.23
ATP1A1	Sodium/potassium-transporting ATPase subunit alpha-1	3.71	2.85
PTCD3	Pentatricopeptide repeat domain-containing protein 3, mitochondrial	3.31	2.72
CSNK2A1;CSNK2A3	Casein kinase II subunit alpha;Casein kinase II subunit alpha 3	3.04	2.39
CPNE1	Copine-1	2.99	2.79
PIP4K2A;PIP4K2B	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha/beta	2.71	2.71
PLCB4	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4	2.39	3.34

Table 11. Protein interactors of UBE2K in H9 hESCs. Protein label-free quantification (LFQ) from coimmunoprecipitation (co-IP) experiments with UBE2K antibody compared to control co-IP with FLAG antibody (n=3, Student's t-test, FDR< 0.05 is considered significant).

With the strong interaction between UBE2K and H3.3, we asked whether loss of UBE2K modulates epigenetic marks of pluripotent stem cells. In hESCs, chromatin repressive marks such as H3K9me3 are usually reduced whereas the levels of transcriptional activations marks are globally increased^{101,106} Notably, knockdown of UBE2K induced a dramatic increase in the levels of H3K9me3 in two independent hESC lines as well as iPSCs (Figure 17 B-C). Once differentiated into NPCs, UBE2K KD cells maintained high levels of H3K9me3 compared with control cells (Figure 17 D). Taken together, these data indicate that UBE2K regulates the levels of the transcriptional repressive mark H3K9me3 in hESCs and this epigenetic alteration is transmitted to their neural counterparts.

To assess whether increased H3K9me3 levels impair the expression of specific genes, we performed chromatin immunoprecipitation (ChIP) in UBE2K KD hESCs. We found a >2-fold enrichment for H3K9me3 marks in 71 genes upon UBE2K knockdown. Among them, GO biological process term analysis indicated the strongest enrichment for genes involved in transcriptional regulation (Figure 18).




Figure 18. Significantly enriched GO Biological Processes in UBE2K KD hESCs in ChIP experiments with H3K9me3 antibody. The 71 genes enriched for H3K9me3 in ChIP experiments comparing UBE2K shRNA #1 and UBE2K shRNA #2 H9 hESCs with non-targeting shRNA H9 hESCs were analyzed for enriched GO Biological Processes (p-value <0.05 is considered significant).

These regulators include 7 zinc finger proteins (ZNF263, ZNF274, ZNF416, ZNF559, ZNF562, ZNF844, ZNF879), the transcription factor GBX1 and the bHLH transcription cofactor HES6. GBX1 is highly expressed in the neuroectoderm and modulates midbrain/forebrain formation by determining the positioning of the midbrainhindbrain boundary organizer in the early neural plate⁵⁵. HES6 promotes neuronal differentiation by allowing the transcription factor ASCL1 to induce the expression of genes required for neurogenesis at early stages of development ¹⁶⁰. Besides these transcription factors, loss of UBE2K induced an enrichment for H3K9me3 marks in several genes involved in nervous system formation, neuronal function, establishment of neuronal connections, synapse stabilization, and neurotransmission (e.g., ADRA2B, CELSR1, CPEB1⁵⁶, KCNA3, KCNA5, KCNF1, OPRD1⁵⁸, PCDHB15, SMC1B, and the GABA receptor subunit GABRR1). Prompted by these findings, we tested whether H3K9me3 modifications result in decreased expression of these pro-neural genes by quantitative analysis of the transcriptome in UBE2K KD hESCs. Integrated analysis of ChIP and transcriptomics data did not show significant downregulated expression of most of the genes enriched for H3K9me3 in UBE2K KD hESCs. Taken together, our data indicate that high levels of UBE2K in hESCs maintain low levels of H3K9me3 marks in key pro-neural and neuronal genes.

3.2.3 UBE2K modulates JARID2 levels

To determine potential targets of UBE2K involved in the trimethylation of H3K9, we performed quantitative proteomics comparing control hESCs with UBE2K KD hESCs (Table 12). Interestingly, loss of UBE2K induced an increase in the levels of the histone methyltransferase regulator JARID2 and also METTL7A, a methyltransferase of unknown function.

List of proteins upregulated upon knockdown of UBE2K in hESCs

6.8 prosphase kapp 1.4875091 1.25114172 1.5198724 1.19817248 CHTRS Chromesome transission (felding) 1.51014788 0.98948257 1.36953823 0.84903988 ITFG3 Drobe in Fixon (FG3 1.5001774 0.77629471 1.91758658 3.55274137 MTX2 Metaxin-2 1.472535706 1.19953841 1.9143298 2.29395557 RTN3 Reticulon-3 1.113007571 0.824962128 1.973097322 1.456925563 AKT2 KRR thans 0.970000272 0.82301573 1.275081416 1.190626398 PKK Peroissome assembly factor 2 0.944560077 0.94746279 1.663016233 1.81815276 HNRK Some hirronine-protein protein protein assembly factor 2 0.944560077 0.94746379 1.64316034 4.19317083 PPPICC Poine-info protein 12 0.91029956 0.74081346 4.434130041 4.19317083 PPPICC Poine-info protein 12 0.91129956 0.74081346 4.434130041 4.19317083 PR12 Proline-info protein 12 0.89393939			T-test difference		-log P-value	
Apopticic chromatin condensation inducer in the nucleus 3.13811111 1.800709554 2.16746478 0.799579478 CAMMATT Calmodulin-kaine N 13.18000055 1.36643224 3.519000039 2.557985309 PTFRK,DPF,2696C22 Respencing variantission fielding 1.61975841 1.21114172 1.198912482 CHTPB Protein 8 homologi isoform 2 1.51014788 0.98948227 1.39858324 2.2328524137 MTX2 Metaxin-2 1.472357706 1.98928641 1.9142288 2.232868229 MTX2 Metaxin-2 1.4725057706 0.89446227 1.970307302 1.4282825157 AKT2 KRN test aserino threading protein 1.075600272 0.82015213 1.275081416 1.19069161 KRR test aserino threading protein 2.044600573 0.90807575 0.40800575 1.03807122 1.5120253157 HARRY Perinsiem protein bio protein 2 0.94782475 0.511442579 1.58014623 1.71271242 PEX Perinsiem protein bio protein 2 0.94460721 0.8248027 1.43857142 1.53205423 1.7272142 HARRY Semmithrononine protein	Gene names	Protein names				
ACIN1 Inducer in the nucleus 3.11311111 1.80070954 2.1674478 0.79857478 CAMMAT Camodulin-spine M- methylinanternae 1.81050905 1.36643234 3.519000039 2.557986300 PTPRRADEG/SeG22 Reveals Lapon 1.81047886 0.980948257 1.98957384 1.19897384 1.49998384 1.9997392 1.429925157 A A 2.9998875 0.80989751 1.92098146 1.99997392 1.11990747 1.910984474 0.914997476 0.91492747 0.91474539 0.91414529 1.65091023 1.91097477 1.910974477 1.910974477 1.910974	PDIA3		3.766822433	3.537664413	1.630461609	1.526517826
CAMONT methyltransferase 1.81000055 1.35664224 3.519000302 2.55796300 CPTRK.DKF2686CC Receptor-type (rosine-protein protein b tomolog isofem 2 1.51017556 0.98094257 1.368633822 0.84003986 CHTF3 andera b tomolog isofem 2 1.51017556 0.98094257 1.37550155 1.68025503 ITFG3 Andera b tomolog isofem 2 1.51017556 0.98046272 1.9758687 1.97087502 1.27506755 1.68025503 RTN3 Reliculon-3 1.15871196 0.83486007 1.37530155 1.68025503 RKA RAC-beta serine/threorine-protein protein bracks, character constraint 0.975060273 0.82015213 1.275061416 1.19006161 KRR1 MR1 samisch constraint 0.94660077 0.82015213 1.2350423 1.77271042 PHXRK Serine/threonine-protein phosphales, character lise protein protein phosphales, character lise protein protein lise protein protein lise protein protein lise protein complex protein phosphales, character lise protein phosphales, character lise protein phosphales, character lise protein phosphales, character lise protein phosphales,	ACIN1		3.113811111	1.800709534	2.16746478	0.799576478
PTPRK.DR/22686C22 Reseptor-type tyrosine-protein phosphase kappa orden 8 homosome transmission Mellity orden 8 homosome transmission Mellity 1.251145172 1.51987334 1.19812485 CHTra Chromosome transmission Mellity orden 8 homosome transmission Mellity 1.51014786 0.980948257 1.386838829 0.849038968 ITFG3 Protein ITFG3 1.507017764 1.077624247 1.9182588 2.92898223 MTX2 Metaxin:2 1.1727357206 1.398538122 1.93907312 1.428965157 AKT Reficulon:3 1.11303771 0.349462128 1.97307702 1.428965157 AKT RAC-beta serif-threonine-bronken phosphatae.Serif-ethreonine-b	CAMKMT		1 810609055		3 519090939	2 557966309
Chromosome transmission fidelity protein Findonia (add/m. 2) 1.510147285 0.980948257 1.38683822 0.849033888 ITFG3 Protein TFG3 1.67201764 1.07762471 1.917895833 1.382571137 MTx2 Metaxin-2 1.47233706 1.19963841 1.91429843 2.29986822 RTN3 Bettoulon-3 1.113307571 0.349462128 1.973097302 1.425925157 AKT2 KR1 rans allustup pocessme 1.075060272 0.82015213 1.275061416 1.190269161 KR1 rans allustup pocessme 0.94029575 0.800683975 1.43307121 1.510229396 PEX6 Peroxisome assembly factor 2 0.94727475 0.61445527 1.65091023 1.81915276 HNRPK Semetherhoroime-protein 1 0.94029555 0.90149526 3.701768866 1.43327127 1.502293964 PPEX6 Deroxisome assembly factor 2 0.9471310 0.9113562 3.5330423 1.72727242 METTL7 Methytranferase-like protein 2 0.92121310 0.9113562 3.70957514 1.33225167 TMAGL1 Tuuloinuteration protein 1	PTPRK;DKFZp686C22	Receptor-type tyrosine-protein				
ITFG3 Protein ITFG3 1.507901784 1.077829471 1.91785863 1.53257137 MTX2 Metaxin-2 1.125255706 1.199605841 1.9142298 2.29989229 RTN3 Reficulon-3 1.11507157 0.94946212 1.97399730165 1.689025503 RTN3 RAC-beta same/breanne-protein omponent homolog 0.930365753 0.94946212 1.973997302 1.425295151 KR11 RR1 small subunit processome component homolog 0.94056277 0.64145279 1.658016233 1.81881526 HWRFK Serine/threanne-protein proteinasse Serine/threanne- proteinasse Serine/threanne- proteinasse Serine/threanne- proteinasse Serine/threanne- proteinasse Serine/threanne- mage 0.941460307 0.94146399 2.144466544 3.70178666 PR12 Prothe-rich protein proteinasse Serine/threanne- proteinasse Serine/threanne- tike 0.910209656 3.705815146 1.432231170 0.91015952 1.533050423 1.772712042 METT.7A Methytransferine-serine proteinasse Mrodel 0.83993939 1.655990962 2.23092675 2.226474669 ZMF423 Znc finger protein LAMTOR2 0.794325226 0.69099562 2.3095675114 <	68		1.649758911	1.251145172	1.519857384	1.189812485
MTX2 Metasin-2 1.472535706 1.199636841 1.9143296 2.299968229 RTN3 Reliculor-3 1.11307571 0.349462128 1.973097302 1.425925157 RTN3 Reliculor-3 1.11307571 0.349462128 1.973097302 1.425925157 AKT2 KRF1 small suburit processore component homolog 0.89006757 0.62015213 1.275061416 1.19066161 HRPK Sorinell memine-protein processore protein processore protein catabitic suburit 0.947927475 0.614145279 1.668016293 1.918915276 HRPK Sorinell memine-protein processore protein processore protein catabitic suburit 0.947027475 0.614145279 1.658016293 1.712712042 METT_7A Methyltransforme protein protein processore protein processore catabitic suburit 0.9302675 2.2009075 2.222474669 TMAGL1 Tubulointesting protein 18 0.779428256 0.680399652 2.23092675 2.222474669 ZVF42 Zn6 Indrap protein 42 0.7794282576 0.680399652 2.23092675 2.226474669 ZVF42 Zn6 Indrap protein 42 0.7794282576 0.6803999652 <t< td=""><td>CHTF8</td><td></td><td></td><td></td><td></td><td></td></t<>	CHTF8					
Instructure 1.15671196 0.963488007 1.337530165 1.669025503 RTN3 Reliculon-3 1.13307571 0.344462128 1.973097302 1.425925157 AKT2 RAC-beita seme/htraconic protein binase 0.95006272 0.82015121 1.275001416 1.19066161 KR11 Component hemolog 0.98036753 0.620083975 1.43367122 1.150263398 PEK6 Peroxisome asembly factor 2 0.94726776 0.61414527 1.65801623 1.818151276 HNRPK Scrine/htreonic-protein protein protein protein protein protein protein protein protein protein catabic suburit 0.91029856 0.740813446 4.434130041 4.19317083 PRR12 Methytransferase-like protein LAMTOR2 0.823093939 1.65599062 1.43052146 0.32219675 2.02247659 ZWF423 Znc finger protein (423 0.787024898 0.67055066 1.43165146 0.322196238 TINACL1 Titulicite protease ATC44 0.68998522 0.2032677 2.202476593 ZWF423 Znc finger protein (23 0.78702489 0.67055066 1.438159146 0.322199234 <tr< td=""><td>ITFG3</td><td>Protein ITFG3</td><td>1.507901764</td><td>1.077629471</td><td></td><td></td></tr<>	ITFG3	Protein ITFG3	1.507901764	1.077629471		
RTN3 Reticulor.3 PR12 1.113007571 0.349462128 1.973097302 1.42592157 AKT2 RAC-beta submit processom protein submit processom component homolog 0.820015213 1.272061416 1.19066161 KR11 RR1 small submit processom component homolog 0.80085753 0.80083876 1.43507122 1.150263988 PEK8 Peroxisome assembly factor 2 0.94792475 0.614145279 1.658016233 1.81815276 HNRPK Serinethreonine-protein protein phosphases Serinethreonine- protein phosphases 2005399399 0.41032905 3.705915148 1.432172042 METL7 Tubulorinetation protein LAMTOR2 0.79125226 0.68093526 2.3092072 2.0122656 2.025746355 TIPN Tubulorinetation protein 423 0.787024689 0.67056906 1.438159146 0.92196923 TIPN Tubulorinetation protein 423 0.787024689 0.40028071 2.91292667 1.7764654466 <	MTX2	Metaxin-2				
RAC2 Norman 1.07506027 0.823015213 1.275061416 1.19066161 KRR1 small subuit processome 0.98038575 0.800683975 1.43387122 1.19066161 KRR1 PEX6 Peroxisome assembly factor 2 0.947927475 0.614145279 1.658016233 1.818815276 HNRPK SatineThreorine-protein prophrates Scinothreorine- protein phosphates Scinothreorine- protein phosphates Scinothreorine- protein phosphates Scinothreorine- protein phosphates PP1-gamma 0.910209656 0.740813446 4.434130041 4.19317083 PR12 Proline-rich protein 1 0.80039339 1.655990862 1.410828002 1.82731679 LMTOR2 Ragulator complex protein bike 0.80398399 0.650990862 2.20092675 2.2047669 ZNF423 Zinc finger protein 423 0.787024899 0.67005806 1.438159146 0.921989323 TIFIN TMELES-interacting protein 0.80398224 0.59024511 1.97238067 1.784654486 Signal recognition particle receptor subunit beta 0.67051682 0.73467911 1.910974477 2.17000455 TVF1 Twespera stratin subunit protesat atration protein facto: Batrati						
KRR1 KR1 smal suburit processome normonent homolog 0.980366753 0.800683975 1.43367122 1.150263988 PEX6 Peroxisome assembly factor 2 0.947927475 0.614145279 1.658016233 1.818815276 HNRPK Serine/htreonine-protein phosphatase/Serine/htreonine- protein phosphatase/Pri-gamma catalytic suburit 0.910209656 0.74081346 4.434130041 4.19317083 PPTICC Certalytic suburit 0.910209653 0.4101329056 3.769815148 1.43322187 ThuAcL1 Proline-rich protein 17 0.80039939 1.655999962 1.41082002 1.52271679 LAMTOR2 Raguiator complex protein LAMTOR2 0.787024689 0.67005806 1.433159146 0.921969238 TIPIN TIMELESS-interacting protein 9.063705862 0.93026797 2.01428658 2.020576435 TWF1 Tumfilin-1 0.66599895 0.47342224 3.466383113 2.00576448 PTPRZ1 Receptor-robitis antigen- suburit 0.65898957 0.442600021 2.3166975614 1.573171444 PTPRZ1 Tumfilin-1 0.66599895 0.47342224 3.466338113 2.005764	RTN3	Reticulon-3 RAC-beta serine/threonine-protein	1.113307571	0.349462128	1.973097302	1.425925157
KR1 component homolog 0.90366753 0.000683975 1.43367122 1.150283986 PEX6 Peroxisome assembly factor 2 0.94496007 0.94446007 1.658016293 1.818815276 HNRPK Serine/Threonine-protein phosphatase Serine/Threonine- protein phosphatase Serine/Threonine- protein phosphatase PP1-gamma 0.910299656 0.740813446 4.434130041 4.19317083 PR12 Proline-rich protein 12 0.991211319 0.91619562 1.533360423 1.772712042 Methytransferase-like protein 0.88906338 0.410329056 3.705915148 1.433225187 Tubulointeristilian portial antigen- like 0.7942325256 0.680993952 2.2032675 2.22644629 ZNF423 Znc finger protein 0.693198013 0.903326797 2.01428658 2.025764352 ATG4E Cysteine proteine 0.693939801 0.90326797 2.01428658 2.025764352 ATG4E Cysteine proteine 0.693938013 0.90326797 2.01428658 2.025764635 Signal recorption particle receptor 0.879892624 0.405607386 1.975171444 0.9219265411 1.97238067	AKT2		1.075060272	0.823015213	1.275061416	1.19066161
HNRPK Serine/freconine-protein protein prosphatese Serine/freconine- protein prosphatese protein general-o-autointegration fractor.Barrier-o-aut	KRR1		0.980365753	0.800683975	1.43367122	1.150263958
Serine threenine-protein protexphases. Serine/threenine- protexphases. Serine/threenine- protexphases. Serine/threenine- protexphases. Serine/threenine- protexphases. Serine/threenine- protein phosphases. PP1-gamma 0.910209656 0.740813446 4.434130041 4.19317083 PR12 Proline-rich protein 12 0.910209656 0.740813446 4.434130041 4.19317083 METTL7A Trubulointeratian rephritis antigen- like 0.891211319 0.916115952 1.655900982 1.10828002 1.5282731679 LAMTOR2 Rayulator complex protein LAMTOR2 0.794325256 0.680993652 2.23092675 2.226474669 ZINE finge protein 423 0.787024689 0.67005806 1.438159146 2.025764635 ATG4B Cysteine proteinese ATG4B 0.669398012 0.903326797 2.01426658 2.025764635 SRPRB Signal recognition particle receptor 0.660595986 0.427342224 3.465383113 2.00576648 PTPR21 Dexpshtase zeta 0.65899697 0.432607386 2.806932771 1.297262912 MIMI Barrier-to-autointegration phosphtases zeta 0.63824382 0.40686501 2.816604112 1.731231712 MYO1D:DFCF	PEX6	Peroxisome assembly factor 2	0.947927475	0.614145279	1.658016293	1.818815276
protein phosphatase /Stringhtmenine- protein phosphatase /Stringhtmenine- protein phosphatase /Stringhtmenine- actabilit subunit 0.910209656 0.740813446 4.434130041 4.19317083 PRR12 Proline-rich protein TA 0.88805338 0.410320956 3.705815148 1.433225187 METLTA Tubulointersitial netperitis antigen- tike 0.850393999 1.655990982 1.41082002 1.582731679 TINAGL1 Ike 0.850393999 0.67005806 1.438159146 0.92199238 ZNF423 Zinc finger protein LAMTOR2 0.787024689 0.67005806 1.438159146 0.92199238 TIPIN TMELESS-interacting protein subunit beta 0.699352224 0.59026451 1.972398067 1.784654486 SRPRB Signal recognition particle receptor subunit beta 0.6998505 0.42734224 3.465383113 2.0057648 PTFR1 Twintlin-1 0.6656998967 0.428200021 2.316607561 1.575171444 DNA primase:DNA primase small ractor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrier-to-autointegration factor, Narrie	HNRPK		0.944860077	0.994746399	2.144466584	3.701768666
prprice protein phosphatase PP1-gamma 0.910209656 0.740813446 4.434130041 4.19317083 PR12 Proline-rich protein 0.991211319 0.916115952 1.533050423 1.772712042 METTL7A Methyltrasterase-like protein 0.888065338 0.410329056 3.705815148 1.433225187 TINAGL1 Tubuloinerstillai nephrits antigen- 0.850399399 1.655990982 1.410828002 1.582731679 LAMTOR2 Zanc finger protein 0.794325256 0.6809393652 2.23092675 2.226474689 ZNF423 Zinc finger protein 0.693198013 0.903326791 2.01428658 2.02576435 ATG4B Systeme protesse ATG4B 0.689398013 2.0132676435 2.01428658 2.02576435 SRPRB Receptor-type tyrosine- protein 0.65695865 0.42734224 3.466333113 2.00576648 PTPR21 Perphrase ase anal 0.656969865 0.42734224 3.466338113 2.00576648 PTPR21 Partominally processed 0.63624327 0.4068501 2.816604112 1.731231712 MYO1D.DKF26686A01 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
PRR12 Proline-rich protein 12 0.891211319 0.916115952 1.533050423 1.772712042 METTLTA TA 0.88905338 0.410329056 3.705815148 1.433225187 TINAGL1 Tubulointersitial nephritis antigen- like 0.850393399 1.65590982 1.410828002 1.582731679 LAMTOR2 LAMTOR2 LAMTOR4 0.87024689 0.67005806 1.438159146 0.921969238 TIPIN TIMELESS-interacting protein 0.781325256 0.680939357 2.01428658 2.025764635 ATG4B Crysteine proteins eXTG4B 0.689398224 0.590264511 1.972398067 1.786454486 Signal recognition particle receptor 0.656698957 0.48260021 2.316897561 1.575171444 PTRZ1 Receptor-type tyrosine-protein 0.65698967 0.48260021 2.816604112 1.297262912 BarNF1 DM primase SMA primase small 0.63624382 0.400567366 2.60932771 1.297262912 MCND/PE2p686A01 Unconventional myosin-ld 0.632105637 0.6538633525 1.70442973 1.684702669 MYP11	DDD100	protein phosphatase PP1-gamma	0.040000050	0.740040440	4 40 44 000 44	4 4004 7000
METTLYA Methyltransforzase-like protein like 0.888065338 0.410329056 3.705815148 1.433225187 TINAGL1 Tubulointersitial nephritis antigen- like 0.85039399 1.655990982 1.410828002 1.582731679 ZNF423 Zinc finger protein 423 0.787024689 0.67005806 1.438159146 0.921989238 TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 ATG4B Cysteine protease ATG4B 0.69039892224 0.590264511 1.972398007 1.764654486 Signal recognition particle receptor 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinfilin-1 0.666598985 0.427342224 3.46638113 2.00576648 PTFRZ1 Receptor-type tyrosine-protein factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Barrier-to-subrintegration factor: Parkinet-to-subrintegration factor: Barrier-to-subrintegration factor: Parkinet-to-subrintegration factor: Parkinet-to-subrintegration factor: Parkinet-to-subrintegration factor: Parkinet-to-subrintegration factor: Parkinet-to-subrintegratio fastor: Parkinet-to-subrintegr						
TINAGL1 Tubulointersitial nephritis anligen- like 0.850399399 1.655990982 1.410828002 1.582731679 LAMTOR2 LAMTOR2 0.794325256 0.680993652 2.23032675 2.226474669 ZINF423 Zinc finger protein 423 0.787024689 0.67005806 1.438159146 0.292169238 TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 ATG4B Cysteine protease ATG4B 0.68098982224 0.590264511 1.972398067 1.764654486 Signal recophion particle receptor 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinflin-1 0.666596985 0.427342224 3.466333113 2.00576648 PTR21 Phosphatase zeta 0.650949867 0.482600021 2.316697561 1.575171444 PRIM1 Subunit 0.6324382 0.40088501 2.816604112 1.731231712 MYO1D.DKF2p686A01 Incorv.entional myosin-Id 0.652106637 0.653863525 1.7044297 1.684702669 WRNIP1 ATPase WRNIP1 0.61505	PRR12			0.916115952	1.533050423	1.//2/12042
TINAGL1 Ike 0.85039339 1.655903952 1.410828002 1.582731679 LAMTOR2 Raguidaro complex protein LAMTOR2 0.794325256 0.680993652 2.23092675 2.22647469 ZNF423 Zinc finger protein 423 0.787024689 0.67005806 1.438159146 0.921969238 TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 SRPRB subunit beta 0.670551682 0.735467911 1.970374477 2.170009455 TWF1 Twinfilin-1 0.666596985 0.427342224 3.466333113 2.00576648 PTRZ1 Receptor-type tyrosine-protein factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioningration factor.Barriet-to-autioning protein factor.Barriet-to-autioning protein factor.Barriet-to-autioning protein factor.Barriet-to-autioning protein factor.Barriet-to-autioning protein factor.Barriet-to-autioning protein diposphologosaccharde-protein diposphologosaccharde-protein diposphologosaccharde-protein diposphologosaccharde-protein diposphologosaccharde-prote	METTL7A		0.888065338	0.410329056	3.705815148	1.433225187
LAMTOR2 LAMTOR2 0.794325256 0.68093652 2.23092675 2.226474669 ZNF423 Zinc finger protein 423 0.787024689 0.670058066 1.439159146 0.921989238 TIPIN TIMELESS-interacting protein 0.693198013 0.90326797 2.01428658 2.025764635 ATG4B Crysteine protessa ATG4B 0.68039892224 0.590264511 1.972398067 1.764654486 Signal recognition particle receptor 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinfilin-1 0.666599895 0.427342224 3.466383113 2.00576648 PTPRZ1 DNA primase transi 0.653824942 0.405867366 2.60932771 1.297262912 MYOLD_DK72666A01 Barrier-to-autiontegration factor. Patientegration factor.	TINAGL1	like	0.850399399	1.655990982	1.410828002	1.582731679
TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 ATG4B Cysteine protease ATG4B 0.689982224 0.590264511 1.972398067 1.764654486 Signal recognition particle receptor 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinfilin-1 0.666596985 0.427342224 3.466383113 2.00576648 PTPRZ1 phosphatase zeta 0.636949967 0.482600021 2.316697561 1.575171444 DNA primase DNA primase small 0.63824942 0.40088051 2.816604112 1.731231712 MYODD.DKF2p686A01 Itactor, N-terminally processed 0.63624382 0.40088051 2.816604112 1.731231712 MYODD.DKF2p686A01 Unconventional myosin-id 0.632105637 0.53983525 1.70442979 1.684702669 WRNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.83986688 1.583248395 Dickryl- glybocsyltransferase subunit 2 0.609716034 0.47336998 1.59734272 1.293983071 AP251 AP-2 complex subunit sigma </td <td>LAMTOR2</td> <td></td> <td>0.794325256</td> <td>0.680993652</td> <td>2.23092675</td> <td>2.226474669</td>	LAMTOR2		0.794325256	0.680993652	2.23092675	2.226474669
TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 ATG4B Cysteine protease ATG4B 0.689982224 0.590264511 1.972398067 1.764654486 SRPRB suburit beta 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinflin-1 0.666596995 0.427342224 3.466383113 2.00576648 PTRZ1 phosphatiase zeta 0.6599967 0.482600021 2.316697561 1.575171444 PRM1 suburit valuointegration 1.6307566 2.609932771 1.297262912 Barrier-to-autointegration 1.6367566 2.609932771 1.297262912 MVOD.DKrZp666A01 1.60075637 0.65386325 1.70442979 1.684702669 WNNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 diphosphooligosaccharideprotein 0.47336998 1.593784272 1.293983071 AP251 AP-2 complex suburit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Lipri	ZNF423	Zinc finger protein 423	0.787024689	0.67005806	1.438159146	0.921969238
ATG4B Cysteine protease ATG4B 0.689982224 0.590264511 1.972398067 1.764654486 SRPRB subunit beta 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinfilm-1 0.666596985 0.427342224 3.46683113 2.00576648 PTPR21 phosphatase zeta 0.65098967 0.482600021 2.316697561 1.575171444 DNA primase; DNA primase small subunit 0.63924942 0.40088501 2.816604112 1.731231712 MYO1D;DKF2p686A01 factor, N-terminally processed 0.632105637 0.65386325 1.70442979 1.684702669 WRNIP1 ATPase WRNIP1 0.61505847 0.590971756 1.639858688 1.583248395 Dilichy- diphosphooligosaccharideprotein glycosyltransferase subunit 2 0.609716034 0.47369988 1.593764272 1.293983071 AP251 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.47369685 2.499737533 2.499028144 EHD4 EH domain-containing protein 4	TIPIN		0.693198013	0.903326797	2.01428658	2.025764635
SRPRB subunit beta 0.670551682 0.735467911 1.910974477 2.170009455 TWF1 Twinfilin-1 0.66699085 0.42734224 3.466383113 2.00576648 PTPR21 DNA primase protein phosphatase zeta phosphatase zeta ubunit 0.65999867 0.482600021 2.316697561 1.575171444 PRM1 Sature to-autointegration factor, N-terminally processed 0.63824942 0.40088501 2.816604112 1.731231712 WTODD,DKF2p686A01 factor, N-terminally processed 0.63624382 0.40088501 2.816604112 1.731231712 WTOD,DKF2p686A01 iffector, N-terminally processed 0.63624382 0.40088501 2.816604112 1.731231712 WTOD,DKF2p686A01 iffector,N-terminally processed 0.63624382 0.40088501 2.816604112 1.731231712 WTOD,DKF2p686A01 iffector,N-terminally processed 0.63624382 0.40088501 2.816804112 1.8393129 MVRIP1 ATPase WRNIP1 0.615055847 0.466293335 1.99416999 1.8393129 PF161 Liprin-alpha-1 0.545404721 0.476158905 2.809737533	ATG4B					
TWF1 Twinfilin-1 0.666596985 0.427342224 3.466383113 2.00576648 PTPRZ1 phosphatase zeta 0.65698967 0.482600021 2.316697561 1.575171444 PRIM1 DNA primase:DNA primase small 0.63924942 0.405867386 2.609932771 1.297262912 Barrier-to-autointegration factor;Barrier-to-autointegration factor;Barrier-to-autointegration factor;Barrier-to-autointegration 0.632105637 0.653863525 1.70442979 1.684702669 WYOID.DKFZp686A01 Unconventional myosin-Id 0.615055847 0.590971756 1.6393858688 1.583248395 WNIP1 ATPase VRNIP1 0.615055847 0.466293335 1.499416999 1.8393129 PDFIA1 Liptin-alpha-1 0.554604721 0.47658905 2.809737533 2.49028144 EHD4 EH domain-containing protein 4 0.538651067 0.296683121 3.010269694 1.567925445 JARID2 Protein Jumonji 0.538651067 0.296683121 3.010269694 1.567925445 Diphthamide biosynthesis protein PDS5B Diphthamide biosynthesis protein PDS5B 0.497331238 0.820111465 1.9683			0 670551692	0 725467011	1 010074477	2 170000455
PTPRZ1 Receptor-type tyrosine-protein phosphatase zeta 0.65698967 0.482600021 2.316697561 1.575171444 PRIM1 DNA primase DNA primase small subunit 0.63924942 0.405867386 2.609932771 1.297262912 Barrie-to-autointegration factor;Barrie-to-autointegration factor;Barrie-to-autointegration 0.63824382 0.40088501 2.816604112 1.731231712 MYOID;DKFZp686A01 Unconventional myosin-ld 0.632105637 0.553863525 1.70442979 1.684702669 WRNIP1 ATPase VRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 Dolichy- diphosphooligoasccharideprotein glycosyltransferase subunit 2 0.609716034 0.47336998 1.593784272 1.233983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.536531067 0.296683121 3.010269694 1.567925445 JARID2 Protein Jumonji 0.536531067 0.296683121 3.0102696						
DNA primase:DNA primase small subunit 0.63924942 0.405867386 2.609932771 1.297262912 Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Neterninally processed 0.632105637 0.653863525 1.70442978 1.684702669 WYOID_DKFZp686A01 Unconventional myosin-Id 0.615055847 0.590971756 1.639858688 1.583248395 WRNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 MVDID_phooligosaccharideprotein diphosphooligosaccharide-protein glycosyltransferase subunit 2 0.699716034 0.47336998 1.593784272 1.293983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PFFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.536531067 0.296683121 3.010269694 1.567925445 JARID2 Protein Jumonji 0.538499069 0.643983459 2.415416658 2.090819064 Ubiquitin carboxyl-terminal vboration carboxyl-term		Receptor-type tyrosine-protein				
PRIM1 subunit 0.63924942 0.405867386 2.609932771 1.297262912 BANF1 factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration factor,Barrier-to-autointegration policity- diphosphooligosaccharide-protein RPN2 0.6321056347 0.40088501 2.816604112 1.731231712 AP2S1 AP-2 complex subunit 0.615055847 0.590971756 1.638958688 1.583248395 JARID2 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 JPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.54529686 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.538631067 0.296683121 3.010269694 1.567325445 Diphthamide biosynthesis protein PDS5 homolog B 0.511237717 0.460929871 1.775184545 2.4587	PTPRZ1	phosphatase zeta DNA primase:DNA primase small	0.65698967	0.482600021	2.316697561	1.575171444
BANF1 factor:Barrierto-autointegration 0.63624382 0.40088501 2.816604112 1.731231712 WYO1D;DKFZp686A01 Unconventional myosin-Id 0.632105637 0.653863525 1.70442979 1.684702669 WRNIP1 ATPase WRNIP1 0.615055847 0.593863525 1.70442979 1.684702669 WRNIP1 Daticityl- diphosphooligosaccharideprotein 0.615055847 0.463293355 1.499416999 1.83993129 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.54529686 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.538499069 0.643983459 2.415416658 2.090819064 USpt47 byqtrolase 47 0.536531067 0.296683121 3.010269694 1.567925445 DPH2 Diphthamide biosynthesis protein PDS5B Diphthamide biosynthesis 0.497331238 0.820111465 1.968375602 3.884416406 <td>PRIM1</td> <td>subunit</td> <td>0.63924942</td> <td>0.405867386</td> <td>2.609932771</td> <td>1.297262912</td>	PRIM1	subunit	0.63924942	0.405867386	2.609932771	1.297262912
173 Unconventional myosin-ld 0.632105637 0.653863525 1.70442979 1.684702669 WRNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 Dolichyl- diphosphooligosaccharideprotein glycosyltransferase subunit 2 0.609716034 0.47336998 1.593784272 1.293983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.54526866 0.284342194 2.78753207 1.887558689 JARID2 Protein jumonji 0.538499069 0.463983459 2.415416658 2.090819064 USP47 hydrolase 47 0.536531067 0.296683121 3.010269694 1.567325445 Diphthamide biosyntein PDS58 protein jumonji 0.49731238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyttransferase subunit QTRTD1 0.49731238 0.820111465 1.968375602 3.884416406 QTRTD4 R		factor;Barrier-to-autointegration	0.63624382	0.40088501	2.816604112	1.731231712
WRNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 Miphosphooligosaccharideprotein glycosyltransferase subunit 2 0.609716034 0.47336998 1.593784272 1.293983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.53659066 0.284342194 2.78753207 1.887556689 JARID2 Protein Jumonji 0.538699069 0.643983459 2.415416658 2.090819064 USP47 Ibigutin carboxyl-terminal hydrolase 47 0.53651067 0.296683121 3.010269694 1.567925445 PDS58 Erbornolog B 0.511237717 0.460929871 1.775184545 2.458753426 DPH2 Diphthamide biosynthesis protein subunit OTRTD1 0.45495987 0.549682617 1.788886809 1.796082833 NA3815M8 Nalca awritary subunit 0.3982872 0.551329803 2.235873173 3.890010684 PPP1R14B<		Unconventional myosin-ld	0.632105637	0.653863525	1.70442979	1.684702669
diphosphooligosaccharide-protein glycosyltransferase subunit 2 0.609716034 0.47336998 1.593784272 1.293983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.5452666 0.284342194 2.78753207 1.887558689 JARD2 Protein Jumonji 0.536531067 0.296683121 3.010269694 1.567925445 Ubiquitin carboxyl-terminal 0.536531067 0.296683121 3.010269694 1.567925445 PDS5B Sister chromatid cohesion protein PDS5B homolog B 0.511237717 0.460929871 1.775184545 2.486753426 Queuine tRNA-ribosyltransferase subunit QTRTD1 0.49731238 0.82011165 1.868375602 3.884416406 Queuine tRNA-ribosyltransferase 38, NA385LSM8 NaEd axitary subunit 0.458888245 0.388759232 2.644654471 1.832552553 RABEP1 protein 1 0.45459587 0.549686171 1.788886809 1.796082833 N	WRNIP1	ATPase WRNIP1	0.615055847	0.590971756	1.639858688	1.583248395
RPN2 glycosyttransferase subunit 2 0.609716034 0.47336998 1.593784272 1.293983071 AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.54529686 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.53659066 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.53651067 0.296683121 3.010269694 1.567925445 Ubiquitin carboxyl-terminal 0.511237717 0.460929871 1.775184545 2.458753426 DPH2 Diphtmaride biosynthesis protein 0.497331238 0.820111465 1.968375602 3.884116406 Queuine tRNA-riboxyltransferase subunit QTKTD1 0.445495987 0.549682617 1.78886809 1.796082833 NA338LSM8 NaG12axuting yroubunit 0.39732622 0.551329803 2.235873173 3.890010684 PPP1R14B Nacit awriting yroubunit		Dolichyl-				
PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 EHD4 EH domain-containing protein 4 0.54528666 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.536399069 0.643983459 2.415416658 2.090819064 USP47 Ubiquitin carboxyl-terminal 0.536531067 0.296683121 3.010269694 1.567925445 PDS58 Sister chromatid cohesion protein 0.511237717 0.460929871 1.775184545 2.458753426 DPH2 Olphthamide biosynthesis protein 0.49731238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyltransferase 0.45888245 0.388759232 2.644654471 1.832552553 RABEP1 protein 1 0.458489587 0.549682617 1.788886809 1.796082833 NAA38;LSM8 NatCi auxiling y suburit 0.39982872 0.55132903 2.235873173 3.890010684 PP1R14B Suburit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1:MAP7D1 MAP7 domain-containing protei	RPN2		0.609716034	0.47336998	1.593784272	1.293983071
EHD4 EH domain-containing protein 4 0.54529686 0.284342194 2.78753207 1.887558689 JARID2 Protein Jumonji 0.538499069 0.643983459 2.415416658 2.090819064 USP47 Ubiquitin carboxyl-terminal PDS5B 0.536531067 0.296683121 3.010269694 1.567925445 DDipthinamide biosynthesis protein DPH2 0.511237717 0.460929871 1.775184545 2.458753426 Queuine tRNA-ribosyttransferase subunit QTRTD1 0.497331238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyttransferase subunit QTRTD1 0.45888245 0.388759232 2.644654471 1.832552553 RABEP1 protein 1 0.45459587 0.549682617 1.788886809 1.796082833 NA338;LSM8 NatCi auxiting subunit 0.39982872 0.551329803 2.235873173 3.890010684 PP1P114B Subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1:MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141528 KIAA1068:NUDCD3 NudC do	AP2S1	AP-2 complex subunit sigma	0.586634827	0.466293335	1.499416999	1.83993129
JARID2 Protein Jumonji 0.538499069 0.643983459 2.415416658 2.090819064 USP47 Ubiquitin carboxyl-terminal hydrolase 47 0.536531067 0.296683121 3.010269694 1.567925445 DSSB Sister chromatid cohesion protein PDS5B 0.511237717 0.460929671 1.775184545 2.458753426 Diphthamide biosynthesis protein DPH2 0.49731238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyttransferase subunit QTRTD1 0.445495987 0.549682617 1.788886809 1.796082833 NA3B NaBpha-acetyttransferase 38, NA438;LSM8 Natic auxilary subunit 0.39882872 0.551329803 2.235873173 3.890010684 PP114B subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1:MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141528 KIAA1068:NUDCD3 Nuc2 domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 POU2671;POU2F3;POU2F3;POU domain, class 2, transcription factor 1;POU domain, class 2, transcription factor 1;POU domain, class 2, transcriptio	PPFIA1	Liprin-alpha-1	0.554604721	0.476158905	2.809737533	2.499028144
Ubiquitin carboxyl-terminal hydrolase 47 0.536531067 0.296683121 3.010269694 1.567925445 Sister chromatid cohesion protein PDS5B Sister chromatid cohesion protein PDS5B 0.511237717 0.460929871 1.775184545 2.458753426 Diphthamide biosynthesis protein DPH2 Queuine tRNA-ribosyttransferase subuni QTRTD1 0.497331238 0.820111465 1.968375602 3.884416406 QTRTD1 Rab GTPase-binding effector protein 0.445495987 0.549682617 1.788886809 1.796082833 NA38;LSM8 Nafbha-acetyltransferase subuni 14B 0.39982872 0.551329803 2.235873173 3.890010684 PP114B Subuni 14B 0.397634161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 Nuc2 domain-containing protein 1 0.376734161 0.356851196 2.1082335 2.381141628 MASTL greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU2671;POU2F3;POU2F3;POU1dranscription factor 1;POU1 domain, class 2, ranscription factor 1;POU domain, class 2, transcription factor 2 0.349388885 0.288489151 3.30995442 2.093793691	EHD4	EH domain-containing protein 4	0.54529686	0.284342194	2.78753207	1.887558689
USP47 hydrolase 47 0.53631067 0.296683121 3.010269694 1.567925445 PDS5B Diphthamide biosynthesis protein PDS5B 0.511237717 0.460929871 1.775184545 2.458753426 DPH2 Diphthamide biosynthesis protein Subuni 0TRTD1 0.4597331238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyttransferase GTRTD1 0.459888245 0.388759232 2.644654471 1.832552553 Rab CTPase-binding effector Protein 1 0.445495987 0.549682617 1.78886609 1.796082833 NAA38;LSM8 Nacia auxilary subunit 0.3982872 0.551329803 2.235873173 3.890010684 PPP1R14B Protein phosphatase 1 regulatory subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 Nuc2 domain-containing protein 1 0.364876556 0.264849472 2.200170848 2.27645822 POU domain, class 2, transcription factor 1;POU domain, class 2, 2F2 Class 2, transcription factor 2 0.349388885 0.	JARID2		0.538499069	0.643983459	2.415416658	2.090819064
PDS5B Sister chromatid cohesion protein PDS5 homolog B 0.511237717 0.460929871 1.775184545 2.458753426 Diphthamide biosynthesis protein DPH2 0.49731238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyltransferase subunit QTRTD1 0.49731238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyltransferase subunit QTRTD1 0.45888245 0.388759232 2.644654471 1.832552553 RABEP1 protein 1 0.445495987 0.549682617 1.788886809 1.796082833 NAA38;LSM8 NatC auxiling vsubunit 0.39982872 0.551329903 2.235873173 3.890010684 PP1R14B subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1:MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 NudC domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 POU267:;POU2F3;POU domain, class 2, transcription factor 1;POU domain, class	USP47		0.536531067	0.296683121	3.010269694	1.567925445
DPH2 Diphthamide biosynthesis protein 2 0.497331238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyltransferase subunit QTRTD1 0.497331238 0.820111465 1.968375602 3.884416406 Queuine tRNA-ribosyltransferase subunit QTRTD1 0.458888245 0.388759232 2.644654471 1.832552553 Rab CTrase-binding effector 0.445495987 0.549682617 1.788886809 1.796082833 NAA38,LSM8 NatG auxiliary subunit 0.39982872 0.551329803 2.235873173 3.890010684 PP1R14B subunit 148 0.38158226 0.381012344 2.195343025 1.719191952 RRC1:MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 NudC domain-containing protein 3 0.3726622 0.39627533 3.15229659 3.267324489 Serine/Itreonine-protein kinase MASTL greatwall 0.354876556 0.264849472 2.200170848 2.276245822 POU20F1;POU2F3;POUUtamascription factor 3;POU domain, 2F2 class 2, transcription factor 2 0.349388885 0.288489151 3.30995442		Sister chromatid cohesion protein				
Queuine tRNA-ribosyttransferase subunit QTRTD1 0.458888245 0.388759232 2.644654471 1.832552553 RAB GTPase-binding effector protein 1 0.458888245 0.388759232 2.644654471 1.832552553 NABEP1 protein 1 0.454895987 0.549682617 1.788886809 1.796082833 NAA38;LSM8 Nafc auxiliary subunit 0.39982872 0.551329803 2.235873173 3.890010684 PPP1R14B subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.37326622 0.39627533 3.152229659 3.267324489 Serine/threonine-protein kinase greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU2671;POU2F3;POU domain, class 2, transcription factor 1;POU domain, 2F2 0.349388886 0.288489151 3.30995442 2.093793691 Isochorismatase domain- Itass chronisming edomain, 1;POU2673;POU domain, class 2, transcription 0.349388886 0.288489151 3.30995442 2.093793691						
OTRTD1 subunit QTRTD1 0.458888245 0.388759232 2.644654471 1.832552553 RABEP1 protein 1 0.445495987 0.549682617 1.788886809 1.796082833 NAA38;LSM8 N-alpha-acetyltransferase 38, NA338;LSM8 N-alpha-acetyltransferase 38, NA338;LSM8 0.549682617 1.788886809 1.796082833 PP1141 Subunit 14B 0.39982872 0.551329903 2.235873173 3.890010684 PP11418 subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 NudC domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 MASTL greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU267;POU2F3;POU2F3;POU domain, class 2, transcription factor 1;POU domain, class 2, transcription factor 2; 0.349388885 0.288489151 3.30995442 2.093793691 ZF2 chorkinsmate domain- 0.349388885 0.284849151 3.30995442	DPH2	2 Queuine tRNA-ribosyltransferase	0.497331238	0.820111465	1.968375602	3.884416406
RABEP1 protein 1 0.445495987 0.549682617 1.788886809 1.796082833 NAA38,LSM8 Natio auxiliary subunit 0.39982872 0.551329803 2.235873173 3.890010684 PP1E114B subunit 148 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1:MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.366851196 2.11082335 2.381141628 KIAA1068;NUDCD3 NudC domain-containing protein 3 0.3726622 0.99627533 3.152229659 3.267324489 Serine/Itreonine-protein kinase 0.364876556 0.264849472 2.200170848 2.276245822 POU20F1;POU2F3;POU1domain, class 2, transcription factor 3;POU domain, class 2, transcription factor 3;POU domain, class 2, class 3, class 4, class 3, class	QTRTD1	subunit QTRTD1	0.458888245	0.388759232	2.644654471	1.832552553
NAA38;LSM8 NatCauxiliary subunit 0.39982872 0.551329803 2.235873173 3.890010684 PPP1R14B subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 NudC domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 Serine/threonine-protein kinase greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, 2F2 class 2, transcription factor 2 0.349388885 0.288489151 3.30995442 2.093793691 Schorborismatsee domain- 0.349388885 0.288489151 3.30995442 2.093793691	RABEP1		0.445495987	0.549682617	1.788886809	1.796082833
PP1R14B Protein phosphatase 1 regulatory subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068;NUDCD3 Nu4C domain-containing protein 3 0.3726622 0.39627533 3.152229659 3.267324489 MASTL greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, 2F2 0.349388885 0.288489151 3.30995442 2.093793691 Isochorismatase domain- lext 0.349388885 0.288489151 3.30995442 2.093793691	NAA384 SM8		0 30082872	0 551329803	2 235873173	3 890010684
RPRC1:MAP7D1 MAP7 domain-containing protein 0.376734161 0.356851196 2.11082335 2.381141628 KIAA1068:NUDCD3 NudC domain-containing protein 0.37226622 0.39627533 3.152229659 3.267324489 Serine/Ihreonine-protein kinase greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, 2F2 0.39938885 0.288489151 3.30995442 2.093793691 Isochorismatese domain- Isochorismatese domain- 0.349388885 0.288489151 3.30995442 2.093793691		Protein phosphatase 1 regulatory				
KIAA1068:NUDCD3 NudC domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 Serine/Threonine-protein kinase greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, 2F2 0.39938885 0.288489151 3.30995442 2.093793691 L L 0.34938885 0.288489151 3.30995442 2.093793691						
Serine/threonine-protein kinase greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, class 2, POU2F1;POU2F3;POU transcription factor 2 0.364876556 0.264849472 2.200170848 2.276245822 POU2F1;POU2F3;POU transcription factor 1;POU domain, 2F2 class 2, transcription factor 2 0.349388885 0.288489151 3.30995442 2.093793691 Isochorismatase domain- Isochorismatase domain 0.34938885 0.288489151 3.30995442 2.093793691						
MASTL greatwall 0.364876556 0.264849472 2.200170848 2.276245822 POU domain, class 2, transcription factor 1;POU domain, class 2, r r	KIAA1068;NUDCD3	NudC domain-containing protein 3 Serine/threonine-protein kinase	0.37326622	0.39627533	3.152229659	3.267324489
factor 1;POU domain, class 2, factor 1;POU domain, class 2, POU2F1;POU2F3;POU[transcription factor 3;POU domain, class 2, transcription factor 2 0.349388885 0.288489151 3.30995442 2.093793691 Isochorismatase domain- Isochorismatase d	MASTL	greatwall	0.364876556	0.264849472	2.200170848	2.276245822
Isochorismatase domain-		factor 1;POU domain, class 2, transcription factor 3;POU domain,	0 34030000F	0 288490151	3 30005442	2 003702604
ISOC2 containing protein 2, mitochondrial 0.348838043 0.475136185 2.388902268 1.892604518		Isochorismatase domain-				

List of proteins downregulated upon knockdown of UBE2K in hESCs

Dart Translots (UP) 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.2855207 2.5555207 1.5577277 1.1077461 VERTING Collage and processing from the collage and prom the collage and prom the collage and processing fro	-					-	
DeckaPper MeRC general in a protein in a submit of a s	Gene names	Protein names	UBE2K	UBE2K	UBE2K	UBE2K	
Darabotic QLP*, protect -2.2955007 -2.2955007 -2.2955007 -1.4971023 -0.2971024 RED protect -2.2455276 -2.2150277 -2.1571027 -0.1571124 RED protect -2.2452000 -7.465233 -0.1571243 -0.1571244 SPIL Protect protect protect -1.0571270 -1.0571244 -1.0571244 SPIL Protect protect protect -1.0571270 -1.0571244 -1.0571244 SPIL Protect protect protect -1.0571240 -1.0571244<	CDC42BPG	MRCK gamma	-3.308805466	-3.671895218	2.313874392	2.572145401	
Bits Discussion 2-742017 2-221000 1.4850000 0.017214 DP01L Systems 1-Mar protein 2-0420000 2-27489-33 19/97232 2.003344 DP01L Systems 1-Mar protein 2-0420000 2-27489-33 19/97232 2.003344 Stati Arrange 1-10000000 1.00000000 1.0000000	GUF1	Translation factor GUF1,	-2.985452271	-2.228926849			
Dynamics Dynamics 2.84240000 2.72489423 1.8770720 2.0023144 NRMMANDE / 4 and antranangehout monach		Iron-responsive element-binding					
shtms/201		Glycerol-3-phosphate					
Seg 0 Name of mumoropholin dominal 2 1.5914000 1.5914000 COL AL Collegen after 10, due -1.8974200 -1.79041380 3.0917427 COL AL Collegen after 10, due -1.99742000 1.0924900 3.0917427 CAR Collegen after 10, due -1.9974200 1.2924900 1.2921920 CAR Collegen after 10, due -1.9974200 1.29244500 2.07552207 0.2927297 CHE Collegen after 10, due for 10, d	HNRNPA2B1	achydrogenado i niko proteini					
CDL1A1 Colagon anthe 110 sham -1.89742200 -1.79843802 3.8974327 1.79843802 3.8974327 1.79843802 3.8974327 1.2912353 LOP1 Nonolog -1.89148980 -1.19427915 1.9999980 0.9977427 LAR -7.8974767 -6.89151745 1.91158902 1.2921353 BESENF1 Andre & Bengonie -1.69049037 -0.38479300 0.38572277 0.98772270 Start & Bengonie -1.6944903 -1.91164902 1.2922882 -0.9869905 1.2922882 4.989990 1.2922882 4.989990 1.2922882 4.989990 1.999990 1.999990 1.999990 1.999990 1.999990 1.999990 1.999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.9999990 1.999990 0.999990 1.999990 0.9999990 1.9999990 0.9999990 1.9999990 1.9999990 1.9999990	VSIG1	V-set and immunoglobulin domain- containing protein 1		-2.415558243			
E.OF1 Transcription elengetion factor 1.8016800 1.19027981 1.2902900 0.80171847 CAR CM -0.7467785 1.68115115 1.016880 1.2017281 CAR CM -0.7667785 1.68115115 1.016880 1.2017281 CRENET Biol & Ensition factor -1.8006218 -0.8007285 1.53116892 1.0505201 CRENET -1.8006218 -0.8007286 1.5111692 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.22224221 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222421 1.2222441 1.2222441 1.2222441 1.2222441 1.2222441 1.2222441 1.22224411 1.22224411 1.222							
DAR - 1.487478 - 1.8313512 - 1.1016388 1.201232 RF3 APF-Renoration Level - 1.00002118 - 0.8070279 2.0752227 0.0000217 RF3 APF-Renoration Level - 1.00002118 -0.8070278 1.00002118 0.997028 0.080708 RF10 -1.60708441 -1.00002118 -0.8070278 1.0000211 0.202227 1.2224422 C1111 -1.9074801 -1.4090446 -1.491221 2.2027227 1.2224422 SRPA -1.0000101 -1.4504448 -1.491221 2.2027227 1.2224422 SRPA -1.0000101 -1.4504458 -0.7050502 2.2027227 1.2224422 SRPA -1.0000101 -1.4504458 -0.7050502 2.2071473 1.500007 SRPI -1.0000101 -1.1370142 -0.7050502 2.207148 3.807170 SRPI -1.000007 -0.2070502 2.207148 3.807170 3.501172 -0.7060502 -0.207148 3.807170 SRPI -1.000007 -0.207111 -1.1507141 -1.1508044 3.907804		Transcription elongation factor 1	-1.801469803	-1.104278183	1.79999936		
ABC3 ADP-description lack of a support support of a support of a support of a support of a supp	CALR					1.22012352	
EFENT into & Emagodaria -1.60062186 -0.88728554 1.53118942 D.000977 EFE1D Interface -1.60062186 3.537029 0.2863052 Cheffac Interface -1.6064405 -1.6046037 1.824024 1.2005717 Address Interface -1.4330246 -0.8523457 2.20087229 1.228442 SPRA Annal moder memory	ARF3	ADP-ribosylation factor 3	-1.706129074	-1.226445007	2.075322275	0.897027955	
21et52 PFE30 parties Cutt2 1.5944033 -1.04140037 1.820246 1.905311 GPNT5 hapdren dyeers/springhame -1.48304468 -1.4140037 1.225442 SNBA A small nuclear molecontext -1.44330286 -0.88324437 2.20037229 1.222442 SNBA A small nuclear molecontext -1.42330286 -0.86324437 2.20037229 1.222442 SNBA A small nuclear molecontext -1.37960156 -0.20231164 2.407147214 1.728260 SNBA Hateomador SNB 18 -1.27974028 -0.86323487 2.4011486 4.8010746 SNB1 Hateomador SNB 18 -1.272842813 -1.41696243 1.35969664 2.2119116 SNB1 Hateomador SNB 18 -1.05282022 -1.6119824 2.28250644 1.1044327 APC0EC 28 Audior and uning mayme -1.05282027 -0.85213142 2.28250644 1.1044327 APC0EC 28 Audior and uning mayme -0.052713142 2.28250644 1.1044327 APC0EC 28 Audior and uning mayme -0.054202457 -0.352131422 2.2827272	EIF4ENIF1		-1.609062195	-0.896789551	1.531168942	1.00059775	
Haybin for any series 1.4850448 1.49192341 2.20057207 1.222442 SNEPA J. and muchan formula protein 1.4530428 1.21632888 4.151197 SNEPA J. and muchan formula protein 1.14230228 1.21632888 4.151197 SNEPA J. and muchan formula protein 1.127204282 1.21632847 0.2038000 1.900287 SNEPA Snefet local accients 1.127204282 1.7208887 2.44518805 4.851197 SNEPA Market macerone ASE1 1.127244283 1.12606664 1.797144 SNEPA Market macerone ASE1 1.13737147 0.444219423 1.92666664 1.797144 SNEPA Another macerone ASE1 1.15330724 0.4922945 1.890586 2.1911916 APCAL Another macerone ASE1 1.15330775 0.4922945 1.890586 2.1911916 APCAL Another macerone ASE1 0.052077 1.92058658 1.1971948 APCAL Another macerone ASE1 0.052077 1.1615919 1.1620586 1.9904238 2.2027223 STE1	EEF1D		-1.547586441	-1.001054382	1.35970928	0.82569350	
GPATS indemoderative again -1.48304469 -1.49303141 220872221 2.20872221 5.226442 BSPA A Indextomadin-ska praten 3 -1.42330223 -6.142532341 6.24538000 1.1020277 DLPAL3 Offlactomadin-ska praten 3 -1.42532284 -0.35532437 6.22638000 1.930277 DLPAL3 Derate KB1 homolog -1.32764283 -1.27024813 1.24144263 1.2301172 0.00007 4.0011742 0.0001747 0.0001747 0.0001747 0.0001747 0.0001747 0.000174	C1orf52	UPF0690 protein C1orf52	-1.506440353	-1.041460037	1.82405246	1.09050319	
SNPPA A -1.49201228 -1.11682086 -1.12162288 A.1511107 OLRMA Difficientedin-Regretein 3 -1.32780015 -0.82243156 -2.08714721 17.528000 RIT Protein KB1 thomolog -1.33780015 -0.82243156 2.067147216 17.528000 RUT Statel locus geomics -1.33780015 -0.82243156 2.067147216 17.528000 SET2 Statel locus geomics -1.13237227 0.75053022 2.4513800 4.010746 SET3 Malsone changenoue ASF18 -1.15237222 -1.15781470 -0.4244510 2.20050864 2.1006397 SET4 Abstone changenoue ASF18 -1.0650007 -0.39213422 2.228500842 1.194557 APCEC 38 MALGH (18.000000 -0.39213424 2.289500842 1.191595 1.10704001 SERIE Selicing hear-spread -0.09213424 2.282500842 1.191595 1.10704001 1.01704001 SERIE Selicing hear-spread -0.0921462 -0.39213424 2.28250864 1.10704001 1.10714001 1.11714001 1.10714001	AGPAT5	acyltransferase epsilon	-1.483044434	-1.491923141	2.202672297	1.22254422	
n 1.3799095 -0.8224355 2.07147213 1.722905 Suffel Loose protein 2 1.34292263 0.70503052 2.19209462 0.00509452 Suffel Loose protein 2 1.13231217 0.97269115 2.4019805 4.8017747 TAGLM Transgein 1.132326542 1.678313446 1.9839960 3.2500193 NUEster Transport -1.133271477 0.40692353 1.55417712 1.00530978 APOEEC3B PAVAGC-31-eding enzyme -1.0653067 0.30213142 2.28250662 1.1914357 APOEEC3B PAVAGC-31-eding enzyme -1.06540717 -1.8113863 1.87791657 1.679033209 1.5911597 APOEEC3B PAVAGC-31-eding enzyme -0.90271993 -1.11122466 1.5993229 1.5911597 BERDHOM Tasseded -0.90271993 -1.11122466 1.39932266 2.0227123 BERDHOM Tasseded -0.9027462 0.2581675107 1.9594228 2.0227123 STS1 Granuft-AGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SGranuft-SG	SNRPA	U1 small nuclear ribonucleoprotein A	-1.443012238	-1.914863968	1.216235856	4.16511167	
SRII Protein KRII homolog 1.34292288 0.72563302 2.1820455 0.9090455 SRF2 Subtractionage control 1.23132172 0.9726911 2.0101468 3.0627274 SRF2 Hatten chapeone ASF1B 1.27262833 1.41806424 1.3255066 1.7977240 NRF2 Hatten chapeone ASF1B 1.127264231 1.7881744 1.0853727 0.0065373 1.15751477 1.0063277 APOL2 Apologoretin 1.2 1.137574770 0.48224469 1.55559986 2.2189159 APOL2 Apologoretin 1.2 1.13751477 0.48224469 1.55559986 2.2189159 APOLEC3B Apologoretin 1.2 0.92220459 0.3801207 1.95933299 1.5112591 MERLA Apologoretin 1.2 0.92220459 0.4593240 1.2256421 1.256574 MERLA Caral 5 Thransenin 0.9024462 0.5516750 1.1546101 TOTEL Caral 5 Thransenin 0.9022462 0.5516750 1.955828 1.255674 MERLA Caral 5 Thransenin 0.90224624 0.55052694 4.4	OLFML3	Olfactomedin-like protein 3	-1.423392868	-0.385329437	6.236388008	1.9002374	
Buff-2 Suffet Isous protein 2 -1.28313217 -0.9729118 2.91013488 -3.9837261 TAGLM Transelin -1.273743263 -1.180692451 -2.2620681 -7.1767504 NSF1E Halson chaperona ASF18 -1.272424313 -1.081962451 -2.2620681 -7.1767504 NSF1E Audiat reseptor-binding factor 2 -1.19326542 -1.6539167 -0.30813142 -2.8220686 -1.1093067 APOLE C3B PAVA 62-41 editing enzyme -1.05395077 -0.33213142 -2.8220568 -1.0519307 Spelloc fattor 3B suburit -1.05395077 -0.32213142 -2.8220568 -1.0519307 Spelloc fattor 3B suburit -1.05395077 -0.35331207 1.6959428 -2.0227123 ST3 - -0.90214963 -0.2230569 -0.65331207 1.6959428 -2.0227123 ST3 - -0.9031442 -0.23005052 -1.0559025 1.1561015 Granults - Commins - Communic - C			-1.379608154	-0.822431564	2.067147219	1.7528805	
DAGLM Trassanin 1.2794928 1.7809897 2.44519855 4.40107466 SRTB Hatere chapter binding factor 2 1.19322624 1.67831346 1.32894007 2.000133 VRFGZ Molder receptor binding factor 2 1.19327624 1.67831346 1.32894007 2.000133 APOL2 Apollogotatini L2 1.13578107 0.40294405 1.3599407 2.000133 APOEC.28 Splicing factor 28 mahariti 4 1.0550707 0.39213142 2.28209642 1.1948357 SPEM Splicing factor 28 mahariti 4 1.054270117 1.851135635 1.57749155 1.6769820 JBER/HZ Molder Springer Paragemeting 0.90220495 0.63312007 1.9984288 2.0227123 STESI Carolin S Phane expression 0.09224642 0.58167610 1.9758328 1.1256674 Granulin - Granul	KRI1	Protein KRI1 homolog	-1.342892838	-0.750530624	2.182094652	0.90980943	
SETIB Hazane observed ASF IB -1.7272423 -1.81086243 1.22509065 -1.7877344 NRBF2 Hudear mergeto-binding factor 2 1.19327242 2.67831346 1.98319840 3.260139 APOL2 Apoligorotein L2 1.137781477 -0.440224693 1.85599286 2.2189185 APOLEC3B APOLEC3B -1.06540717 1.81513651 1.77791657 HATORES APOLEC3B APOLEC3B -0.06540777 0.58113624 2.92206622 1.1943574 MRPL2 Mitch-coll-galing mayme E2 0.94203246 -0.23005658 6.0522188 2.12291816 STRET Stands Phase-expressed -0.9224667 1.81313621 1.9785423 2.0278232 STRET Granuline-CommunParagranuing -0.90246462 -0.58167810 1.9584238 2.0278232 STRET Granuline-CommunParagranuing -0.9024642 -0.58167810 1.9584238 2.0278232 STRET Granuline-CommunParagranuing -0.9024642 -0.58167810 1.9359095 1.2556744 STRENB2 Symin B -0.90224645 -0.781	SURF2	Surfeit locus protein 2	-1.283132172	-0.97299118	2.910134881	3.96372761	
NBBF2 Nuclear mesoper-binding factor 2 1.193225542 -1.673313444 1.93393640 3.2000333 APOL2 Apolipopretiin 1.2 1.193271477 Apolipopretiin 1.2 1.193271477 Apolipopretiin 1.2 1.193271477 Apolipopretiin 1.2 1.193271477 Apolipopretiin 1.2 1.19327147 2.292206642 1.1943570 SPEAL Splicing factor 38 subunit 4 -1.054370171 -1.65313643 1.277491557 1.67068001 SPEAL Splicing factor 38 subunit 4 -1.054370171 -1.63236686 6.0522188 2.1229161 SPEAL Displant-comparison 2.2 -0.0220469 0.63331200 1.9534238 2.0227023 STR3 Granuline-Acrogranin-Paragranuline-Splantine-	TAGLN					4.80107466	
Image: space of the s	ASF1B					1.79675048	
upCl2 psisting-output 1.135781477 0.49224403 1.83560968 2.219115 APOBEC3B APAGEC3B 1.0500077 0.3213142 2.28250642 1.1994357 SF3H Split incorring urbins 0.07219837 1.1125466 1.2593320 1.277491857 1.570491857 SF3H Split incorring urbins 0.07219837 1.1125466 1.2593320 1.29593320 2.02279323 STSE1 S2 and 5 phase expressed 0.94203242 0.2550568 6.05221482 2.12291816 STSE1 S2 and 5 phase expressed 0.942032442 0.2550568 6.05221482 2.02279323 STSE1 S2 and 5 phase expressed 0.9224657 1.61000675 1.156101 STSE1 S2 and 5 phase expressed 0.9224642 0.251677102 1.9793328 1.2156674 SERPINBD Semania-S, Granulin-S, Granulin-S	INRBF2	Nuclear receptor-binding factor 2				3.26001938	
DNA 62-cli-eding exyme -1.0630677 -0.39213142 2.28250642 1.194357 SF3B4 Spicing factor 28 suburit 4 -1.0650677 -1.8113653 1.377491857 1.6706803 MPPLE2 Mitochondrial -0.92799831 -1.1125466 1.28932329 1.5012637 JBE2X-HIP2 Za and 5 phase-expressed -0.9220495 -0.633312607 1.6934238 2.1223181 JBE2X-HIP2 Za and 5 phase-expressed -0.9220495 -0.53312607 1.516908575 1.1546103 JBE2X-HIP2 Simulin-A congume Paragranula -0.90214476 -1.33248657 1.81908673 1.256674 SRN Granulin-C and monocomal protein -0.9023462 -0.58167612 1.9758326 2.886733 SRN Granulin-T and monocomal protein -0.89394831 -0.38204552 4.640291608 2.886733 MRPL30 Mitochonomal protein -0.891757272 -0.705495453 1.3558805 1.830007 MACD1 Mitochonomal protein -0.81775727 -0.705495453 1.3441888 1.7226174 MILO Mado signese-refn domain -0.80	4001.2	Applingmentain 1.0					
SF3B4 Splicing factor 38 subunit 4 -1.054370117 -1.8513668 1.377401857 1.67008001 MRPLs2 Disk absorbance movime in 52, -0.3219933 -1.11235466 1.25993329 1.5011299 UBE 2X-HIP2 K -0.940032244 -0.25005685 6.05221883 2.1229181 JEE 2X-HIP2 K -0.94014477 -1.339248657 1.61908677 1.15461013 JTS1 Granufan-Consult+Scientures -0.90024462 -0.581676102 1.9783328 1.21568746 Granufan-Consult+Scientures -0.90024642 -0.581676102 1.9783328 1.21568746 SRN Granufan-Consult Protein Cap -0.90024642 -0.581676102 1.9783328 1.21568746 SRN More and protein Cap -0.90024642 -0.581676102 1.34319409 1.3891846 MRPL30 Stationa chromosomal protein -0.90024642 -0.581676102 1.34319409 1.3891846 MRC11 -0.91024642 -0.78164703 -0.46403882 1.24119999 1.3811846 MRC11 -0.91710877 -0.781677733 -0.644038927 1.9		DNA dC->dU-editing enzyme					
MRPLS2 398 fitosonal protein LS2, mitochondria 0.97219631 -1.123546 1.25993329 1.50112591 UBEXK-HIP2 Ubiquin conjugating excyre E2 0.94203224 0.2550563 6.0522188 2.1229181 GTSET protein 1 0.922045 0.2550563 6.0522188 2.1229181 GTSET protein 1 0.9220467 -1.3324865 1.8199627 1.154017 Granulin-4, Caraulin-S, Granulin-G, Granulin-G, Granulin-4, Caraulin-S, Granulin-G, Granulin-G, Granulin-G, Granulin-G, Granulin-G, Granulin-G, Manulin-S, Granulin-G, Manulin-G, Manulin-S, Granulin-G, Manulin-S, Granulin-G, Manulin-S, Granulin-G, Manulin-S, Granulin-G, Manulin-G, Manulin-G							
Ubicultin-conjugaling enzyme E2 0.94203224 0.23505085 6.0522188 2.1221181 STE1 Drolen 1 0.9021476 0.33312607 1.96394238 2.0227923 STE3 Drolen 1 0.9021476 0.33312607 1.96394238 2.0227923 STE3 Drolen 1 0.9021476 1.339248657 1.9759336 1.21566746 STE3 Oranulin-S, Caronulin-S, Caron		39S ribosomal protein L52,					
UBE2K/HIP2 K 0.94203242 0.235005688 0.65221888 2.1229181 STSE1 Drotein 1 0.9221456 0.433312607 1.9594238 2.022792X STR3 Granulin-S, Cargunin-P, argurgunin 0.39214476 1.332248657 1.51960747 SRN Granulin-S, Cargunin-S, argurgunin 0.90234642 0.581676102 1.9758326 1.21566746 SRN Granulin-S, Cargunin-S, Granulin-S, Gra			-0.972199631	-1.11235466	1.259933299	1.50112591	
CTSE1 protein 1 -0.9220458 -0.63312607 1.63942384 2.0279235 STR3 Granulin-S, Corganin-Pargranulin-S, Granulin-S, Granulin	UBE2K;HIP2	ĸ	-0.942032242	-0.235050583	6.052221883	2.12291818	
Granuline.Actogranin.Paragranuline Granulin-4.Granulin-5, Granulin-5, Granulin-6, Granulin-6, Granulin-1, Granulin-	GTSE1	protein 1	-0.92220459	-0.633312607	1.963942384	2.022792307	
Caraular-LGranular-Scanul	BTF3	Grapulins:Acrograpin:Paragrapulin	-0.90814476	-1.339248657	1.619096575	1.154610138	
GRN Granulin-7 -0.00234642 -0.58175102 1.755328 1.1556726 SERPINB9 Serin B9 389 hostondal -0.88599513 -1.07512102 1.640291608 2.8862738 MRP130 Non-histone dromosomal protein 10, mitechondral -0.885959513 -1.075121022 1.433190498 1.39813845 MRN1 LM and cysteme-rich domains -0.81708285 -0.389153843 3.02441736 0.9191335 JMCD1 LM and cysteme-rich domains -0.81707826 -0.389154328 3.34491885 1.72361742 SIA1 Abbra 1 protein Cells, Gep junction -0.814079254 -0.399154328 3.34491885 1.72361742 SIA1 Miln 1 -0.80524991 -0.31871032 2.09371789 2.374268 RASC Bas-reliated orotein Rab-SC 0.800119781 -0.239589882 1.574167923 1.39619945 PYSL3 Jordein James, Scharbonylating -0.7594771 0.8177027 1.5564425 SASSI Arginohusucchate synchase -0.7051977216 2.773724515 3.16244575 Large eutral amon acids -0.701167		Granulin-1;Granulin-2;Granulin-3;					
393 Shoosmal protein 130, mitochondral -0.88539581 -1.076121902 1.34319048 1.3961364 HMSN1 MMC-14 -0.88539581 -0.70549545 1.3858865 1.6380667 LMCD1 LM and cystem-inch domains -0.81792727 -0.705495453 3.34481885 1.7281742 LMCD1 Casp junction protein/Gap junction/Gap j	GRN	Granulin-4, Granulin-5, Granulin-6, Granulin-7	-0.90234642	-0.581676102	1.9758326	1.215667468	
MRPL30 mitochnodnial -0.88539513 -1.076121902 1.343190489 1.3861364 HMGN1 Mon-histone dromosomal protein 0.86175727 0.705496452 1.38568060 1.5380067 LMCD1 Main orgetene-rich domains 0.81079285 0.3084147366 0.919133 GA1 Mabh-1 protein 0.81079285 0.38816388 3.344418885 1.72837478 AlL1 Valin-1 0.80524991 0.731871032 2.803870769 2.3724284 RABSC Ras-relisted protein Rab-SC 0.8000119781 0.29566827 1.5101014 1.47999951 DPVS13 DPhydropyrminase-relisted 0.76995773 0.64463824 1.574167923 1.55044592 MRPL48 385 riboosmal protein L48, sphosphoguconate 0.73450927 0.65760383 2.06917207 1.55644252 SLC755 att Large neutral amino acids 0.7047778 0.65760392 2.07377749 2.4081422 SLC765 Att Angeinosuccinate synthase 0.729293656 0.801021657 1.8443075 1.4348762 CD055ASRPI reutral amino acids 0.70477782	SERPINB9	Serpin B9	-0.89896431	-0.352035522	4.640291608	2.896273366	
HMCN1 HMC-14 -0.81757278 -0.705496453 1.38568805 1.6380067 LMCD1 protein 1 -0.81757278 -0.705496453 1.38568805 1.6380067 LMCD1 protein 1 -0.817088969 -0.899365368 3.04417364 0.9191335 SJA1 Salp incrition protein; Cap junction -0.81072289 -0.73171032 2.03527782 2.3724267 VIL1 Vilin -1 -0.805224991 -0.73171032 2.03527782 2.3724267 RABSC Raminise-material -0.70997733 -0.44433824 1.574167923 1.35046087 DPVSLs protein 3 -0.709967733 -0.64433824 1.574167923 1.35046087 SSSASS1 Argin hour contain synthase -0.72699645 -0.60750392 2.0917207 1.5544455 SSSASS1 Argin hour contain synthase -0.70477752 -0.65550151 1.887752441 2.01596425 SLCZAS Large neutral amino acids -0.70477752 -0.751037216 2.77372451 3.91624867 SLCZAS Large neutral amino acids -0.70477752 -0.5703032716 2.97372451	MRPL30	mitochondrial	-0.885395813	-1.076121902	1.343190499	1.396136452	
LMCD1 protein 1 -0.817088969 -0.893986388 -0.24417364 0.1919133 Gap Jurcitori protein, Gag junction 0.814079286 -0.390154558 -0.34411868 1.72381747 GAL Wiln 1 Viln - 0.805224991 -0.731871038 2.803879788 2.3724268 ABSC Ras-related protein Rab-5C -0.800119781 -0.23668027 1.9101014 1.47999845 DPYSL3 Dhydropyrimdinase-related -0.76944717 -0.817710876 1.331284178 1.16915904 SS-SSS1 Arginopurconate -0.74560277 -0.657503382 2.06917207 1.55644525 ASSASS1 Arginopurconate -0.72460277 -0.657503382 2.06917207 1.5564452 ASSASS1 Arginopurconate -0.72450277 -0.657505151 1.887752441 2.0156657 ASSASS1 Arginopurconate -0.70177727 -0.55501511 1.887752441 2.0156875 CCD055NSRP1 Nodar spacks splicing -0.62239655 -0.801021957 1.8443075 1.544826 CCD055NSRP1 Nodar spacksproprotails -0.55169924 <td< td=""><td>HMGN1</td><td>HMG-14</td><td>-0.861757278</td><td>-0.705495453</td><td>1.38586805</td><td>1.6380067</td></td<>	HMGN1	HMG-14	-0.861757278	-0.705495453	1.38586805	1.6380067	
GAT absh-1 protein -0.81407228 -0.30154358 3.344818885 1.7281747 VIL1 Vilin-1 0.805224991 -0.731871033 2.803570789 2.3724285 ABSC Ras-related protein Rab-SC 0.800119781 0.29568027 1.9101014 1.47299951 DPV5L3 Drotein 3 -0.7696773 0.64453852 1.57416792 1.35046026 MRPL48 Patochondial -0.7696773 0.64750388 2.06917207 1.5564425 ASS.ASS1 Anginicate-citate struthand -0.72999544 -0.607500382 2.06917207 1.5564425 ASS.ASS1 Anginicate-citate struthand -0.72999544 -0.6075002 2.973746 2.4061422 ASS.ASS1 Anginicate-citate struthand -0.72999544 -0.65501511 1.887752441 2.01596976 ANXA3 Annesin ASAmeain -0.71616776 -0.75103716 2.77372415 3.91624817 CCDC55NSRP1 Induaraterizad protein 1 -0.55169629 -0.4417305 1.1543762 9.27373452 CS104743 Uncharacterizad protein 150 -0.551690827	LMCD1		-0.817088699	-0.889386368	3.024417364	0.919913399	
ML1 Valin-1 -0.80522499 -0.73187103 2.803870769 2.3724288 RABSC Ras-related protein Rab-SC 0.800119781 -0.29566827 1.9101014 1.47999951 DPYSLS protein 3 -0.769857733 0.64453824 1.574167923 1.5046095 MRPLa8 385 ribosomal protein L48, shoptophoutonate dehydrogenase, decaboylating -0.76995773 0.64453824 1.574167923 1.55644255 ASSASSL Argininauccinate synthase -0.72929545 0.80750302 2.073727748 2.40814252 Large neutral amino acids -0.701567078 0.751037216 2.773724515 3.91424661 NAXA3 Annexin A3Annexin -0.701567078 0.751037216 2.73724515 3.91424661 CDC055.NSRPI regulatory protein 1 -0.655803387 -0.7417305 1.48430755 1.4548762 C10443 Uncharacterizate protein 1 -0.6558023877 0.7417305 1.71818075 0.75303271 C2055.NSRPI regulatory protein 1 -0.545432745 0.400045712 1.8717354 1.8817323 1.3744564 UNA	GJA1		-0.814079285	-0.369154358	3 344818885	1.72361745	
DPytR13 DPytR14 -0.76965773 -0.64453822 1.574167923 1.35046096 MRPL48 385 Rhosomal protein L48, mitochondiati -0.76965773 -0.64453824 1.574167923 1.35046096 MRPL48 Shosomal protein L48, mitochondiati -0.76904717 -0.817710876 1.331284178 1.16615944 SSASS1 Argininesuccinate synthase charge neutral amon acids -0.729299544 -0.66750392 2.97372749 2.40814222 SLC7A5.strl Imagenetral amon acids -0.70156778 -0.55350151 1.88775244 2.01996577 SLC7A5.strl Imagenetral amon acids -0.70156778 -0.7013077 2.77372441 2.0199657 SLC7A5.strl Imagenetral amon acids -0.70156778 -0.70140775 -1.5438782C CCD055XISRP Nuckar speckle splicing -0.62930565 -0.801021957 1.5438782C C160rd3 Uncharraterized protein 1010 -0.55199827 -0.42811267 2.77372445 -0.80731957 FPM -0.51492774 -0.4026712 1.81374455 1.8374455 DNA/C3 member 3 -0.545	VIL1					2.3724286	
DPYSL3 protein 3' -0.769867733 -0.64433824 1.574167923 1.50046096 MRPL48 305 ribosomal protein L48, mitochondrial -0.76794471 -0.817710576 1.331264178 1.16915944 MRPL48 mitochondrial -0.734099275 -0.65780383 2.06917207 1.55644255 SSS.SSS1 Argrinosuccinate synthase -0.72929954 -0.60750302 2.97573749 2.40611222 Large neutral amino acids -0.701567072 -0.751037216 2.773724515 3.91624661 SLC765.StRSP1 regional syntha -0.701567078 -0.751037216 2.73724515 3.91624661 CC025.SNSP1 regional syntha -0.701567078 -0.751037216 2.73724515 3.91624661 C2025.SNSP1 regional intrase C (Frotein Kinase C) -0.55691984 -0.44667053 2.310459425 2.237838125 PRCKA alpha type -0.551309337 -0.74117305 1.71818075 0.7374455 IMMC -0.554302745 -0.40042612 1.68113322 1.5374455 IMMC -0.554302745 -0.400426712 1.715180762<	RAB5C	Ras-related protein Rab-5C	-0.800119781	-0.295869827	1.9101014	1.479999516	
MREPL48 mitochnodnal -0.75794471 -0.81710876 1.33264178 1.16815994 Sephosphoguconate dehydrogenase, decarboyulsing -0.73609277 -0.85703838 2.06917207 1.55644255 SSSASS1 Argrinosuccinate synthase -0.72929945 -0.85703838 2.06917207 1.55644255 SSCASS1 Argrinosuccinate synthase -0.72929945 -0.85753011 1.887752441 2.01969275 SLC7A5.tart transporter small skuhuri -0.70477527 -0.55101716 2.737724515 3.91624867 CC05.5NSRP1 regulatory protein -0.629239656 -0.801021957 1.4543782 C2005.5NSRP1 regulatory protein 1 -0.629239656 -0.40102157 1.78138075 1.538782 C2005.5NSRP1 regulatory protein 1 -0.55169962 -0.4417305 1.718180754 0.97031957 PRCA alpha type -0.551699622 -0.428171627 3.778522928 1.414325 LIMOZ LIM domain-containing protein 7. -0.5433997 -0.342870441 1.715134625 1.8271334 DNALCS Dmal hornolog subfamily C <td< td=""><td>DPYSL3</td><td>protein 3</td><td>-0.769957733</td><td>-0.644638824</td><td>1.574167923</td><td>1.350460988</td></td<>	DPYSL3	protein 3	-0.769957733	-0.644638824	1.574167923	1.350460988	
B-phosphogluconate dehydrogenase, decarboxytaing dehydrogenase, decarboxy	MRPI 48	39S ribosomal protein L48, mitochondrial	-0 767944717	-0.817710876	1.331264178	1 16915994	
ASSASS1 Anginiosuccinate synthase -0.72329954 -0.6075302 2.973673749 2.40814222 SLG7A5_btt1 Large nutral amino acids -0.70177527 -0.653501511 1.887752441 2.01596576 SLG7A5_btt1 Annexin alkunin 1 -0.7014777527 -0.653501511 1.887752441 2.01596576 NXKA3 Annexin alkunin 1 -0.7014777527 -0.553051511 1.887752441 2.01596576 DCDC5.SNRPPI traulatory trolein 1 -0.629239656 -0.801021957 1.4548782 DCDC5.NRPPI traulatory trolein 1 -0.557565419 -0.44467052 2.210569422 2.37838122 2.37744522 2.37784522 2.377445242 2.37784522 1.8711532 1.3744564 Protein Kinase C -0.551699822 -0.42873721 1.75154622 1.82713634 DNA/C3 Dnah homding sublamily C -0.554282746 -0.04042812 1.88119325 1.35744564 DNA/C3 Dnah homding sublamily C -0.554282746 -0.04042812 1.8571956 1.88010602 DNA/C3 Dnah homding sublamily C -0.554282746 -0.04042812 <td></td> <td>6-phosphogluconate</td> <td></td> <td></td> <td></td> <td></td>		6-phosphogluconate					
Large neutral amino acids transporter analis skunit 1 -0.70477752 -0.65350151 1.88775241 2.0159857 ANXA3 Annexin A3-Annexin -0.70477752 -0.65350151 1.88775244 2.0159857 ANXA3 Annexin A3-Annexin -0.701567078 -0.751037216 2.77374515 3.91624861 CCDC55.SNSP1 regulatory protein 1 -0.629239655 -0.801021957 1.84439775 1.4543782 C190rH3 Undmarcherized protein 1 (190rH3 -0.575003387 -0.74417305 2.10469425 2.9738125 Protein Namae C, Potein Kinse C -0.573003387 -0.74417305 1.718180754 0.97301957 PML domain-containing protein 2 -0.54582746 -0.40042612 1.8731325 1.53744554 JIM02 LM domain-containing protein 2 -0.54282746 -0.40042612 1.88101062 1.82713845 JIM02 LM domain-containing protein 7 -0.52000504 -0.300480142 2.50784455 1.8801062 PL19 Rboornal protein 119 -0.51336286 -0.57076128 1.330561041 1.4528953 SP1 Advirated RNA polymer	455-4551						
ANXA3 Annexin A3,Annexin -0.70166707 -0.751037216 2.773724515 3.9162461 CCDC55NSRP1 Nudkar speckle splicing regulatory protein 1 -0.629239655 -0.801021957 1.84430775 1.54387820 CCDC55NSRP1 Uncharacterized protein 1 -0.629239655 -0.801021957 1.84430775 1.54387820 C19dr43 Uncharacterized protein 1 (19:043) -0.57564194 -0.444667055 2.31465425 2.37583727 PRKCA alpha type -0.573003387 -0.74417305 1.716180756 0.97031857 PMM -0.551699820 -0.428111267 3.7765220201 1.6413225 1.87744554 MRP27 285 0hoosmal protein 7, entorhondial -0.54282746 -0.400942612 1.881931325 1.33744554 NRP27 285 0hoosmal protein 1.90 -0.513403766 -0.426737213 1.775519636 1.40289535 DNALC3 member 3 -0.522000504 -0.36056044 2.1308713 1.3268713 P11 ohosamal protein 1.19 -0.513403786 -0.47678128 1.830620421 1.3208713 P21.5 Ac		Large neutral amino acids					
Nuclear speckle splicing regulatory rotein 1 0.629239655 0.801021957 1.84430775 C106r43 Unbarancetrized protein (120r43) 0.57564139 0.444667058 2.10456425 2.37538125 PRCA Bipha type 0.573003387 0.74417305 1.718180756 0.7031957 PRCA Bipha type 0.5513003387 0.74417305 1.718180756 0.7031957 PRCA Bipha type 0.55199822 0.428111267 3.778522828 1.618113222 UND2 LM domain-containing protein 2 0.545282746 0.402074512 1.81819325 1.53744565 NRPS7 Trabschonding 0.522000504 0.342670441 1.715134622 1.8271853 DNALC3 Drah homolog sublamity C 0.522000504 0.36058044 2.25078465 1.88010602 SP1 Trabschonding -0.513430766 0.46737213 1.77551668 1.66289585 SP1 Transcriptional protein 1.19 0.50402176 0.46737213 1.77551668 1.6628958 SP1 Transcriptional protein 1.19 0.50402177 0.478718375 3.0444						2101000010	
C19orH43 Uncharacterized protein C19orH4 -0.575564119 -0.444667052 2.310450425 2.37838124 PRKCA Aphra type -0.551699826 -0.42111267 3.775522328 1.61413222 LIMD2 LIM domain-containing protein 2 -0.551699826 -0.42111267 3.775522328 1.61413222 LIMD2 LIM domain-containing protein 2 -0.54589976 -0.442511267 3.775522328 1.61413222 LIMD2 LIM domain-containing protein 2 -0.545280744 -1.1715134625 1.53744554 MRPS7 mitochondrain -0.5436997 -0.343670441 1.715134625 1.82713534 DNALC3 member 3 -0.51340396 -0.426737218 1.775519638 1.8628058 SF1 -0.51340286 -0.572000544 2.250744455 1.808020442 1.32867133 SVLP1 Protein-L19.8005 -0.51340376 -0.46737218 1.775519638 1.6628958 SULP1 Protein-Containing -0.513402865 -0.572005442 2.13246713 3.94400123 3.9755228 SVAR Cell growth-requalating nucleolar		Nuclear speckle splicing					
Protein kinase C, Protein K, Charles C, Protein K, Prote							
TPM1 -0.551699829 -0.428111267 3.776522928 1.61413222 LIMO2 LIM domain-containing protein 2 -0.554698274 -0.40042612 1.81931325 1.53744554 MRPS7 285 ribosomal protein 1 -0.5435937 -0.42870441 1.71514625 1.82713334 DNALG3 Dnal homolog subfamily C -0.543435937 -0.34270441 1.71514625 1.82713334 DNALG3 Dnal homolog subfamily C -0.52000504 -0.36050444 2.25078455 1.88010802 SPL19 Robosomal protein L19.605 -0.513302786 -0.426737213 1.773516636 1.63062042 SPL19 Activated RNA polymerase II -0.513362886 0.57607128 1.63062042 1.33075123 SULP1 PTB doman-containing includer -0.50821376 0.447818375 3.09440012 3.07552325 SULP1 PTB doman-containing includer -0.50821376 0.447818375 3.09440012 3.07552325 SULP1 PTB doman-containing includer -0.468778046 0.3842688 2.01241163 1.3094404 VAR protein -0.46852		Protein kinase C;Protein kinase C					
LIMD2 LM domain-containing protein 2 -0.545282748 -0.400942612 1.681931325 1.53744554 MRPS7 285 Orbosomal protein 1 -0.54435997 -0.342670441 1.715134625 1.82713834 DNALG3 Dinal. homologic subfamily C -0.522000504 -0.360580444 2.250784455 1.88010602 DNALG3 member 3 -0.522000504 -0.360580444 2.250784455 1.48001062 SPL member 3 -0.513403786 -0.626737213 1.775510636 1.46029935 SP1 Activated RNA polymerase II -0.513403786 -0.64707213 3.09440012 3.30765223 SULP1 menguliment adapter protein 1 -0.50409317 -0.44718375 3.09440012 3.30785232 SULP1 menguliment adapter protein 1 -0.50409317 -0.468228857 -0.380561011 1.94033114 2.1902949 CAL Cell growth-regulating nucleolar -0.468528857 -0.380561011 1.94033114 2.1902949 CAL Lastore initiation factor 1A, Y -0.419506454 -0.395159915 2.255663822 1.57159715		alpha type					
VRPS7 285 Rhosomal protein 57, matechondrills -0.5443599 -0.342670441 1.715134625 1.82713634 DNALC3 Dnal homolog subfamily C materbandrills -0.5435997 -0.342670441 1.715134625 1.82713634 DNALC3 Dnal homolog subfamily C materbandrills -0.51330786 -0.426737213 1.775516856 1.66299355 SF1 -0.51382886 -0.576076126 1.63020442 1.13236713 PC4.SUB1 Activated FNA polymemas II -0.513822886 -0.576076126 1.63020442 1.3236713 PC4.SUB1 Activated FNA polymemas II -0.5040317 -0.478718375 3.094400122 3.07652226 SQLP1 engultemat adapter protein -0.5040317 -0.45027044 2.120208778 2.28845023 SQLP1 regultemat adapter protein -0.4695057 -0.38442888 2.012341163 1.30844045 RPL26_KRBA2 SQS fobsomal protein L26 -0.46850557 -0.30661011 1.9433114 2.19029494 CALD1 Exter 1A, Y -0.41950454 -0.31951899 2.1554751 1.34495782 PSPLD2 EXS		LIM domain-containing protein 2					
Data homolog subfamily C member 3 Obstatomily C member 3 <thobstatomily c<br="">member 3 <thomstatomily c<="" td=""><td></td><td>28S ribosomal protein S7,</td><td></td><td></td><td></td><td></td></thomstatomily></thobstatomily>		28S ribosomal protein S7,					
DNALG3 member 3 -0.522000504 -0.360560444 2.250784455 1.88010602 RPL19 Rbosomal protein L19,605 -0.513302786 -0.426737213 1.77351638 1.66289538 SF1 -0.513302786 -0.5767125 1.73551638 1.66289538 C4/SUB1 Immergional protein L19 -0.513302786 0.57670218 1.30260442 1.3233715 C4/SUB1 Immergional protein L30 -0.5640371 0.447618573 3.09440012 3.0765225 SULP1 managetional protein L26 -0.5640931 -0.660829044 2.120989789 2.68465097 SULP1 mayufimeri adaptic protein 1 -0.5409317 -0.660829044 2.120989789 2.68465097 VAR Cargometh-regulating nucleolar -0.46852857 -0.3842688 2.012341163 1.3084404 VAR Softworder -0.46852857 -0.38061011 1.9433114 2.19029494 CALD1 Eukaryotic translation initiation factor 1A, Y -0.419506454 -0.31951991 2.15547511 1.34495783 C40 proteinsomal protein L26 -0.449506454 -0.3861		DnaJ homolog subfamily C					
SF1 -0.51382888 -0.576076128 1.83062042 1.13236713 PC4.SUB1 Actinated FNA polymerase II 5 -0.50821376 -0.447818575 3.094400122 3.07652326 SULP1 PTB domain-containing -0.50821376 -0.447818575 3.094400122 3.07652326 SULP1 Proglamment adapter protein 1 -0.50821376 -0.447818575 3.094400122 3.07652326 Cell growth-regulating nucleolar -0.485778046 0.38442688 2.012341163 1.3084404 RPL26.KRBA2 805 ribosomal protein L26 -0.486328857 -0.380661011 1.40033114 2.10929494 Eckaryotic translation initiation factor 1A, Y -0.465300557 -0.502504349 2.83528892 3.59796511 EirtAX:EIF1AY Proteinson in factor 1A, Y -0.419508454 -0.319515991 2.15547511 1.34495783 PSMD9 regulatory suburk 9 -0.419508454 -0.3821612 2.20789106 1.72919761 PLA absorbio-mal protein S6 -0.404511261 -0.2632164 2.288698898 2.4700975 PLA absorbio-mal-containing protein -		member 3 Ribosomal protein L19;60S					
Activated RNA polymerase II transcriptional coechwater p15 -0.5062137 -0.44781837 3.09440012 3.0762322 SULP1 manarciptional coechwater p16 -0.5062137 -0.44781837 3.09440012 3.0762322 SULP1 manarciptional coechwater p16 -0.5062137 -0.6662304 2.120080768 2.68465097 SULP1 moldifier -0.485778046 -0.38442688 2.012341163 1.30844045 VAR Call growth-regulating nucleolar -0.485778046 -0.380406101 1.94033114 2.19029494 CALD Exkaryotic translation initiation factor 1A, Y -0.419506454 -0.30951901 2.19547511 1.34495783 SPMD9 SS2 proteasome non-XTPase splMD9 SS2164 2.295663822 1.67159175 PR56 40.51051026 -0.44952162 -0.2032162 2.2958068322 1.72197917 PLA SS proteasome non-XTPase splMD9 SS2164 2.295806382 1.67159175 1.24495783 PSG 40.5 rhoosmal protein 56 -0.4413570458 -0.332164 2.295806822 2.2756433 PLA Station minimi protein	RPL19	ribosomal protein L19				1.662895384	
BITS domain-containing rugulfmet adapter protein protein -0.5040931 -0.66022904 2.12028778 2.6845007 LVAR Cell growth-regulating nucleolar protein -0.48577804 -0.38442688 2.012341163 1.30844045 RPL26XRBA2 EX5 thosomal protein L26 -0.46577804 -0.38042688 2.012341163 1.30844045 CALD -0.46577804 -0.38042688 2.012341163 1.30944045 CALD -0.465803057 -0.502504348 2.39253802 3.59796511 Factor 1A, X- chromosomalt-Elviaryotic translation instation factor 1A, Y- chromosomalt-Elviaryotic translation instation factor 1A, Y- chromosomalt-Elviaryotic translation instation factor 1A, Y- chromosomalt-Cellargenet non-XTPase -0.419506454 -0.319515991 2.15547511 1.34495783 PSID9 2625 protesome non-XTPase regulatory subanti 9 -0.419504545 -0.43851691 2.295663822 1.67159715 RPS6 405 shosomal protein 56 -0.414750458 -0.34612961 2.295680622 2.3755433 SIPC1 SIPC1 -0.37811677 -0.42045111 2.27880423 2.3754333 SIPC1 SIPC1 -0.3741486 -0.37831177 2.	SF1	Activated RNA polymerase II					
SULP1 engulment adapter protein 1 -0.50400317 -0.65023044 2.12028778 2.8845097 LYAR Cell growth-regulating nucleolar -0.485778046 -0.38442688 2.012341163 1.30844045 RPL26.KRBA2 S05 ribosomal protein L26 -0.48528857 -0.380661011 1.94033114 2.19029494 CAL D1 -0.465328657 -0.502504345 2.83523892 3.59796511 Eukaryotic translation initiation initinionininitiation initiation initiation initiation initiat	PC4;SUB1	transcriptional coactivator p15	-0.50621376	-0.447818375	3.094400122	3.076523262	
VAR protein -0.485778048 -0.38425888 20.12341163 1.3084404 RPL26,KRBA2 S0S ribosomal protein L26 -0.485328857 -0.380661011 1.94033114 2.19029494 ALD1 -0.465328857 -0.502504349 2.83523892 3.59796511 Eukaryotic translation initiation lactor 1A, X- bromosomal -0.419506454 -0.319515991 2.155475711 1.34495783 PSMD9 regulator yabuni 9 -0.413506454 -0.319515991 2.155475711 1.34495783 PSMD9 regulator yabuni 9 -0.413750458 -0.349612961 2.295653822 1.67159716 PSMD9 regulator yabuni 9 -0.413750458 -0.34821641 2.20780108 1.72919761 PSMD9 regulator yabuni 9 -0.403290176 -0.440326416 2.88998988 2.4709715 PLAA antigen -0.403290176 -0.40326141 2.278680422 2.37654333 PD2 domain-containing protein -0.32821631 -0.40048141 2.278680422 2.37654333 SIPC1 SIPC1 -0.3774197996 -0.38281937 3.02410415	GULP1	engulfment adapter protein 1	-0.50409317	-0.650629044	2.120089789	2.684650973	
CALD1 -0.465930557 -0.502504348 2.83523892 3.59796511 Intervention Inter	LYAR	protein	-0.485778046	-0.38442688	2.012341163	1.308440452	
Eukaryotic translation initiation rator 14, X- bromosomalEckaryotic translation mitiation RSS protessome non-APPse -0.419506454 -0.319515991 2.15547511 1.34495783 PSMD9 regulatory suburit 9 -0.413750455 -0.364612961 2.255663822 1.6751971 PSMD9 regulatory suburit 9 -0.413750455 -0.364612961 2.25665822 1.6751971 RPS6 405 ribosomal protein S6 -0.404511261 -0.2632164 2.20789106 1.72919761 HLA class 1 histocompatibility -0.43229178 -0.440826416 2.88990898 2.47009715 HLA-A artigen -0.328216315 -0.40020414 2.278890423 2.37564333 SIPC1 SIPC1 -0.377431488 -0.373931177 2.41984506 1.47117915 VDDC Nuclear migration protein nudC -0.377431484 -0.3783117971 2.241984506 1.57117915 PSPH Phosphosetrine phosphatase -0.34809951 -0.46913414 2.873791518 2.3585433 PSPA Phosphosetrine phosphatase -0.342092133 -0.35016066 2.435034365 2.6462281 Extrit, Tyrosine	RPL26;KRBA2	60S ribosomal protein L26	-0.468328857	-0.380661011	1.94033114	2.190294946	
Factor 1A, X- bromosonal-EUkaryotic translation initiation factor 1A, Y- detormotion -0.419606454 -0.319515991 2.15547511 1.34495783 PSMDD 26S proteasome non-ATPase regulatory ubunti 9 -0.413750458 -0.364612961 2.295663822 1.67159715 PSMDD 26S proteasome non-ATPase regulatory ubunti 9 -0.413750458 -0.364612961 2.295663822 1.67159715 PSMDD 403/350476 -0.40391076 -0.40028416 2.286969898 2.47009716 PLA-A antigon -0.30291076 -0.40028416 2.286894989 2.47009716 PLA-A antigon -0.302916315 -0.40024141 2.276880423 2.37654333 SIPC1 SIPC1 -0.371879196 -0.38218316 -0.40048141 2.278680423 2.37654333 SIPC1 SIPC1 SIPC1 -0.371879196 -0.3821873 3.021408182 1.56217917916 VIDOC Nuclear migration protein nudC -0.371879196 -0.386913014 2.87391518 2.3365433 PSPH Phosphoaserine phosphatase -0.34099518 -0.46913414 2.87391518 2.3564365	CALD1	Eukaryotic translation initiation	-0.465930557	-0.502504349	2.83523892	3.597965113	
Instalation initiation factor 14, Y- chromoscome non-RTPase -0.419606454 -0.319515991 2.15547511 1.34495783 PSMD9 26S proteasome non-RTPase regulatory tubunti 9 -0.413760458 -0.346512961 2.256663822 1.67159716 PSMD9 regulatory tubunti 9 -0.413760458 -0.364612961 2.295663822 1.67159716 PSMD9 regulatory tubunti 9 -0.413760458 -0.364612961 2.296663822 1.67159716 PPSD2 -0.40329076 -0.400262162 2.20789106 1.27219767 HLA-dass I histocompatibility -0.382916315 -0.40026414 2.276860422 2.37654333 SIPC1 SIPC1 -0.371871956 -0.38216315 -0.40048141 2.276860423 2.37654333 SIPC1 SIPC1 SIPC1 -0.371871956 -0.38218736 3.021408182 1.547179151 VUDC Nuclear migration protein n200 -0.371871956 -0.38619376 3.021408182 1.58515434 PSPH Phosphoaserine phosphatase -0.34099518 -0.365018068 2.435034865 2.66462281 Exritr_Tyronis protein fixes		factor 1A, X-					
26S proteasome on-ATPaee regulatory subuntil 9 -0.413750458 -0.364612961 2.295663822 1.67159715 RP56 405 ribosomal protein S6 -0.40320076 -0.40320176	FIEAAV.FIEA	translation initiation factor 1A, Y-	0.4405	0.0405	0.455	4	
PSMD9 regulatory subunit 9 -0.413750458 -0.364612961 2.25665822 1.77159715 RPS6 405 Ribosomal protein S6 -0.40451263 -0.2632164 2.20789106 1.721919761 RPS6 405 Ribosomal protein S6 -0.40451263 -0.2632164 2.20789106 1.721919761 HLA class I histocompatibility -0.403290176 -0.403290176 2.28689423 2.47099715 HLA-A amigen -0.382816131 -0.42048141 2.287869423 2.37654333 GIPC1 GIPC1 -0.377431488 -0.37391577 2.241864505 1.547169715 NUDC Nuclear migration protein nutC -0.371879196 -0.36281137 3.021408182 1.56215643 SPFH Phosphoserine phosphatase -0.348099518 -0.46913414 2.873791518 2.35854335 RPS20 405 Rhosomal protein S20 -0.342092133 -0.350918068 2.435034365 2.56462261		26S proteasome non-ATPase					
IPD52 -0.403290178 -0.440826416 2.288698698 2.47009716 HLA-dass I histocompatibility antigen -0.382816315 -0.42048141 2.27680423 2.37654333 PD2 domain-containing protein GIPC1 -0.377431488 -0.37383117 2.241864505 1.54717915 NUDC Nuclear migration protein nudC -0.371879198 -0.388219376 3.021408182 1.56215643 PSPH Phosphoserine phosphatase -0.34099518 -0.46913414 2.873791518 2.3585432 PS20 40S ribosomal protein R20 -0.342092133 -0.350618066 2.435034365 2.56462281	PSMD9	regulatory subunit 9				1.671597156	
HLA-lass histocompability antigen -0.382816315 -0.420048141 2.276860423 2.37654333 PDZ domain-containing protein GIPC1 0.177431488 -0.370331177 2.241864505 1.54717915 NUDC Nudear migration protein nudC -0.371879198 -0.368218376 3.021408182 1.552156433 PSPH Phosphoserine phosphatase -0.348099518 -0.46913414 2.873791518 2.3565433 RPS20 405 rhosomal protein S20 -0.342092133 -0.35018066 2.435034365 2.56462261	RPS6	40S ribosomal protein S6				1.729197619	
PDZ domain-containing protein GIPC1 -0.377431488 -0.37831177 2.241864505 1.54717915 NUDC Nudear migration protein nudC -0.371879196 -0.368219376 3.021408182 1.56215643 PSPH Phosphaserine phosphatase -0.348099518 -0.46913414 2.873791518 2.35856432 RPS20 405 rhosomal protein S20 -0.342092133 -0.356018065 2.435034365 2.56462261							
SIPC1 SIPC1 -0.377431488 -0.3733117 2.241844505 1.547154 NUDC Nudsar migration protein nudC -0.371879196 -0.38219376 3.021408182 1.5621564 SPH Phosphoserine phosphatase -0.34099516 -0.4691414 2.873791516 2.568462261 RPS20 HQS rhosomal protein 520 -0.342092133 -0.35016066 2.435034365 2.56462261	HLA-A	antigen	-0.382816315	-0.420048141	2.278680423	2.37654333	
PSPH Phosphoserine phosphatase -0.348099518 -0.46913414 2.873791518 2.35855433 RPS20 40S rhosomal protein S20 -0.342092133 -0.359018068 2.435034365 2.56462281 Eprint/Tyroline protein Inage -0.342092133 -0.359018068 2.435034365 2.56462281	GIPC1	GIPC1	-0.377431488	-0.373831177	2.241864505	1.547179196	
RPS20 40S ribosomal protein S20 -0.342092133 -0.356018066 2.435034365 2.56462281 Ezrin; Tyrosine-protein kinase	NUDC					1.562156434	
Ezrin;Tyrosine-protein kinase	PSPH					2.358554325	
EZR;EZR-ROS1 receptor -0.308622742 -0.210961151 3.806140691 3.63289125	RPS20	40S ribosomal protein S20 Ezrin:Tyrosine-protein kinase	-0.342092133	-0.356018066	2.435034365	2.564622818	
	EZR;EZR-ROS1		-0.308622742	-0.210961151	3.806140691	3.63289125	

Table 12. Quantitative proteomic analysis of UBE2K KD hESCs. Knockdown of UBE2K induces an increase in the levels of JARID2 and METTL7A. Data represent the Student's t-test difference. Means are calculated from the log2 of label-free quantification (LFQ) values (LFQ UBE2K shRNA hESCs/Non-targeting shRNA hESCs). Statistical comparisons were made by Student's t-test (n=3, FDR< 0.05 is considered significant).

4 Discussion

4.1 HTT

The ubiquitous subcellular localization of HTT does not facilitate the definition of its function. Multiple roles have been described for wild-type HTT such as vesicular transport^{51,62,64,161} and mitotic spindle orientation⁷². Furthermore, HTT functions as a scaffolding protein to induce selective autophagy¹⁶¹. In addition, HTT modulates gene expression by binding numerous transcription factors and regulators such as the cAMP-response element (CREB)-binding protein (CBP), specificity-protein 1 (SP1), neuroD1, p53 or the nuclear factor-kB (NF-kB)⁶. Loss of transcriptional function of HTT could contribute to explain the transcriptional dysregulation observed in postmortem HD brains and distinct HD mouse models^{6,109}.

In this study, we identified Activating transcription factor 7-interacting protein 1 (ATF7IP), also known as MBD1-containing chromatin-associated factor 1 (MCAF1) or ATFa-associated modulator (AM), as a new interactor of HTT (Figure 1). In addition, our co-immunoprecipitation experiments followed by western blot indicate that HTT could form a complex together with ATF7IP and SETDB1 (Figure 1 G). ATF7IP regulates chromatin formation by binding and directing transcriptional factors to the general transcriptional machinery. The protein thereby impinges transcriptional regulation. Depending on the subcellular conditions the protein can operate either as an activator or a repressor^{116–119}. The mechanism for gene silencing by ATF7IP via methylation is explained in the following paragraphs.

ATF7IP controls methylation based transcriptional repression through interaction with the methyl-CpG binding domain 1 (MBD1) (hence its synonym MCAF1). The multifunctional nuclear protein acts as a transcriptional regulator and transcriptional repression domain. It embodies two conserved domains that interact with MBD1 and transcription factor Sp1. Like ATF7IP, SP1 can activate or repress transcription depending on the context. ATF7IP acts like a co-activator and enables Sp1-guided transcription. By modifying Sp1 on methylated promoter regions ATF7IP blocks transcription activity ¹¹⁶.

Histone methylation is essential for chromatin structure and function. The histone methyltransferase (HMTase) activity of Histone-lysine N-methyltransferase SETDB1 (SETDB1) depends on the assistance of ATF7IP. It triggers the transformation of the dimethyl (H3K9me2) to the trimethyl state (H3K9me3) by increasing the turnover rate of the reaction, both in vitro and in vivo. The functional consequence of H3K9 trimethylation on the promoter region is transcriptional repression¹⁴¹. Moreover, ATF7IP aids in the gene expression of the two telomerase enzymes by specificity protein 1 (TERT) and interaction with SP1 in cancer cells. Knockdown of ATF7IP leads also to decreased levels of transcriptionally active RNA polymerase II and the general transcription factor ERCC3 in the TERT promoter and consequently diminished telomerase activity. Interestingly, in naturally occurring abnormal proliferative cancer cells ATF7IP was regularly found to be overexpressed¹¹⁸.

Notably, although not further studied, previous findings already indicated a link between HD age of onset and genetic variation within the ATF7IP gene: ATF7IP genetic variation correlated with age of onset in HD patients¹⁶². Together with our data, this suggests that ATF7IP is a potential modifier of the HD chromatin landscape in stem cells that determines the epigenetic changes of the disease: Knockdown of ATF7IP in hESCs decreased nuclear SETDB1 levels as well as trimethylation of H3K9 (Figure 3 A-B), which indicates the ATF7IP also regulates H3K9me3 in these cells. ATF7IP interacts with the H3K9 methyltransferase of SETDB1, facilitating H3K9 trimethylation and heterochromatin formation^{116,141}. Moreover, ATF7IP stabilizes SETDB1 in the nucleus of human cell lines¹⁴⁴. We also found that H3K9me3 levels upon HTT knockdown were drastically increased (Figure 3 D-E) in two independent hESC lines (Figure 4 A-B). Interestingly this effect was also observed when the cells were differentiated into NPCs (Figure 3 F-G).

Among polyQ diseases exhibiting epigenetic imbalances, HD is the one most commonly studied. There are different classes of epigenetic mechanisms. DNA modifications entail methylation and hydroxymethylation, post-translational histone modifications entail acetylation, di- and tri-methylation, phosphorylation, ubiquitylation, SUMOylation and ADP ribosylation and lastly, the exchange of the histone variants H1, H3.3, H2A.Z, H2A.X¹⁰⁹. Our findings show for the first time that H3K9 is induced by loss of HTT. This is a novel observation that however is in a larger context of broad epigenetic modulations induced by loss of HTT. The loss of HTT leads to failure of global H3K27 trimethylation in embryoid bodies (EBs) derived from ESCs. However, H3K27 dimethylation was unaffected in HTT null EBs. H3K27 is a site predominantly targeted by PRC2 that has enzymatic activity to assist in gene silencing. Loss of HTT in embryos showed parallel phenotypes to those with lack of PRC2, although they were not as severe as in PRC2 null embryos. This shows that HTT only aids PRC2 in order to stimulate its methyltransferase activity, and does not work as its core component that is directly responsible for methylation. Specifically the polyQ region is interacting with PRC2, leading to more trimethylation of H3K27 with expanding polyQ tract¹⁶³. In contrast, Htt CAG size, though changing histone H3K27me3, is prominently associated with altered histone H3K4me3 at 'active' loci⁶⁷.

Via ChIP-Seq we found 61 genes involved in transcriptional regulation (Figure 9) with increased H3K9 trimethylation at promoter sites. H3K9 trimethylation is a mark of transcriptional repression and in the stages of neuronal differentiation we found indeed that HTT knockdown led to reduced expression of ASCL2, GBX1 (Figure 7 D-E) and DLX3 (Figure 10), which all 3 regulate developmental transcription. ASCL2 is a pro-neural factor involved in the determination of neuronal precursors of the nervous system and its transcription is regulated via histone modifications during neural differentiation from hESCs¹⁶⁴. The homebox protein DLX3 is thought to have a role in the modulating the development of the ventral forebrain¹⁶⁵. GBX1 is highly expressed in the neuroectoderm and regulates the positioning of the midbrain-hindbrain boundary organizer in the early neural plate, affecting forebrain and midbrain formation¹⁶⁶. Furthermore, we found reduced expression of SMC1B, a structural maintenance protein involved in chromosome movements (Figure 10). SMC1B is a meiosis-specific cohesin member also has an important role in cellular response to DNA damage. Loss of SMC1B results in impairment of gene expression¹⁶⁷. Although mutations in SMC1B have been linked to cancer cell formation¹⁶⁷ and sterility in mice¹⁶⁸, there is currently no evidence for its contribution to polyQ diseases. However, these findings provide potential new targets to study transcriptional imbalances in HD. Taken together, our results indicate that HTT is a modulator of H3K9me3 and thereby controls the expression of important neural genes.

Neural cultures derived from HD patient-iPSCs exhibit H3K4me3 and H3K27ac epigenetic alterations, resulting in decreased levels of neurodevelopmental factors

involved in GABA signaling, axonal guidance and calcium influx⁹⁰. Likewise, targeted mutations that expand the CAG stretch in one HTT allele is sufficient to impair H3K4me3 marks in both mouse ESCs and their NPC counterparts⁶⁷. Brain tissues of HD patients exhibit increased H3K9 trimethylation¹¹¹⁻¹¹⁴ which led us to the hypothesis that this epigenetic mark could also be changed in HD-iPSCs. In our study, we indeed found that knockdown of ATF7IP in iPSCs derived from HD patients rescues the hypermethylation of H3K9, which suggests ATF7IP is a potent regulator of the epigenetic landscape. In our results obtained by immunofluorescence, we could observe increased H3K9me3 levels in two mutant HD-iPS cell lines, with either 71 or 180 polyQ repeat expansions (Figure 11 A). Interestingly, we also found that mutations (triplet expansion) in HTT reduces its interaction with ATF7IP and very likely induces H3K9me3 levels (Figure 11 B). As mentioned before, the benefit of using HD-iPSC lines is that each cell expresses one mutant copy of HTT and one normal copy, as it is the case in HD-patients¹⁵³. This enabled us to observe the different mechanisms resulting from interaction of ATF7IP with either the wild-type or mHTT within the same model.

Interestingly, as opposed to the HTT antibody, the polyQ antibody did not immunoprecipitate ATF7IP and SETDB1. This clearly demonstrates that normal HTT function is necessary to promote interaction with ATF7IP and SETDB1 and thereby regulate trimethylation of H3K9. The underlying reason for this could be manifold: One explanation could be that polyQ regions of different lengths can present different conformations⁵⁸ and therefore it is likely that the specific epitopes recognizing ATF7IP and SETDB1 are not accessible in mHTT. Furthermore, we already know that mHTT is cleaved by proteases and that its C-terminal part is released into the nucleus, and also that HTT forms inclusion bodies upon which the C-terminal domain changes its conformation. This shows the possibility that interaction between ATF7IP and SETDB1 and HTT takes place on this site, whereas the polyQ antibody binds to the C-terminal domain, occluding the two interactors seen with anti-total HTT. However, this does not contradict our observation that loss of normal HTT supports the interaction between ATF7IP and SETDB1 to increase H3K9me3. Notably, we found that another H3K9 methyltransferase, called SUV39H1, which is known to form a complex with SETDB1, was significantly increased upon loss of HTT in hESCs.

In this study we also demonstrate that ATF7IP knockdown decreases H3K9 trimethylation in HD-IPSCs (Figure 12 B-C and Figure 13) and in HD-NPCs (Figure 12 A). Our data show that ATF7IP knockdown can rescue the H3K9 trimethylation HD-iPSCs. Notably, knockdown of ATF7IP does not influence the neuronal differentiation capacity in these cells. In this study, we did not analyze the effect of HTT on histone acetylation, a major regulator of the epigenetic landscape. Histone acetylation is associated with a relaxed chromatin conformation, which allows access of transcription factors and is regulated by the histone (or lysine) acetyltransferase (KAT) and the histone deacetylase family (HDAC). The CREB-binding protein (CBP) with KAT activity was found in intracellular inclusions in postmortem tissues from HD patients, animal model brains and in vitro and presented the first known histone acetylation dysregulation related to HD^{169,170}. Since this initial finding many studies proved dysfunctional histone acetylation in various HD models including neuronal cells from HD Patients¹⁷¹. Surprisingly, some studies showed a global decrease in histone acetylation^{172,173}, while others presented hypoacetylation merely on promoter regions leading to transcriptional downregulation^{174,175}. However, despite of more than a decade of research, the exact mechanism of how CBP and histone acetylation contribute to neurodegeneration is unknown¹⁷⁶.

It should be noted that we found 102 significant interactors of HTT in neurons and only 7 proteins in hESCs (Figure 1 C, E and Table 8). Among the 7 interactors NUP205 and U2AF2 were exclusively co-immunoprecipitated in hESCs whereas the other 5 proteins were also detected in neurons (Figure 1 F). NUP205 is involved in nuclear transport¹⁷⁷, whereas U2AF2 is a spliceosome-associated protein controlling RNA polymerase activity¹⁷⁸. Since these two interactors are located in the nucleus, this indicates that in hESCs the role of HTT is related to nuclear mechanisms and suggests further modes of regulation of HTT on the phenotype in hESCs.

4.2 UBE2K

We performed a neural induction experiment in control and UBE2K knockdown hESCs and found that UBE2K knockdown disables the ability of the cells to differentiate into NPCs with intact neurogenic properties. The dramatic effect started after 20 days of neural induction. In contrast to the control cells, UBE2K KD NPCs showed high levels of the early neural marker PAX6 and decreased levels of neural and neuronal markers (Figure 16 D-G). Moreover, when differentiated to neurons, UBE2K KD cells did not show neuronal extensions (Figure 16 H). The neuronal markers (MAP2, NEFL) were decreased compared to control neurons and PAX6 levels remained high (Figure 16 H-K).

Co-immunoprecipitation experiments followed by a single shot label-free proteomic approach revealed UBE2K, mitochondrial fission factor (MFF) and the histone H3.3 as most enriched proteins (Table 11). H3.3 is involved in cell differentiation and cell reprogramming^{158,159}, which suggests a role of UBE2K in the nucleus. In line with this assumption, we found tremendous amounts of UBE2K in nuclear fractions of hESCs (Figure 17 A). Strikingly, upon UBE2K knockdown, we observed also increased H3K9 trimethylation. This effect was consistent in two independent hESC lines as well as iPSCs (Figure 17 B-C). Also, upon differentiation into NPCs, high levels of H3K9me3 were maintained in the UBE2K knockdown cells (Figure 17 D). This indicates that UBE2K regulates the levels of H3K9me3 in hESCs and their neural counterparts, and that loss of UBE2K leads to transcriptional repression of distinct genes. Particularly, the lack of MAP2, NEFL and other genes playing a role in the development and identity of NPCs and neurons (Figure 16 H-K), can be associated with the observed histone modifications. After performing ChIP-seq using UBE2K KD hESCs we found 71 genes presenting H3K9me3 marks with strongest enrichment for genes involved in transcriptional regulation (Figure 18).

Remarkably, many genes with high enrichment for H3K9me3 marks were involved neuronal processes such as the formation of the nervous system, neuronal function and establishment of neuronal connections, supporting our results with disturbed differentiation into NPCs and neurons. These genes include ADRA2B, CELSR1, SMC1B, and the GABA receptor subunit GABRR1. In conclusion, our data indicate that loss of UBE2K induces changes in the H3K9me3 landscape of hESCs impairing the induction of key neuronal factors.

When we compared control hESCs with UBE2K KD hESCs via quantitative proteomics we found increased levels of the histone methyltransferase regulator JARID2 and also METTL7A, a methyltransferase of unknown function in UBE2K knockdown cells (Table 12). Jarid2 is required for differentiation of mouse ESCs and its inhibition leads to a reduction of H3K27me3 by regulating the PRC2 complex¹⁰⁸. Furthermore, Jarid2

activates trimethylation of H3K9 via specific interaction with the histone H3K9 methyltransferase SETDB1 during heart development¹⁷⁹. This suggests that further interplay of epigenetic and non-epigenetic mechanisms, is potentially modified by Ube2k. This requires further studies and is currently under investigation.

4.3 Conclusion and the missing link between HTT and UBE2K

In this study, we analyzed the effect of HTT and UBE2K knockdown on the epigenetic landscape of hESCs and HD-patient derived IPSCs. Consistent with previous studies, we discovered a strong modulation of the epigenetic landscape in these cells upon knockdown of both HTT and UBE2K. Particularly, promoter sites showed increased methylation by H3K9me3, representing transcriptional repression of these genes.

For the first time, we identified ATF7IP as a novel interactor of HTT and found increased trimethylation of H3K9 induced upon loss of HTT in hESCs and HD-IPSCs and their neuronally differentiated counterparts. Markedly, the genes most affected were involved in neuronal functions, particularly important for the correct differentiation into NPCs and neurons.

Moreover, the H3K9 methyltransferase SETDB1, a known interactor of ATF7IP, was decreased upon ATF7IP knockdown in hESCs. This indicates that ATF7IP is indeed a modulator of the chromatin landscape in hESCs and HD-IPSCs and thereby maintains proper transcriptional induction of genes. Since loss of HTT promotes the interaction of ATF7IP with SETDB1, HTT very likely regulates the interaction of SETDB1 with its activator ATF7IP to control trimethylation of H3K9.

Among the transcriptional regulators that we identified via ChIP-seq in UBE2K KD cells, we found the bHLH transcription cofactor HES6. As mentioned in the results, HES6 facilitates the transcription factor ASCL1 to induce the expression of important genes for neurogenesis at the early stages of development¹⁶⁰. Remarkably, we found ASCL1 not only exhibiting enriched H3K9me3 marks on its promoter in HTT KD cells, but could also verify its decreased expression in NPCs on mRNA level.

Although previously found and confirmed as HTT interactor, we were not able to copurify UBE2K together with HTT: This could suggest that the interaction could be transient and could be associated with direct degradation of the HTT protein by UBE2K and associated E3 ligases. Also, it might play a role only in specific cell types, organelles or settings of hESCs. A study showed for example that the polyQ domain of normal HTT can present different conformations depending on its subcellular location⁵⁸.

The phenotype of UBE2K knockdown of neural differentiation is much more prominent as compared to HTT, and could be mediated by an increase of the histone methyltransferase regulator JARID2, which in turn regulates PRC2 in mice ESCs and promotes H3K9 trimethylation via interaction with methyltransferase SETDB1. As mentioned before, HTT facilitates PRC2 to stimulate its methyltransferase activity. Therefore, UBE2K and HTT are responsible for balancing epigenetic function and determining hESC fate, and PRC2 could be a common node between the two proteins that requires further investigation. These studies are currently underway. Interference with these mechanisms and the further characterization in models of disease may help to find novel therapies for human neurodegenerative diseases.

References

1. Vonsattel, J. P. G. & Difiglia, M. Huntington Disease. *J. Neuropathol. Exp. Neurol.* **57**, 369–384 (1998).

2. Roos, R. A. Huntington's disease: a clinical review. *Orphanet J. Rare Dis.* **5**, 40 (2010).

3. Walker, F. O. Huntington's disease. *Lancet Lond. Engl.* **369**, 218–228 (2007).

MacDonald, M. E. *et al.* A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* **72**, 971–983 (1993).
 Cattaneo, E., Zuccato, C. & Tartari, M. Normal huntingtin function: an alternative

approach to Huntington's disease. *Nat. Rev. Neurosci.* **6**, 919–930 (2005).

6. Saudou, F. & Humbert, S. The Biology of Huntingtin. *Neuron* **89**, 910–26 (2016).

7. Vonsattel, J. P. G., Keller, C. & Pilar Amaya, M. del. Neuropathology of Huntington's Disease. **89**, 599–618 (2008).

8. Ikeda, H. *et al.* Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo. *Nat. Genet.* **13**, 196–202 (1996).

9. Finkbeiner, S. Huntington's Disease. *Cold Spring Harb Perspect Biol* **3**, (2011).

10. Ehrlich, M. E. *et al.* ST14A cells have properties of a medium-size spiny neuron. *Exp. Neurol.* **167**, 215–226 (2001).

11. Dragatsis, I., Levine, M. S. & Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. *Nat. Genet.* **26**, 300–306 (2000).

12. Gauthier, L. R. *et al.* Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules. *Cell* **118**, 127–138 (2004).

13. Gunawardena, S. *et al.* Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. *Neuron* **40**, 25–40 (2003).

14. O'Kusky, J. R., Nasir, J., Cicchetti, F., Parent, A. & Hayden, M. R. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. *Brain Res.* **818**, 468–479 (1999). 15. Trushina, E. *et al.* Mutant huntingtin impairs axonal trafficking in mammalian

15. Trushina, E. *et al.* Mutant huntingtin impairs axonal trafficking in ma neurons in vivo and in vitro. *Mol. Cell. Biol.* **24**, 8195–8209 (2004).

16. Ho, L. W., Brown, R., Maxwell, M., Wyttenbach, A. & Rubinsztein, D. C. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. *J. Med. Genet.* **38**, 450–452 (2001).

17. Leavitt, B. R. *et al.* Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. *Am. J. Hum. Genet.* **68**, 313–324 (2001).

18. Leavitt, B. R. *et al.* Wild-type huntingtin protects neurons from excitotoxicity. *J. Neurochem.* **96**, 1121–1129 (2006).

19. Rigamonti, D. *et al.* Wild-type huntingtin protects from apoptosis upstream of caspase-3. *J. Neurosci. Off. J. Soc. Neurosci.* **20**, 3705–3713 (2000).

20. Sun, Y., Savanenin, A., Reddy, P. H. & Liu, Y. F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. *J. Biol. Chem.* **276**, 24713–24718 (2001).

21. Zuccato, C. *et al.* Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science* **293**, 493–498 (2001).

22. Zuccato, C. *et al.* Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. *Nat. Genet.* **35**, 76–83 (2003).

23. Everett, C. M. & Wood, N. W. Trinucleotide repeats and neurodegenerative disease. *Brain* **127**, 2385–2405 (2004).

24. Perutz, M. F., Johnson, T., Suzuki, M. & Finch, J. T. Glutamine Repeats as Polar Zippers: Their Possible Role in Inherited Neurodegenerative Diseases. *Proc. Natl. Acad. Sci. U. S. A.* **91,** 5355–5358 (1994).

25. Steffan, J. S. *et al.* SUMO Modification of Huntingtin and Huntington's Disease Pathology. *Science* **304**, 100–104 (2004).

26. Neuwald, A. F. & Hirano, T. HEAT Repeats Associated with Condensins, Cohesins, and Other Complexes Involved in Chromosome-Related Functions. *Genome Res.* **10**, 1445–1452 (2000).

27. Andrade, M. A. & Bork, P. HEAT repeats in the Huntington's disease protein. *Nat. Genet.* **11**, 115–116 (1995).

28. MacDonald, M. E. Huntingtin: alive and well and working in middle management. *Sci. STKE Signal Transduct. Knowl. Environ.* **2003**, pe48–pe48 (2003).

29. Xia, J., Lee, D. H., Taylor, J., Vandelft, M. & Truant, R. Huntingtin contains a highly conserved nuclear export signal. *Hum. Mol. Genet.* **12**, 1393–1403 (2003).

30. Cornett, J. *et al.* Polyglutamine expansion of huntingtin impairs its nuclear export. *Nat. Genet.* **37**, 198–204 (2005).

31. Goldberg, Y. P. *et al.* Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. *Nat. Genet.* **13**, 442–449 (1996).

32. Wellington, C. L. *et al.* Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. *J. Biol. Chem.* **273**, 9158–9167 (1998).

33. Wellington, C. L. *et al.* Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. *J. Biol. Chem.* **275**, 19831–19838 (2000).

34. Davies, S. W. *et al.* Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* **90**, 537–548 (1997).

35. DiFiglia, M. *et al.* Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* **277**, 1990–1993 (1997).

36. Kim, Y. J. *et al.* Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 12784–12789 (2001).

37. Lunkes, A. *et al.* Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. *Mol. Cell* **10**, 259–269 (2002).

38. Wellington, C. L. *et al.* Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. *J. Neurosci. Off. J. Soc. Neurosci.* **22**, 7862–7872 (2002).

39. Gafni, J. *et al.* Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. *J. Biol. Chem.* **279**, 20211–20220 (2004).

40. Gafni, J. & Ellerby, L. M. Calpain Activation in Huntington's Disease. *J. Neurosci.* **22**, 4842–4849 (2002).

41. Wang, K. K. Calpain and caspase: can you tell the difference? *Trends Neurosci.* **23**, 20–26 (2000).

42. Sepers, M. & Raymond, L. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. *Drug Discov. Today* **19**, 990–996 (2014).

43. Ellis, H. M. & Horvitz, H. R. Genetic control of programmed cell death in the nematode C. elegans. *Cell* **44**, 817–829 (1986).

44. Ona, V. O. *et al.* Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. *Nature* **399**, 263–267 (1999).

45. Kalchman, M. A. *et al.* Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. *J. Biol. Chem.* **271**, 19385–19394 (1996).

46. Hackam, A. S. *et al.* Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. *J. Biol. Chem.* **275**, 41299–41308 (2000).

47. Humbert, S. *et al.* The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. *Dev. Cell* 2, 831–837 (2002).
48. Warby, S. C. *et al.* Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. *Hum. Mol. Genet.* 14,

1569–1577 (2005).

49. Luo, S., Vacher, C., Davies, J. E. & Rubinsztein, D. C. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. *J. Cell Biol.* **169**, 647–656 (2005).

50. Huang, K. *et al.* Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. *Neuron* **44**, 977–986 (2004).

51. Difiglia, M. *et al.* Huntingtin Is a Cytoplasmic Protein Associated with Vesicles in Human and Rat-Brain Neurons. *Neuron* **14**, 1075–1081 (1995).

52. Harjes, P. & Wanker, E. E. The hunt for huntingtin function: interaction partners tell many different stories. *Trends Biochem. Sci.* **28**, 425–433 (2003).

53. Li, S.-H. & Li, X.-J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. *Trends Genet. TIG* **20**, 146–154 (2004).

54. Sipione, S. & Cattaneo, E. Modeling Huntington's disease in cells, flies, and mice. *Mol. Neurobiol.* **23**, 21–51 (2001).

55. Goehler, H. *et al.* A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. *Mol. Cell* **15**, 853–865 (2004).

56. Marcora, E., Gowan, K. & Lee, J. E. Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 9578–9583 (2003).

57. Trettel, F. *et al.* Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. *Hum. Mol. Genet.* **9**, 2799–2809 (2000).

58. Ko, J., Ou, S. & Patterson, P. H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. *Brain Res. Bull.* **56**, 319–329 (2001).

59. Trottier, Y. *et al.* Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. *Nature* **378**, 403–406 (1995).

60. Ferrante, R. J. *et al.* Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. *J. Neurosci. Off. J. Soc. Neurosci.* **17**, 3052–3063 (1997).

61. Fusco, F. R. *et al.* Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. *J. Neurosci. Off. J. Soc. Neurosci.* **19**, 1189–1202 (1999).

62. Velier, J. *et al.* Wild-Type and Mutant Huntingtins Function in Vesicle Trafficking in the Secretory and Endocytic Pathways. *Exp. Neurol.* **152**, 34–40 (1998).

63. Hilditch-Maguire, P. *et al.* Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. *Hum. Mol. Genet.* **9**, 2789–2797 (2000).

64. Hoffner, G., Kahlem, P. & Djian, P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with β -tubulin:

relevance to Huntington's disease. J. Cell Sci. 115, 941–948 (2002).

65. Kegel, K. B. *et al.* Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. *J. Biol. Chem.* **277**, 7466–7476 (2002).

66. Li, J.-Y., Plomann, M. & Brundin, P. Huntington's disease: a synaptopathy? *Trends Mol. Med.* **9**, 414–420 (2003).

67. Biagioli, M. *et al.* Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. *Hum Mol Genet* **24**, 2442–57 (2015).

68. Duyao, M. P. *et al.* Inactivation of the mouse Huntington's disease gene homolog Hdh. *Science* **269**, 407–410 (1995).

69. Nasir, J. *et al.* Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. *Cell* **81**, 811–823 (1995).

70. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. *Nat. Genet.* **11**, 155–163 (1995).

71. White, J. K. *et al.* Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. *Nat. Genet.* **17**, 404–410 (1997).

72. Godin, J. D. *et al.* Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis. *Neuron* **67**, 392–406 (2010).

73. Conforti, P. *et al.* Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. *Neurobiol Dis* **50**, 160–70 (2013).

74. Nguyen, G. D., Gokhan, S., Molero, A. E. & Mehler, M. F. Selective roles of normal and mutant huntingtin in neural induction and early neurogenesis. *PloS One* **8**, e64368 (2013).

75. Myers, R. H. *et al.* Homozygote for Huntington disease. *Am. J. Hum. Genet.* **45**, 615–618 (1989).

76. Wexler, N. S. *et al.* Homozygotes for Huntington's disease. *Nature* **326**, 194–197 (1987).

77. Batista, C. M. C. *et al.* A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. *J. Neurosci. Off. J. Soc. Neurosci.* **26**, 10452–10460 (2006).

78. Curtis, M. A. *et al.* Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 9023–9027 (2003).
79. Curtis, M. A. *et al.* The distribution of progenitor cells in the subependymal layer

of the lateral ventricle in the normal and Huntington's disease human brain. *Neuroscience* **132**, 777–788 (2005).

80. Molero, A. E. *et al.* Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 21900–21905 (2009).

81. Brandt, J., Shpritz, B., Codori, A. M., Margolis, R. & Rosenblatt, A. Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals. *J. Int. Neuropsychol. Soc. JINS* **8**, 918–924 (2002).

82. Joshi, P. R. *et al.* Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. *J. Neurosci. Off. J. Soc. Neurosci.* **29**, 2414–2427 (2009).

83. Milnerwood, A. J. & Raymond, L. A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. *Trends Neurosci.* **33**, 513–523 (2010).

84. Murphy, K. P. *et al.* Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. *J. Neurosci. Off. J. Soc. Neurosci.* **20**, 5115–5123 (2000).

85. Paulsen, J. S. *et al.* Detection of Huntington's disease decades before diagnosis: the Predict-HD study. *J. Neurol. Neurosurg. Psychiatry* **79**, 874–880 (2008).

86. Paulsen, J. S. *et al.* Brain structure in preclinical Huntington's disease. *Biol. Psychiatry* **59**, 57–63 (2006).

87. Schippling, S. *et al.* Abnormal motor cortex excitability in preclinical and very early Huntington's disease. *Biol. Psychiatry* **65**, 959–965 (2009).

88. Zhang Yu *et al.* Depletion of wild - type huntingtin in mouse models of neurologic diseases. *J. Neurochem.* **87,** 101–106 (2003).

89. Rigamonti, D. *et al.* Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. *J. Biol. Chem.* **276**, 14545–14548 (2001).

90. Consortium, H. D. iPSC. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. *Cell Stem Cell* **11**, 264–78 (2012).

91. Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. *Nature* **292**, 154–156 (1981).

92. Thomson, J. A. *et al.* Embryonic stem cell lines derived from human blastocysts. *Science* **282**, 1145–1147 (1998).

93. Hershko, A. & Ciechanover, A. The ubiquitin system. *Annu. Rev. Biochem.* **67,** 425–479 (1998).

94. Hochstrasser, M. Ubiquitin-dependent protein degradation. *Annu. Rev. Genet.* **30**, 405–439 (1996).

95. Okita, Y. & Nakayama, K. I. UPS delivers pluripotency. *Cell Stem Cell* **11**, 728–30 (2012).

96. Goldberg, A. L. Functions of the proteasome: the lysis at the end of the tunnel. *Science* **268**, 522–523 (1995).

97. David, Y., Ziv, T., Admon, A. & Navon, A. The E2 Ubiquitin-conjugating Enzymes Direct Polyubiquitination to Preferred Lysines. *J. Biol. Chem.* **285**, 8595–8604 (2010).

98. Young, R. A. Control of the Embryonic Stem Cell State. *Cell* **144**, 940–954 (2011).

99. Hu, X.-L., Wang, Y. & Shen, Q. Epigenetic control on cell fate choice in neural stem cells. *Protein Cell* **3**, 278–290 (2012).

100. Watanabe, A., Yamada, Y. & Yamanaka, S. Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **368**, 20120292 (2013).

101. Meshorer, E. *et al.* Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. *Dev. Cell* **10**, 105–116 (2006).

102. Loh, Y.-H. *et al.* Genomic approaches to deconstruct pluripotency. *Annu. Rev. Genomics Hum. Genet.* **12**, 165–185 (2011).

103. Bibikova, M. *et al.* Human embryonic stem cells have a unique epigenetic signature. *Genome Res.* **16**, 1075–1083 (2006).

104. Gan, Q., Yoshida, T., McDonald, O. G. & Owens, G. K. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. *Stem Cells Dayt. Ohio* **25**, 2–9 (2007).

105. Bernstein, B. E. *et al.* A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* **125**, 315–326 (2006).

106. Hawkins, R. D. *et al.* Distinct epigenomic landscapes of pluripotent and lineagecommitted human cells. *Cell Stem Cell* **6**, 479–491 (2010).

107. Meshorer, E. & Misteli, T. Chromatin in pluripotent embryonic stem cells and

differentiation. Nat. Rev. Mol. Cell Biol. 7, 540-546 (2006).

108. Pasini, D. *et al.* JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. *Nature* **464**, 306–310 (2010).

109. Valor, L. M. Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective. *Mol. Neurobiol.* **51**, 406–423 (2015).

110. Glajch, K. E. & Sadri-Vakili, G. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis. *J. Huntingt. Dis.* **4**, 1–15 (2015).

111. Ferrante, R. J. *et al.* Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease. *J. Neurosci. Off. J. Soc. Neurosci.* **24**, 10335–10342 (2004).

112. Gardian, G. *et al.* Neuroprotective Effects of Phenylbutyrate in the N171-82Q
Transgenic Mouse Model of Huntington's Disease. *J. Biol. Chem.* 280, 556–563 (2005).
113. Ryu, H. *et al.* ESET/SETDB1 gene expression and histone H3 (K9) trimethylation

in Huntington's disease. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 19176–19181 (2006).

114. Stack, E. C. *et al.* Modulation of nucleosome dynamics in Huntington's disease. *Hum. Mol. Genet.* **16**, 1164–1175 (2007).

115. Becker, J. S., Nicetto, D. & Zaret, K. S. H3K9me3-Dependent Heterochromatin: Barrier to Cell Fate Changes. *Trends Genet. TIG* **32**, 29–41 (2016).

116. Fujita, N. *et al.* MCAF mediates MBD1-dependent transcriptional repression. *Mol. Cell. Biol.* **23**, 2834–2843 (2003).

117. Ichimura, T. *et al.* Transcriptional Repression and Heterochromatin Formation by MBD1 and MCAF/AM Family Proteins. *J. Biol. Chem.* **280**, 13928–13935 (2005).

118. Liu, L. *et al.* MCAF1/AM is involved in Sp1-mediated maintenance of cancerassociated telomerase activity. *J. Biol. Chem.* **284**, 5165–5174 (2009).

119. Sasai, N., Saitoh, N., Saitoh, H. & Nakao, M. The Transcriptional Cofactor MCAF1/ATF7IP Is Involved in Histone Gene Expression and Cellular Senescence. *PLOS ONE* **8**, e68478 (2013).

120. Li, W., Tu, D., Brunger, A. T. & Ye, Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. *Nature* **446**, 333–337 (2007).

121. Bae, Y., Choi, D., Rhim, H. & Kang, S. Hip2 interacts with cyclin B1 and promotes its degradation through the ubiquitin proteasome pathway. *FEBS Lett.* **584**, 4505–4510 (2010).

122. Tanno, Y. *et al.* Localization of huntingtin-interacting protein-2 (Hip-2) mRNA in the developing mouse brain. *J. Chem. Neuroanat.* **17**, 99–107 (1999).

123. Christensen, D. E., Brzovic, P. S. & Klevit, R. E. E2–BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. *Nat. Struct. Mol. Biol.* **14**, 941–948 (2007).

124. Song, S. *et al.* Essential Role of E2-25K/Hip-2 in Mediating Amyloid-β Neurotoxicity. *Mol. Cell* **12**, 553–563 (2003).

125. Howard, R. A. *et al.* Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation. *BMC Cell Biol.* **8**, 32 (2007).

126. de Pril, R., Fischer, D. F., Roos, R. A. C. & van Leeuwen, F. W. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. *Mol. Cell. Neurosci.* **34**, 10–19 (2007).

127. Kikuchi, J. *et al.* Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **20**, 128–134 (2000).

128. Park, I.-H. *et al.* Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* **451**, 141–146 (2008).

129. Park, I.-H. *et al.* Disease-specific induced pluripotent stem cells. *Cell* **134**, 877–886 (2008).

130. Chambers, S. M. *et al.* Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* **27**, 275–280 (2009).

131. Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrixassisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. *Anal. Chem.* **75**, 663–670 (2003).

132. Cox, J. *et al.* Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol. Cell. Proteomics MCP* **13**, 2513–2526 (2014).

133. Cox, J. & Mann, M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics* **13**, S12 (2012).

134. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinforma. Oxf. Engl.* **29**, 15–21 (2013).

135. Trapnell, C. *et al.* Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat. Protoc.* **7**, 562–578 (2012).

136. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinforma. Oxf. Engl.* **25**, 2078–2079 (2009).

137. Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. *Nat. Protoc.* **7**, 1728–1740 (2012).

138. Machanick, P. & Bailey, T. L. MEME-ChIP: motif analysis of large DNA datasets. *Bioinforma. Oxf. Engl.* **27**, 1696–1697 (2011).

139. Peters, M. F. & Ross, C. A. Isolation of a 40-kDa Huntingtin-associated Protein. *J. Biol. Chem.* **276**, 3188–3194 (2001).

140. Fujita, K. *et al.* A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases. *Nat. Commun.* **4**, 1816 (2013).

141. Wang, H. *et al.* mAM Facilitates Conversion by ESET of Dimethyl to Trimethyl Lysine 9 of Histone H3 to Cause Transcriptional Repression. *Mol. Cell* **12**, 475–487 (2003).

142. Ichimura, T. *et al.* Transcriptional Repression and Heterochromatin Formation by MBD1 and MCAF/AM Family Proteins. *J. Biol. Chem.* **280**, 13928–13935 (2005).

143. Minkovsky, A. *et al.* The Mbd1-Atf7ip-Setdb1 pathway contributes to the maintenance of X chromosome inactivation. *Epigenetics Chromatin* **7**, 12 (2014).

144. Timms, R. T., Tchasovnikarova, I. A., Antrobus, R., Dougan, G. & Lehner, P. J. ATF7IP-Mediated Stabilization of the Histone Methyltransferase SETDB1 Is Essential for

Heterochromatin Formation by the HUSH Complex. *Cell Rep.* **17,** 653–659 (2016). 145. Patrick Callaerts, Georg Halder & Gehring, and W. J. Pax-6 in Development and

Evolution. *Annu. Rev. Neurosci.* **20**, 483–532 (1997). 146. Peters, A. H. F. M. *et al.* Partitioning and Plasticity of Repressive Histone

Methylation States in Mammalian Chromatin. *Mol. Cell* **12**, 1577–1589 (2003).

147. Rea, S. *et al.* Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature* **406**, 593–599 (2000).

148. Fritsch, L. *et al.* A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. *Mol. Cell* **37**, 46–56 (2010). 149. Bestman, J. E. & Cline, H. T. The RNA binding protein CPEB regulates dendrite morphogenesis and neuronal circuit assembly in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 20494–20499 (2008).

150. Bezprozvanny, I. & Hayden, M. R. Deranged neuronal calcium signaling and Huntington disease. *Biochem. Biophys. Res. Commun.* **322**, 1310–1317 (2004).

151. Nair, A. G., Bhalla, U. S. & Hellgren Kotaleski, J. Role of DARPP-32 and ARPP-21 in the Emergence of Temporal Constraints on Striatal Calcium and Dopamine Integration. *PLoS Comput. Biol.* **12**, (2016).

152. Bardoni, R. *et al.* Delta Opioid Receptors Presynaptically Regulate Cutaneous
Mechanosensory Neuron Input to the Spinal Cord Dorsal Horn. *Neuron* 81, 1443 (2014).
153. Noormohammadi, A. *et al.* Mechanisms of protein homeostasis (proteostasis)
maintain stem cell identity in mammalian pluripotent stem cells. *Cell. Mol. Life Sci.* 75, 275–290 (2018).

154. The HD iPSC Consortium *et al.* Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. *Nat. Neurosci.* **20**, 648–660 (2017).

155. Araki, K. & Nagata, K. Protein Folding and Quality Control in the ER. *Cold Spring Harb. Perspect. Biol.* **3**, a007526 (2011).

156. Vilchez, D. *et al.* FOXO4 is necessary for neural differentiation of human embryonic stem cells. *Aging Cell* **12**, 518–522 (2013).

157. Vilchez, D. *et al.* Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. *Nature* **489**, 304–8 (2012).

158. Harada, A. *et al.* Chd2 interacts with H3.3 to determine myogenic cell fate. *EMBO J.* **31**, 2994–3007 (2012).

159. Wen, D. *et al.* Histone variant H3.3 is an essential maternal factor for oocyte reprogramming. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 7325–7330 (2014).

160. Bae, S., Bessho, Y., Hojo, M. & Kageyama, R. The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal differentiation. *Development* **127**, 2933–2943 (2000).

161. Rui, Y.-N. *et al.* Huntingtin functions as a scaffold for selective macroautophagy. *Nat. Cell Biol.* **17**, 262–275 (2015).

162. Valcárcel-Ocete, L. *et al.* Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene. *PLoS ONE* **10**, (2015).

163. Seong, I. S. *et al.* Huntingtin facilitates polycomb repressive complex 2. *Hum. Mol. Genet.* **19**, 573–583 (2010).

164. Ziller, M. J. *et al.* Dissecting neural differentiation regulatory networks through epigenetic footprinting. *Nature* **518**, 355–359 (2015).

165. Zhu, H. & Bendall, A. J. Dlx3 is expressed in the ventral forebrain of chicken embryos: implications for the evolution of the Dlx gene family. *Int. J. Dev. Biol.* **50**, 71–75 (2006).

166. Rhinn, M., Lun, K., Ahrendt, R., Geffarth, M. & Brand, M. Zebrafish gbx1 refines the Midbrain-Hindbrain Boundary border and mediates the Wnt8 posteriorization signal. *Neural Develop.* **4**, 12 (2009).

167. Mannini, L. *et al.* SMC1B is present in mammalian somatic cells and interacts with mitotic cohesin proteins. *Sci. Rep.* **5**, 18472 (2015).

168. Takabayashi, S., Yamauchi, Y., Tsume, M., Noguchi, M. & Katoh, H. A spontaneous smc1b mutation causes cohesin protein dysfunction and sterility in mice. *Exp. Biol. Med. Maywood NJ* **234**, 994–1001 (2009).

169. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. *Proc. Natl. Acad. Sci.* **96**, 11404–11409 (1999).

170. Steffan, J. S. *et al.* Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* **413**, 739–743 (2001).

171. Yeh, H. H. *et al.* Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. *Brain Res.* **1504**, 16–24 (2013).

172. Lim, S. *et al.* D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease. *PLOS ONE* **6**, e24620 (2011).

173. Giralt, A. *et al.* Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. *Hum. Mol. Genet.* **21**, 1203–1216 (2012). 174. McFarland, K. N. *et al.* Genome-Wide Histone Acetylation Is Altered in a

Transgenic Mouse Model of Huntington's Disease. *PLOS ONE* **7**, e41423 (2012).

175. Valor, L. M., Guiretti, D., Lopez-Atalaya, J. P. & Barco, A. Genomic Landscape of Transcriptional and Epigenetic Dysregulation in Early Onset Polyglutamine Disease. *J. Neurosci.* **33**, 10471–10482 (2013).

176. Valor, L. M. & Guiretti, D. What's wrong with epigenetics in Huntington's disease? *Neuropharmacology* **80**, 103–14 (2014).

177. Galy, V., Mattaj, I. W. & Askjaer, P. Caenorhabditis elegans Nucleoporins Nup93 and Nup205 Determine the Limit of Nuclear Pore Complex Size Exclusion In Vivo. *Mol. Biol. Cell* **14**, 5104–5115 (2003).

178. Lin, C.-L. *et al.* RNA structure replaces the need for U2AF2 in splicing. *Genome Res.* **26**, 12–23 (2016).

179. Mysliwiec, M. R. *et al.* Jarid2 (Jumonji, AT Rich Interactive Domain 2) Regulates NOTCH1 Expression via Histone Modification in the Developing Heart. *J. Biol. Chem.* **287**, 1235–1241 (2012).

Erklärung

Ich versichere, dass ich die von mir vorgelegte Dissertation selbständig angefertigt, die benutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit, einschließlich Tabellen, Karten und Abbildungen, die anderen Werken im Wortlaut oder dem Sinn nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich gemacht habe; dass diese Dissertation noch keiner anderen Fakultät oder Universität zur Prüfung vorgelegen hat; dass sie -abgesehen von unten angegebenen Teilpublikationen- noch nicht veröffentlicht worden ist sowie, dass ich eine solche Veröffentlichung vor Abschluss des Promotionsverfahrens nicht vornehmen werde.

Die Bestimmungen der Promotionsordnung sind mir bekannt. Die von mir vorgelegte Dissertation ist von Dr. David Vilchez betreut worden.

Köln, den 18.04.2018

(Dilber Irmak)